Methods and systems for single molecule tracking in cell-free systems
By tracking the contact and motion changes between target molecules and test molecules in a cell-free system, the limitations of scale and sensitivity in existing technologies have been addressed, enabling high-throughput and precise single-molecule analysis.
Patent Information
- Application Number
- CN202480054281.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-12-21
- Filing Date
- 2024-06-26
- Publication Date
- 2026-05-29
AI Technical Summary
Existing methods for single-molecule tracking in cell-free systems are limited in terms of scale, sensitivity, and success.
A single-molecule method is provided for analyzing target molecules in cell-free samples, including contacting the target molecule with the test molecule, tracking its movement and determining its movement changes through a variety of analytical methods to identify interactions or changes in form.
This enables high-throughput and precise identification of interactions between target molecules and test molecules, as well as changes in the form of target molecules, in cell-free systems, thereby improving the scale and sensitivity of the analysis.
Smart Images

Figure CN122122461A_ABST
Abstract
Description
Cross-references to related applications
[0001] This application claims priority to U.S. Provisional Application No. 63 / 523,356, filed June 26, 2023, and U.S. Provisional Application No. 63 / 613,704, filed December 21, 2023, the contents of which are incorporated herein by reference in their entirety. Technical Field
[0002] The topics described in this article relate to methods for analyzing single molecules in cell-free systems. Background Technology
[0003] Molecular motion in cell-free systems is profoundly influenced by the interactions between these molecules and their environment. This environment includes, but is not limited to, the solution in which the molecules are distributed, other molecules present in the solution, and physical conditions. Therefore, monitoring the motion of target molecules can provide biophysical information about those environmental interactions and their effects on the target molecules. Single-molecule tracking (SMT) is a method for capturing the motion of single molecules, for example, as a means of reporting the conformation, interactions, and / or identity of target molecules. In SMT, molecules (e.g., fluorescently labeled molecules) are imaged over time with high spatiotemporal resolution, and their motion is analyzed at the single-molecule level. However, to date, the application of SMT technology in cell-free systems has been limited in terms of scale, sensitivity, and success rate. Summary of the Invention
[0004] This disclosure relates to single-molecule methods for analyzing target molecules in cell-free samples, including, for example, high-throughput methods. This disclosure also provides systems for performing such methods.
[0005] In a first aspect, this disclosure relates to methods (e.g., high-throughput methods) for identifying interactions between test molecules and target molecules, methods comprising: (a) contacting a cell-free sample containing a plurality of target molecules with the plurality of test molecules; (b) tracking the plurality of target molecules over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (c) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the target molecules in the presence of the test molecules; and (d) comparing the motion of the target molecules obtained in (c) with the motion of a reference target molecule, wherein the motion of the reference target molecule is the motion of the target molecule in the absence of the test molecules; wherein a change in the motion of the target molecule compared to the motion of the reference target molecule indicates an interaction between the target molecules and the test molecules. In some embodiments, a decrease in the motion of the target molecule compared to the motion of the reference target molecule indicates an interaction between the target molecules and the test molecules. In some embodiments, an increase in the motion of the target molecule compared to the motion of the reference target molecule indicates an interaction between the target molecules and the test molecules. In some embodiments, the duration and / or reversibility of the change in the motion of the target molecule compared to the change in the motion of the reference target molecule indicates an interaction between the target molecules and the test molecules.
[0006] In some embodiments involving the identification of interactions between a test molecule and a target molecule, the determination of molecular motion can be quantified by analyzing spatiotemporal trajectories. Motion characterized in this way may also include, but is not limited to, measurements of diffusion coefficients. For example, the measurement could be a maximum likelihood estimate of the diffusion coefficient, defined as an estimate of the maximum likelihood diffusion coefficient of multiple spatiotemporal trajectories under a single-state diffusion model with constant localization error. In some embodiments, spatiotemporal trajectories can be used to estimate the fraction of target molecules in multiple dynamic diffusion states, such as different diffusion states, using machine learning methods, such as variational Bayesian inference. Such methods include, but are not limited to, state arrays. In some embodiments, molecular motion can be measured by analyzing the product of link generation algorithms. Motion characterized in this way may include, but is not limited to, the average posterior diffusion coefficient, the average of the posterior probability distributions of coefficients from probabilistic linking algorithms. Motion characterized in this way may include, but is not limited to, the geometrically averaged posterior diffusion coefficient, the average of the log-scaled posterior probability distributions of coefficients from probabilistic linking algorithms. In some embodiments, molecular motion can be measured by performing model correlation analysis on multiple spatiotemporal trajectories. In some embodiments, the determination of molecular motion can be quantified by calculating jump length distributions. For example, for any given set of protein displacements between a time point and subsequent time points, a histogram of the probability of each displacement length (“jump length”) can be constructed. The quantiles of this distribution can be used to describe the motion of the molecule. In some embodiments, the quantile used is the median of the jump length distribution. In some embodiments, the quantile used is the third quartile of the jump length distribution. In some embodiments, the motion of the molecule can be quantified by a measurement of mean square displacement, defined by the average of the squares of all displacements in a spacetime trajectory that is averaged over multiple spacetime trajectories. Motion characterized in this way may also include, but is not limited to, measurements of spacetime trajectory lengths or spacetime trajectory length distributions. Motion characterized in this way may also include, but is not limited to, measurements of the mean radius of gyration, defined by the root mean square distance between all coordinates in the spacetime trajectory and the centroid of the set of points contained in the spacetime trajectory, averaged over multiple spacetime trajectories. Motion characterized in this way may also include, but is not limited to, measurements of the mean bond angle, defined by the angle formed by three consecutive spatial coordinates averaged over multiple spacetime trajectories.
[0007] In some implementations, the determination of molecular motion can be quantified by analyzing measurements of rotational motion. Motion characterized in this way may include, but is not limited to, anisotropic decay time.
[0008] In some embodiments, motion can be characterized by determining the number and wavelength of the conjugated fluorescent markers. In some embodiments, motion can be characterized by determining the polarization of the conjugated fluorescent markers.
[0009] In some embodiments, the determination of molecular interactions can be quantified by analyzing measurements of the spatial extent of the detection. In some embodiments, interactions characterized in this way may include, but are not limited to, measurements of oligomerization. In some embodiments, the oligomerization process is analyzed through one or more detection channels to analyze, but is not limited to, the number and heterogeneity of monomers forming oligomers.
[0010] In some embodiments involving the identification of the interaction between a test molecule and a target molecule, such as where the change in diffusion coefficient relative to the diffusion coefficient of a reference target molecule is used to determine motion, the change in diffusion coefficient relative to the diffusion coefficient of the reference target molecule is at least about 0.001%, at least about 0.005%, at least 0.01%, at least about 0.5%, at least about 1%, at least about 1.5%, at least about 2%, or at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10%.
[0011] In some embodiments involving the identification of the interaction between a test molecule and a target molecule, a change in the motion of the target molecule compared to the motion of a reference target molecule indicates a direct interaction between the target molecule and the test molecule. In some embodiments, a change in the motion of the target molecule compared to the motion of a reference target molecule indicates an indirect interaction between the target molecule and the test molecule. In some embodiments, the interaction between the target molecule and the test molecule results in a conformational change in the target molecule. In some embodiments, the interaction between the target molecule and the test molecule results in an increase in the mass of the target molecule. In some embodiments, the interaction between the target molecule and the test molecule results in a decrease in the mass of the target molecule. In some embodiments, the interaction between the target molecule and the test molecule results in a change in the temperature stability of the target molecule. In some embodiments, the interaction between the target molecule and the test molecule results in an oligomerization process. In some embodiments, multiple target molecules are conjugated to multiple fluorescent labels. In some embodiments, the interaction between the target molecule and the test molecule is reversible. In some embodiments, the interaction between the target molecule and the test molecule is irreversible.
[0012] On the other hand, this disclosure provides methods (e.g., high-throughput methods) for determining the form of a target molecule, these methods comprising: (a) tracking a plurality of target molecules in a cell-free sample over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (b) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the target molecule; and (c) comparing the motion of the target molecule obtained in (b) with the motion of a reference target molecule, wherein the motion of the reference target molecule is a form of motion of the target molecule; wherein: (i) a change in the motion of the target molecule compared to the motion of the reference target molecule indicates that the target molecule has a different form than the reference target molecule; or (ii) no change in the motion of the target molecule compared to the motion of the reference target molecule indicates that the target molecule has the same form as the reference target molecule. In some embodiments, the duration and / or reversibility of the change in the motion of the target molecule, compared to the duration and / or reversibility of the change in the motion of the reference target molecule, indicates that the target molecule has a different form than the reference target molecule. In some embodiments, different forms of target molecules may have the same chemical composition but different conformations. In some embodiments, one form of the target molecule may be the product of alternative splicing. In some embodiments, one form of the target molecule is a post-translational modified form of the target molecule. In some embodiments, one form of the target molecule is the wild-type form of the target molecule. In some embodiments, one form of the target molecule is a mutant form of the target molecule. In some embodiments, one form of the target molecule is a homolog, ortholog, or paralog of the target molecule.
[0013] In some implementations, the motional changes associated with determining the form of the target molecule are the following: (a) the diffusion coefficient obtained from the maximum likelihood estimator; (b) the geometrically mean posterior diffusion coefficient; (c) the median of the jump length distribution; (d) the third quartile of the jump length distribution; (e) the median radius of gyration; (f) the mean posterior diffusion coefficient; (g) the mean square displacement; (h) the median bond angle; (i) the spatiotemporal trajectory length; (j) the anisotropic decay time; (k) the spatial range of the probe; (l) the number and wavelength of the conjugated fluorescent tags; (m) the occupancy of different diffusion states obtained from the state array; (n) the polarization of the conjugated fluorescent tags; or (o) the state occupancy obtained by inference.
[0014] In some embodiments involving determining the form of a target molecule, such as where the change in diffusion coefficient relative to the diffusion coefficient of a reference target molecule is used to determine motion, the change in diffusion coefficient is at least about 0.001%, at least about 0.005%, at least about 0.01%, at least about 0.05%, at least about 0.1%, at least about 0.5%, at least about 1%, at least about 1.5%, at least about 2%, or at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10%.
[0015] In another aspect, this disclosure provides methods for identifying test molecules capable of distinguishing at least two target molecules, such as high-throughput methods. In some embodiments, these methods include: (a) contacting a cell-free sample containing a plurality of first target molecules with a plurality of test molecules; (b) tracking the plurality of first target molecules over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (c) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the first target molecules in the presence of the test molecules; (d) contacting a cell-free sample containing a plurality of second target molecules with the plurality of test molecules; (e) tracking the plurality of second target molecules over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (f) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the second target molecules in the presence of the test molecules; and (g) comparing the motions of the target molecules obtained in (c) and (f); wherein the changes in the motions of the first and second target molecules indicate that the test molecules are capable of distinguishing the two target molecules.
[0016] In some implementations, the motion changes associated with identifying test molecules that can distinguish at least two target molecules are the following: (a) the diffusion coefficient obtained from the maximum likelihood estimate; (b) the geometrically mean posterior diffusion coefficient; (c) the median of the jump length distribution; (d) the third quartile of the jump length distribution; (e) the median radius of gyration; (f) the mean posterior diffusion coefficient; (g) the mean square displacement; (h) the median bond angle; (i) the spatiotemporal trajectory length; or (j) the anisotropic decay time; (k) the spatial range of detection; (l) the number and wavelength of the conjugated fluorescent tags; (m) the occupancy of different diffusion states obtained from the state array; (n) the polarization of the conjugated fluorescent tags; or (o) the state occupancy obtained by inference.
[0017] In some embodiments, the motion changes of the first and second target molecules indicate that the test molecule can distinguish between the two target molecules. In some embodiments, the two target molecules are unrelated. In some embodiments, the two target molecules are related. In some embodiments where the two target molecules are related, the first and second target molecules are the same or different forms of the target molecules. In some embodiments where the two target molecules are related, one form of the target molecule is the wild-type form of the target molecule. In some embodiments where the two target molecules are related, one form of the target molecule is a mutant form of the target molecule. In some embodiments, one form of the target molecule is a post-translational modified form of the target molecule. In some embodiments where the two target molecules are related, the first and second target molecules are homologs, orthologs, or paralogs. In some embodiments where the two target molecules are related, the first and second target molecules are different kinds of target molecules. In some embodiments where the two target molecules are related, the first and second target molecules are different splice isoforms of the target molecules. In some embodiments where the two target molecules are related, the first and second target molecules are target molecules in the same or different conformational states. In some embodiments, the distinction between the first and second target molecules is achieved through differences in their fluorescent labels. In some embodiments, more than two target molecules are analyzed, for example, a third target molecule. For example, but not as a limitation, the method may also include contacting a cell-free sample containing a plurality of third target molecules with a plurality of test molecules; tracking the plurality of said third target molecules over time to provide measurements of a third plurality of spatiotemporal trajectories and / or rotational motions; analyzing the measurements of said third plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of said third target molecules in the presence of said test molecules; and comparing the motion of said third target molecules with the motion obtained in (c) and (f); wherein the change in the motion of said third target molecules relative to the first and second target molecules indicates that the test molecules are able to distinguish the three target molecules.
[0018] In another aspect, this disclosure provides methods, such as high-throughput methods, for identifying test molecules that bind to and induce conformational changes in target molecules. In some embodiments, these methods include: (a) contacting a cell-free sample containing a plurality of said target molecules with a plurality of test molecules, wherein each sample is contacted with a different test molecule; (b) tracking the plurality of said target molecules in each sample over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (c) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the target molecules in the presence of test molecules; and (d) comparing the motion of the target molecules obtained in step (c) with the motion of a reference target molecule, wherein the motion of the reference target molecule is the motion of the target molecule in the presence of a test molecule that does not induce conformational changes in the target molecule; wherein the change in the motion of the target molecule compared to the motion of the reference target molecule indicates an interaction between the target molecule and a test molecule that induces conformational changes in the target molecule. In some embodiments, the duration and / or reversibility of the motion change of the target molecule, compared to the duration and / or reversibility of the motion change of the reference target molecule, indicates the interaction between the target molecule and one or more test molecules that induce the conformational change of the target molecule. In some embodiments, the conformational change of the target molecule is correlated with a change in the temperature stability of the target molecule.
[0019] In some implementations, the motional changes associated with identifying test molecules that bind to and cause conformational changes in the target molecule are the following: (a) the diffusion coefficient obtained from the maximum likelihood estimate; (b) the geometrically mean posterior diffusion coefficient; (c) the median of the jump length distribution; (d) the third quartile of the jump length distribution; (e) the median radius of gyration; (f) the mean posterior diffusion coefficient; (g) the mean square displacement; (h) the median bond angle; (i) the spatiotemporal trajectory length; (j) the anisotropic decay time; (k) the spatial range of detection; (l) the number and wavelength of the conjugated fluorescent tags; (m) the occupancy of different diffusion states obtained from the state array; (n) the polarization of the conjugated fluorescent tags; or (o) the state occupancy obtained by inference.
[0020] In some embodiments involving the identification of test molecules that bind to and cause conformational changes in a target molecule, such as those in which the change in diffusion coefficient relative to the diffusion coefficient of a reference target molecule is used to determine motion, the change in diffusion coefficient relative to the diffusion coefficient of the reference target molecule is at least about 0.001%, at least about 0.005%, at least about 0.01%, at least about 0.05%, at least about 0.1%, at least about 0.5%, at least about 1%, at least about 1.5%, at least about 2%, or at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10%.
[0021] On the other hand, this disclosure provides methods (e.g., high-throughput methods) for determining the dose response of a target molecule to a test molecule, the methods comprising: (a) contacting a plurality of cell-free samples containing a plurality of target molecules with test molecules, wherein the plurality of cell-free samples are contacted with a series of test molecule doses; (b) in the presence of the series of test molecules, tracking the plurality of target molecules over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (c) in the presence of the series of test molecules, analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions of the target molecules to determine the motion of the target molecules at each dose of the test molecules; and (d) comparing the motions of the target molecules obtained in step (c) at different test molecule doses to determine the dose response of the target molecules to the test molecules.
[0022] In some implementations, the motion changes associated with determining the dose response of the target molecule to the test molecule are the following changes: (a) the diffusion coefficient obtained from the maximum likelihood estimator; (b) the geometrically mean posterior diffusion coefficient; (c) the median of the jump length distribution; (d) the third quartile of the jump length distribution; (e) the median radius of gyration; (f) the mean posterior diffusion coefficient; (g) the mean square displacement; (h) the median bond angle; (i) the spatiotemporal trajectory length; or (j) the anisotropic decay time; (k) the spatial range of detection; (l) the number and wavelength of the conjugated fluorescent tags; (m) the occupancy of different diffusion states obtained from the state array; (n) the polarization of the conjugated fluorescent tags; or (o) the state occupancy obtained by inference.
[0023] In some embodiments involving determining the dose response of a target molecule to a test molecule, such as using the change in the diffusion coefficient of the target molecule relative to the change in the diffusion coefficient of the target molecule at each dose of the test molecule to determine motion, the change in the diffusion coefficient of the target molecule relative to the change in the diffusion coefficient of the target molecule at each dose of the test molecule is at least about 0.001%, at least about 0.005%, at least about 0.01%, at least about 0.05%, at least about 0.1%, at least about 0.5%, at least about 1%, at least about 1.5%, at least about 2%, or at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10%.
[0024] In another aspect, this disclosure provides methods (e.g., high-throughput methods) for determining differences in the dose responses of two target molecules to test molecules, these methods comprising: (a) contacting a first plurality of cell-free samples containing a plurality of first target molecules with test molecules, wherein the first plurality of cell-free samples are contacted with a series of test molecule doses; (b) in the presence of the series of test molecule doses, tracking the plurality of target molecules over time to provide measurements of a first plurality of spatiotemporal trajectories and / or rotational motions; and (c) in the presence of the series of test molecule doses, analyzing the plurality of spatiotemporal trajectories of the target molecules. (d) Measuring the rotational motion to determine the motion of the first target molecule at each dose of the test molecule; (c) Comparing the motion of the target molecule obtained in (c) at different doses of the test molecule to determine the dose response of the target molecule to the test molecule; (e) Repeating steps (a)-(d) with a second target molecule to determine the dose response of the second target molecule to the test molecule; and (f) Comparing the dose response of the first target molecule with the dose response of the second target molecule to determine the difference in the response of the first target molecule and the second target molecule to the test molecule. In some embodiments, the distinction between the first target molecule and the second target molecule is achieved by the difference in their fluorescent labels. In some embodiments, more than two target molecules are analyzed, for example, three or more target molecules are analyzed.
[0025] In some implementations, the motion changes associated with determining the difference in dose response of the two target molecules to the test molecule are the following: (a) the diffusion coefficient obtained from the maximum likelihood estimator; (b) the geometrically mean posterior diffusion coefficient; (c) the median of the jump length distribution; (d) the third quartile of the jump length distribution; (e) the median radius of gyration; (f) the mean posterior diffusion coefficient; (g) the mean square displacement; (h) the median bond angle; (i) the spatiotemporal trajectory length; or (j) the anisotropic decay time; (k) the spatial range of detection; (l) the number and wavelength of the conjugated fluorescent tags; (m) the occupancy of different diffusion states obtained from the state array; (n) the polarization of the conjugated fluorescent tags; or (o) the state occupancy obtained by inference.
[0026] In some embodiments involving determining the difference in dose response of two target molecules to a test molecule, the first target molecule and the second target molecule are unrelated. In some embodiments, the first target molecule and the second target molecule are related. In some embodiments where the first target molecule and the second target molecule are related, the first target molecule and the second target molecule are the same or different forms of the target molecule. In some embodiments where the first target molecule and the second target molecule are related, one form of the target molecule is the wild-type form of the target molecule. In some embodiments where the first target molecule and the second target molecule are related, one form of the target molecule is a mutant form of the target molecule. In some embodiments where the first target molecule and the second target molecule are related, one form of the target molecule is a post-translational modified form of the target molecule. In some embodiments where the first target molecule and the second target molecule are related, the first target molecule and the second target molecule are homologs, orthologs, or paralogs of the target molecule. In some embodiments where the first target molecule and the second target molecule are related, the first target molecule and the second target molecule are different kinds of target molecules. In some embodiments where the first target molecule and the second target molecule are related, the first target molecule and the second target molecule are different splice isoforms of the target molecule. In some embodiments where the first and second target molecules are related, the first and second target molecules are target molecules in the same or different conformational states. In some embodiments, the distinction between the first and second target molecules is achieved by the difference in their fluorescent labels. In some embodiments, more than two target molecules are analyzed.
[0027] In some embodiments involving determining differences in the dose response of two target molecules to a test molecule, the target molecule is an organic molecule smaller than about 1 kDa. In some embodiments, the target molecule is selected from the group consisting of peptides, protein domains, proteins, nucleic acid polymers, carbohydrates, and lipids. In some embodiments, the target molecule is selected from the group consisting of glycoproteins, glycolipids, oligosaccharides, polysaccharides, and lipid micelles. In some embodiments, the target molecule is an entity of multiple components (e.g., at least two, at least three, at least four, or at least five components) non-covalently bound together by interactions including, but not limited to, hydrophobic, electrostatic, ionic, hydrogen, and van der Waals forces. In some embodiments, the target molecule is an entity of multiple components covalently bound together. In some embodiments, the target molecule is a multi-subunit protein or protein complex composed of multiple subunits. In some embodiments, the target molecule is a protein composed of one or more polypeptides and one or more ligands. In some embodiments, the target molecule is an exosome composed of proteins, lipids, and other biomolecules. In some embodiments, the target molecule is a virus, viroid, bacteriophage, or other biological particle. In some embodiments, the protein is selected from the group consisting of antibodies, receptors, and enzymes. In some embodiments, the protein contains disordered domains. In some embodiments, the protein does not contain structured domains. In some embodiments, the peptide is a ligand. In some embodiments, the target molecule is a nanomaterial. In some embodiments, the target molecule is a synthetic polymer. In some embodiments, the target molecule is labeled. In some embodiments, the target molecule is fluorescently labeled. In some embodiments, the target molecule is labeled with an organic fluorophore or inorganic fluorescent particles. In some embodiments, the target molecule is labeled with a fluorescent protein. In some embodiments, the target molecule is labeled by conjugation of synthetic nanomaterials or polymers. In some embodiments, the target molecule is purified. In some embodiments, the target molecule is a component of a mixture. In some embodiments, the target molecule is a component of a mixture consisting of bacterial extracts, cell extracts, tissue extracts, plant extracts, or animal extracts. In some embodiments, the bacterial extracts, cell extracts, tissue extracts, plant extracts, or animal extracts are lysates. In some embodiments, the target molecule is a component of a mixture consisting of serum, blood, and other biological samples. In some embodiments, the target molecule is a component of a mixture containing buffer and glycerol.
[0028] In another aspect, this disclosure provides high-throughput methods (e.g., high-throughput methods) for identifying interactions between test molecules and target proteins containing disordered domains, these methods comprising: (a) contacting a cell-free sample containing a plurality of target proteins with a plurality of test molecules; (b) tracking the plurality of target proteins over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (c) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the target proteins in the presence of the test molecules; and (d) comparing the motion of the target proteins obtained in (c) with the motion of a reference target protein, wherein the motion of the reference target protein is the motion of the target protein in the absence of the test molecules; wherein, compared with the motion of the reference target protein, a change in the motion of the target protein containing the disordered domains indicates an interaction between the target protein containing the disordered domains and the test molecule. In some embodiments, the duration and / or reversibility of the motion change of the target protein containing the disordered domain indicates the interaction between the target molecule and the test molecule, compared to the duration and / or reversibility of the motion change of the reference target protein. In some embodiments, the interaction between the target molecule and the test molecule is reversible. In some embodiments, the interaction between the target molecule and the test molecule is irreversible.
[0029] In some implementations, the motion changes associated with identifying the interaction between the test molecule and the target protein containing disordered domains are the following changes: (a) the diffusion coefficient obtained from the maximum likelihood estimate; (b) the geometrically mean posterior diffusion coefficient; (c) the median of the jump length distribution; (d) the third quartile of the jump length distribution; (e) the median radius of gyration; (f) the mean posterior diffusion coefficient; (g) the mean square displacement; (h) the median bond angle; (i) the spatiotemporal trajectory length; or (j) the anisotropic decay time; (k) the spatial range of detection; (l) the number and wavelength of the conjugated fluorescent labels; (m) the occupancy of different diffusion states obtained from the state array; (n) the polarization of the conjugated fluorescent labels; or (o) the state occupancy obtained by inference.
[0030] In some embodiments involving the identification of interactions between a test molecule and a target protein containing disordered domains, such as those where the change in diffusion coefficient relative to the diffusion coefficient of a reference target molecule is used to determine motion, the change in the diffusion coefficient of the target protein containing disordered domains compared to the diffusion coefficient of the reference target protein is at least about 0.001%, at least about 0.005%, at least about 0.01%, at least about 0.05%, at least about 0.1%, at least about 0.5%, at least about 1%, at least about 1.5%, at least about 2%, or at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10%. In some embodiments, the change in the diffusion coefficient of the target protein containing disordered domains compared to the diffusion coefficient of the reference target protein indicates a direct interaction between the target protein containing disordered domains and the test molecule. In some embodiments, the change in the diffusion coefficient of the target protein compared to the diffusion coefficient of the reference target protein indicates an indirect interaction between the target protein containing disordered domains and the test molecule. In some embodiments, a change in the diffusion coefficient of a target protein containing disordered domains, compared to a reference target protein diffusion coefficient, indicates a conformational change in the target protein. In some embodiments, a conformational change in the target protein leads to a change in the temperature stability of the target protein. In some embodiments, a change in the diffusion coefficient of a target protein containing disordered domains, compared to a reference target protein diffusion coefficient, indicates an increase in the mass of the target protein. In some embodiments, a change in the diffusion coefficient of a target protein containing disordered domains, compared to a reference target protein diffusion coefficient, indicates a decrease in the mass of the target protein. In some embodiments, a change in the diffusion coefficient of a target protein containing disordered domains, compared to a reference target protein diffusion coefficient, indicates an oligomerization process. In some embodiments, multiple target proteins are conjugated to multiple fluorescent labels. In some embodiments, the interaction between the target protein and the test molecule is reversible. In some embodiments, the interaction between the target protein and the test molecule is irreversible.
[0031] In some embodiments involving the identification of the interaction between a test molecule and a target protein containing a disordered domain, the target protein containing the disordered domain is selected from the group consisting of antibodies, receptors, structural proteins, and enzymes. In some embodiments, the target protein containing the disordered domain does not contain a structured domain. In some embodiments, the target protein containing the disordered domain is a fragment of a natural full-length protein. In some embodiments, the target protein containing the disordered domain is labeled. In some embodiments, the target protein containing the disordered domain is fluorescently labeled. In some embodiments, the test molecule is fluorescently labeled. In some embodiments, the target protein containing the disordered domain is purified.
[0032] In some embodiments involving the identification of interactions between a test molecule and a target protein containing disordered domains, the test molecule is an organic molecule smaller than about 1 kDa. In some embodiments, the test molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids. In some embodiments, the protein is selected from the group consisting of antibodies, receptors, and enzymes. In some embodiments, the protein contains disordered domains. In some embodiments, the protein does not contain structured domains. In some embodiments, the peptide is a ligand. In some embodiments, the test molecule is a nanomaterial. In some embodiments, the test molecule is labeled. In some embodiments, the test molecule is fluorescently labeled. In some embodiments, the test molecule is labeled with a fluorescent protein. In some embodiments, the test molecule is labeled by conjugation of synthetic nanomaterials or polymers. In some embodiments, the test molecule is purified. In some embodiments, the test molecule is a component of a mixture. In some embodiments, the test molecule is a component of a mixture consisting of bacterial extracts, cell extracts, tissue extracts, plant extracts, or animal extracts. In some embodiments, the bacterial extracts, cell extracts, tissue extracts, plant extracts, or animal extracts are lysates. In some embodiments, the test molecule is a component of a mixture consisting of serum, blood, and other biological samples. In some embodiments, the target molecule is a component of a mixture containing buffer and glycerol.
[0033] In some embodiments involving the identification of interactions between a test molecule and a target protein containing a disordered domain, the interaction between the target protein containing the disordered domain and the test molecule results in a conformational change in the target molecule. In some embodiments, the conformational change in the target molecule results in a change in the temperature stability of the target protein. In some embodiments, the interaction between the target protein containing the disordered domain and the test molecule results in an increase in the mass of the target protein. In some embodiments, the interaction between the target protein containing the disordered domain and the test molecule results in a decrease in the mass of the target protein. In some embodiments, the interaction between the target protein containing the disordered domain and the test molecule results in an oligomerization process.
[0034] On the other hand, this disclosure provides methods for analyzing target molecules in a test solution, such as high-throughput methods. In some embodiments, these methods include: (a) tracking a plurality of the target molecules in the test solution over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (b) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the target molecules in the test solution; and (c) comparing the motion of the target molecules obtained in (b) with the motion of a reference target molecule, wherein the motion of the reference target molecule is the motion of the target molecule in a reference solution; wherein: (i) a change in the motion of the target molecule compared to the motion of the reference target molecule indicates that the target molecule is affected by the test solution; or (ii) no change in the motion of the target molecule compared to the motion of the reference target molecule indicates that the target molecule is not affected by the test solution. In some embodiments, the duration and / or reversibility of the change in the motion of the target molecule indicates that the target molecule is affected by the test solution, compared to the duration and / or reversibility of the change in the motion of the reference target molecule.
[0035] In some implementations, the motion changes associated with the target molecules in the analytical test solution are the following changes: (a) the diffusion coefficient obtained from the maximum likelihood estimate; (b) the geometrically mean posterior diffusion coefficient; (c) the median of the jump length distribution; (d) the third quartile of the jump length distribution; (e) the median radius of gyration; (f) the mean posterior diffusion coefficient; (g) the mean square displacement; (h) the median bond angle; (i) the spatiotemporal trajectory length; or (j) the anisotropic decay time; (k) the spatial range of detection; (l) the number and wavelength of the conjugated fluorescent labels; (m) the occupancy of different diffusion states obtained from the state array; (n) the polarization of the conjugated fluorescent labels; or (o) the state occupancy obtained by inference.
[0036] In some embodiments involving the analysis of target molecules in a test solution, the test solution contains a dissociating agent. In some embodiments, the dissociating agent is urea. In some embodiments, the test solution contains a viscosity agent. In some embodiments, the viscosity agent is glycerol. In some embodiments, the test solution contains a gradient. In some embodiments, the gradient is a temperature gradient, a chemical gradient, or a combination thereof. In some embodiments, the test solution contains at least two phases.
[0037] In some embodiments involving the analysis of target molecules in a test solution, the target molecule is an organic molecule less than 1 kDa. In some embodiments, the target molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids. In some embodiments, the protein is selected from the group consisting of antibodies, receptors, and enzymes. In some embodiments, the protein contains disordered domains. In some embodiments, the protein does not contain structured domains. In some embodiments, the peptide is a ligand. In some embodiments, the target molecule is a nanomaterial. In some embodiments, the target molecule is a synthetic polymer. In some embodiments, the target molecule is labeled. In some embodiments, the target molecule is fluorescently labeled. In some embodiments, the target molecule is labeled with a fluorescent protein. In some embodiments, the target molecule is labeled by conjugation of synthetic nanomaterials or polymers. In some embodiments, the target molecule is purified. In some embodiments, the interaction between the target protein and the test solution leads to a conformational change in the target molecule.
[0038] In some embodiments involving the analysis of target molecules in a test solution, the sample used in conjunction with any of the methods described herein contains a solution. For example, but not as a limitation, when determining the interaction between a target molecule, such as a target protein containing disordered domains, and a test molecule, changes in the interaction between the target molecule and the solution in the presence of the test molecule can be identified. However, in some embodiments, the presence of a test molecule is not required, and the interaction between the target molecule and the solution can be determined by changes in the movement of the target molecule in various solutions. In some embodiments, the solution contains a pH buffer, a salt, a crowding agent, a carrier, a viscosity agent, a detergent, a reducing agent, or a combination thereof. In some embodiments, the viscosity agent includes glycerol, sucrose, polyethylene glycol, dextran, ficoll, polyvinyl alcohol, and / or polyvinylpyrrolidone. In some embodiments, the solution contains at least about 0.1%, 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 99% glycerol or a range of glycerol defined by said glycerol range. In some embodiments, the crowding agent includes urea, guanidine salts, alcohols, or ketones, etc. In some embodiments, the congesting agent includes one or more of the following: polyethylene glycol (PEG) polymers, Ficoll, dextran polymers, or proteins (e.g., ovalbumin or hemoglobin). In some embodiments, the carrier is a protein or a mixture of proteins. For example, but not by limitation, the carrier protein or protein mixture prevents non-specific interactions between the target molecule and / or the test molecule and other molecules and surfaces. Some non-limiting examples of carriers include: bovine serum albumin (BSA); lysozyme; casein; skim milk powder; and other biological extracts. In some embodiments, the solution comprises a temperature gradient, a chemical gradient, at least two liquid phases, or a combination thereof. In some embodiments, the sample volume is up to about 1 mL. In some embodiments, the sample volume ranges from about 0.1 µL to about 100 µL. In some implementations, the sample volume is about 1 µL, about 5 µL, about 10 µL, about 20 µL, about 30 µL, about 40 µL, about 50 µL, about 60 µL, about 70 µL, about 80 µL, about 90 µL, or about 100 µL.
[0039] On the other hand, this disclosure provides methods for analyzing test solutions containing target molecules, such as high-throughput methods. In some embodiments, these methods include: (a) tracking a plurality of target molecules in the test solution over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (b) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the target molecules in the test solution; and (c) comparing the motion of the target molecules obtained in (b) with the motion of a reference target molecule, wherein the motion of the reference target molecule is the motion of the target molecule in a reference solution; wherein the comparison in step (c) is used to determine the properties of the test solution.
[0040] In some embodiments involving analytical test solutions, the motion of the target molecule is calculated as (a) the diffusion coefficient obtained from the maximum likelihood estimate; (b) the geometrically mean posterior diffusion coefficient; (c) the median of the jump length distribution; (d) the third quartile of the jump length distribution; (e) the median radius of gyration; (f) the mean posterior diffusion coefficient; (g) the mean square displacement; (h) the median bond angle; (i) the spatiotemporal trajectory length; (j) the anisotropic decay time; (k) the spatial range of detection; (l) the number and wavelength of the conjugated fluorescent tags; (m) the occupancy of different diffusion states obtained from the state array; (n) the polarization of the conjugated fluorescent tags; or (o) the state occupancy obtained by inference.
[0041] In some embodiments involving the analytical test solution, the test solution contains a dissociating agent. In some embodiments, the dissociating agent is urea. In some embodiments, the test solution contains a viscosity agent. In some embodiments, the viscosity agent is glycerol. In some embodiments, the test solution contains a gradient. In some embodiments, the gradient is a temperature gradient, a chemical gradient, or a combination thereof. In some embodiments, the test solution contains at least two phases. In some embodiments, the test solution is a biological sample obtained from a subject.
[0042] In some embodiments involving analytical test solutions, the target molecule is an organic molecule less than 1 kDa. In some embodiments, the target molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids. In some embodiments, the protein is selected from the group consisting of antibodies, receptors, and enzymes. In some embodiments, the protein contains disordered domains. In some embodiments, the protein does not contain structured domains. In some embodiments, the peptide is a ligand. In some embodiments, the target molecule is a nanomaterial. In some embodiments, the target molecule is a synthetic polymer. In some embodiments, the target molecule is labeled. In some embodiments, the target molecule is fluorescently labeled. In some embodiments, the target molecule is labeled with a fluorescent protein. In some embodiments, the target molecule is labeled by conjugation of synthetic nanomaterials or polymers. In some embodiments, the target molecule is purified. In some embodiments, the interaction between the target protein and the test solution leads to a conformational change in the target molecule.
[0043] In some embodiments involving the analysis of the test solution, the defined properties of the test solution are pH, ion concentration, organic molecule concentration, or viscoelasticity. In some embodiments, viscoelasticity is viscosity. In some embodiments, the properties of the test solution are used to diagnose a disease in the subject. In some embodiments, the disease is cancer.
[0044] In some embodiments involving analytical test solutions, the sample used in conjunction with any of the methods described herein contains a solution. For example, but not as a limitation, when determining the interaction between a target molecule, such as a target protein containing disordered domains, and a test molecule, changes in the interaction between the target molecule and the solution in the presence of the test molecule can be identified. However, in some embodiments, the presence of a test molecule is not required, and the interaction between the target molecule and the solution can be determined by changes in the movement of the target molecule in various solutions. In some embodiments, the solution contains a pH buffer, a salt, a dissociating agent, a crowding agent, a carrier, a viscosity agent, a detergent, a reducing agent, or a combination thereof. In some embodiments, the viscosity agent includes glycerol, sucrose, polyethylene glycol, dextran, polysucrose, polyvinyl alcohol, and / or polyvinylpyrrolidone. In some embodiments, the solution contains at least about 0.1%, 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 99% glycerol or a range of glycerol defined by said glycerol range. In some embodiments, the dissociating agent includes urea, guanidine salts, alcohols, or ketones, etc. In some embodiments, the congesting agent includes one or more of the following: polyethylene glycol (PEG) polymers, Ficoll, dextran polymers, or proteins (e.g., ovalbumin or hemoglobin). In some embodiments, the carrier is a protein or a mixture of proteins. For example, but not by limitation, the carrier protein or protein mixture prevents non-specific interactions between the target molecule and / or the test molecule and other molecules and surfaces. Non-limiting examples of carriers include: bovine serum albumin (BSA); lysozyme; casein; skim milk powder; and other biological extracts. In some embodiments, the solution comprises a temperature gradient, a chemical gradient, at least two liquid phases, or a combination thereof. In some embodiments, the sample volume is up to about 1 mL. In some embodiments, the sample volume ranges from about 0.1 µL to about 100 µL. In some implementations, the sample volume is about 1 µL, about 5 µL, about 10 µL, about 20 µL, about 30 µL, about 40 µL, about 50 µL, about 60 µL, about 70 µL, about 80 µL, about 90 µL, or about 100 µL.
[0045] In some embodiments, the motion changes determined by the disclosed methods are calculated as changes in the polarization of the conjugated fluorescent label. In some embodiments, methods for determining changes in the polarization of the conjugated fluorescent label may include (a) time-correlated single-photon counting (TCSPC), (b) step-scan pump-probe techniques, (c) ultralong-lifetime fluorophores, and / or (d) advanced optics techniques. In some embodiments, the target molecule and / or test molecule is labeled with an ultralong-lifetime fluorophore.
[0046] On the other hand, this disclosure also provides a system for performing the disclosed methods. Attached Figure Description
[0047] This patent or application document includes at least one color drawing. Upon request and payment of the necessary fees, the Patent Office will provide a copy of this patent or patent application publication with color drawings.
[0048] Figures 1A-1C A comparison of the diffusion of two highly similar proteins, HaloTag and Halo-protein1 fusion, using currently disclosed methods is provided. Figure 1A An illustration of the protein database (PBD) structure of an exemplary protein is provided. In the HaloTag illustration on the left, the tail of 51 amino acid residues is represented by a spiral. Figure 1B A table is provided that outlines the theoretical diffusion coefficient and measured diffusion coefficient (measured at 10 pM) for each protein at 10% or 30% glycerol, as determined by the exemplary methods of this disclosure. Figure 1C A graph is provided showing the diffusion coefficients (mean ± / + 98% confidence interval) of HaloTag and Halo-protein 1 as a function of the number of fields of view (FOV) used for calculation.
[0049] Figures 2A-2B It provides analysis of protein-protein interaction (PPI) using SMT. Figure 2A The diffusion coefficient of Halo-protein 1 (40 pM) measured in 30% glycerol at different concentrations of protein 2 is provided, as determined by the exemplary method of this disclosure. Figure 2B The diffusion coefficient of Halo-protein 1 (40 pM), measured in the presence of 30 nM protein 2 and increasing concentrations of unlabeled protein 1 peptide as a competitor, is provided, as determined by the exemplary method of this disclosure.
[0050] Figures 3A-3E An example of using SMT to distinguish conformational changes is provided. Figure 3A The diffusion coefficients of sortase-tagged protein 3 (closed conformation) and protein 3 mutant (open conformation) in 30% glycerol are provided, as determined by the exemplary method of this disclosure. Figure 3B The diffusion coefficients of protein 3 mutants in response to the addition of two small molecule ligands (molecules M1 and M2) that can convert them to a closed conformation are provided, as determined by the exemplary methods of this disclosure. Figure 3C The state array of protein 3 and protein 3 mutants with different concentrations of the added molecule M1 or MX is shown. Figure 3D Provided Figure 3C Quantization in the top left and bottom right images. Figure 3E This is a state array profile and quantification of protein 3 in the presence of 16 μM molecule M1 and dose-titrated molecule MX.
[0051] Figures 4A-4F Examples of buffer changes are provided for analyzing changes induced by the binding of ligands to relatively rigid protein structures. Figure 4A Exemplary structures are provided showing the coverage of protein 4 with and without a ligand (“molecule M3”). Figure 4B The diffusion coefficient of sorting enzyme-tagged protein 4 in 30% glycerol is provided, as determined by the exemplary method of this disclosure, in the presence of DMSO without a ligand or with 3 µM molecule M3 (vector control). Figure 4C The changes in the diffusion coefficient of protein 4 in the presence of different ionizing agents (urea, guanidine salt, acetonitrile, and acetone) with DMSO (without ligand) or in the presence of molecular M3 ligand (3 µM) are shown, as determined by the exemplary methods of this disclosure. Figure 4D The changes in the diffusion coefficient of protein 4 in the presence or absence of different ionizing agents (acetone, acetonitrile, urea, guanidine salt, and DMSO) are shown, as determined by the exemplary methods of this disclosure. Here, a high concentration of DMSO is used as the ionizing agent, which differs from the small amount of DMSO used elsewhere herein as a carrier control for chemical treatment. Figure 4E The changes in the diffusion coefficient of protein 4 are shown in the presence of DMSO (without ligand) containing different concentrations of ionizing agents (urea, guanidinium, and acetone) or in the presence of ligand molecule M3 (3 µM), as determined by the exemplary methods of this disclosure. The data are presented in box plot form. Figure 4F The table shows the dose-response titration of protein 4 by molecule M3 and its analogs (M3 analogs 1 to 6) in the presence of 6 M urea. The table provides the Tm changes measured by differential scanning fluorometry (DSF) and the IC50 determined by fluorescence polarization (FP) assay. 50 Apparent EC measured by SMT 50 Plotting the power relative to DSF (bottom left) and FP (bottom right). Estimating the EC of protein 4 tool compound 2 based on available data. 50 and IC 50 .
[0052] Figure 5 The diffusion coefficient of the intrinsically disordered region (IDR) found in protein 5 and its response to the addition of covalently bound molecule M4 are provided, as determined by exemplary methods of this disclosure.
[0053] Figures 6A-6D The exemplary SMT method of this disclosure is highlighted as enabling the measurement of protein diffusion in solution. Figure 6A JF was provided 549 Representative continuous images of labeled free HaloTag protein in 30% glycerol at 192 x 192 pixel ROI within 200 Hz, SMT (top) with overlapping trajectories (bottom). Scale bar represents 2 mm. Figure 6B It provides the average diffusion coefficient as a function of medium viscosity, compared to the theoretical Stokes-Einstein equation. Figure 6C Halo-protein 1 diffusion (n=8 wells) is provided, measured using dose response of monomeric (monovalent / MV) and dimeric (divalent / BV) protein 2. Figure 6D The diffusion coefficients of the protein 1 / protein 2 complexes, measured in the dose response of unlabeled protein 1 and molecule B1, are provided (n = 32 FOVs, from two different plates). Error bars represent standard deviations. Detailed Implementation
[0054] The currently disclosed subject matter relates to methods for analyzing single molecules in cell-free systems, such as high-throughput methods. In some embodiments, the methods described herein can be used for a variety of biophysical analytical applications, including but not limited to drug discovery activities such as compound library screening and elucidation of structure-activity relationships (SARs). In some embodiments, the methods described herein can be used to characterize the contributions of known and novel pathways to the assembly of larger molecules containing targets, such as protein signaling interaction networks. The currently disclosed subject matter also provides systems for performing such methods.
[0055] The subject matter of this disclosure is described with reference to the accompanying drawings. The drawings are not to scale and are provided only to illustrate aspects of the disclosure herein. It should be understood that the numerous specific details, relationships, and methods depicted are intended to provide a more complete understanding of the subject matter disclosed herein. For the purpose of clarity and not limitation, the detailed description is divided into the following subsections: 1. Definition; 2. molecule; 3. SMT method for biophysical analysis; 4. SMT system for biophysical analysis; 5. Examples; and 6. Exemplary Implementation Scheme 1. Definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In case of any conflict, this document (including the definitions) shall prevail. Preferred methods and materials are described below, although similar or equivalent methods and materials may be used in practicing or testing the subject matter of this disclosure. All publications, patent applications, patents, and other references mentioned herein are incorporated herein by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and not intended to be limiting.
[0056] As used herein, the term "cell-free system" refers to a system that allows for the biophysical analysis of molecules outside of a complete whole-cell environment. Samples containing such a cell-free system do not preclude the presence of complete whole cells or cell fragments. Rather, the analytical focus of a cell-free system is on the exterior of the complete whole cell. For example, but not as a limitation, a cell-free system may contain cell extracts that still contain complete whole cells or cell fragments, but the analytical focus of the cell-free system occurs within the cell extract rather than within the complete whole cell. In some embodiments, the cell-free system does not contain a cell extract, but instead contains a solution in which the target molecules and / or test molecules described herein can be placed. In some embodiments, the cell extract is a lysate, such as a bacterial cell extract, fungal cell extract, animal tissue or cell extract, or plant tissue or cell extract.
[0057] As used herein, the terms “comprising,” “including,” “having,” “has,” “may,” “contain,” and variations thereof are intended as open-ended transitional phrases, terms, or words that do not preclude the possibility of additional actions or structures. Unless expressly provided otherwise in the context, the singular forms “a,” “an,” and “the” include the plural referent. This disclosure also considers other instances of “comprising” the situations or elements presented herein, “consisting of,” and “substantially consisting of,” whether or not explicitly stated.
[0058] With regard to the description of numerical ranges in this document, each intermediate number within the range having the same precision is explicitly included. For example, for the range of 6 to 9, the numbers 7 and 8 are included in addition to 6 and 9, and for the range of 6.0 to 7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly included.
[0059] As used herein, the terms “about” or “approximately” mean that a particular value, as determined by those skilled in the art, is within an acceptable margin of error, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” may mean within three or more standard deviations, according to practice in the art. Alternatively, “about” may mean a range of up to 20%, preferably up to 10%, more preferably up to 5%, and even more preferably up to 1%, of a given value. Or, particularly for biological systems or processes, the term may mean within an order of magnitude of a value, preferably within five times, more preferably within two times.
[0060] The term "antibody" as used herein is used in the broadest sense and encompasses a wide variety of antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies, and antibody fragments, provided they exhibit the desired antigen-binding activity. Non-limiting examples of antibody fragments include Fv, Fab, Fab', Fab'-SH, and F(ab'). 2、 Diabodies, linear antibodies, single-chain antibody molecules (e.g., scFv), and multispecific antibodies formed from antibody fragments.
[0061] As used herein, the term "liquidation agent" refers to a substance that disrupts the structure of macromolecules, such as proteins and nucleic acids (e.g., DNA and RNA), and / or denatures them. In some embodiments, the liquidation agent interferes with intermolecular and / or intramolecular interactions mediated by noncovalent forces, such as hydrogen bonds, van der Waals forces, and hydrophobic effects.
[0062] As used herein, the term “contact” a sample (e.g., a cell-free sample) refers to exposing a sample to molecules, such as test molecules. This contact can be achieved using any suitable method. For example, but not by limitation, “contact” can be achieved by adding molecules (e.g., test molecules) to a sample (e.g., a container holding the sample).
[0063] As used herein, the term "fluorescent molecule" refers to any molecule that emits a fluorescent signal. In some embodiments, fluorescence emission occurs upon illumination with light of a specific wavelength. An example of a naturally occurring fluorescent protein is green fluorescent protein (GFP). However, in some embodiments, the test molecule or target molecule may be adapted to emit a fluorescent signal via the introduction of an encoded fluorescent tag, for example, by fusing a protein sequence with a target protein to induce fluorescence. In some embodiments, the test molecule or target molecule may emit a fluorescent signal by binding to a fluorescent ligand. Non-limiting examples of such encoded fluorescent tags include, but are not limited to, Halo tags, SNAP tags, CLIP tags, TMP tags, and SunTags. Alternatively or additionally, the test molecule or target molecule may be adapted to emit a fluorescent signal via coupling with a fluorescent dye molecule (e.g., an amine or thiol-reactive dye). Alternatively or additionally, the test molecule or target molecule may be adapted to emit a fluorescent signal via coupling with a fluorescent artificial material, such as polystyrene beads, quantum dots, and / or nanodiamonds.
[0064] As defined in this article, molecular "motion" refers to the temporal changes in the position, orientation, conformation, and / or intermolecular bonding of molecules.
[0065] In some implementations, molecular motion can be quantified by analyzing changes in spatial coordinates at consecutive time points, such as analyzing spatiotemporal trajectories. Motion characterized in this way may also include, but is not limited to, measurements of diffusion coefficients. For example, but not limited to, the measurement may be a measurement of the maximum likelihood estimate of the diffusion coefficient, defined as an estimate of the maximum likelihood diffusion coefficient of multiple spatiotemporal trajectories under a single-state diffusion model with constant localization error. In some implementations, molecular motion can be measured by analyzing the product of link generation algorithms. Motion characterized in this way may include, but is not limited to, the average posterior diffusion coefficient or the average of the posterior probability distributions of coefficients from probabilistic linking algorithms. Motion characterized in this way may include, but is not limited to, the geometrically averaged posterior diffusion coefficient or the average of the log-scaled posterior probability distributions of coefficients from probabilistic linking algorithms. Motion characterized in this way may include, but is not limited to, measurements of jump length distributions. For example, for a given set of protein displacements between one time point and subsequent time points, a histogram of the probability of each displacement length (“jump length”) can be constructed. The quantiles of this distribution can be used to describe molecular motion. In some implementations, the quantile used is the median of the jump length distribution. In some embodiments, the quantile used is the third quartile of the jump length distribution. Motion characterized in this way may include, but is not limited to, measurements of mean square displacements, defined by the average of the squares of all displacements in a spacetime trajectory averaged over multiple spacetime trajectories. Motion characterized in this way may also include, but is not limited to, measurements of spacetime trajectory lengths or spacetime trajectory length distributions. Motion characterized in this way may also include, but is not limited to, measurements of the mean radius of gyration, defined by the root mean square distance between all coordinates in the spacetime trajectory and the centroid of the set of points contained in the spacetime trajectory, averaged over multiple spacetime trajectories. Motion characterized in this way may also include, but is not limited to, measurements of the mean bond angle, defined by the angle formed by three consecutive spatial coordinates averaged over multiple spacetime trajectories. In some embodiments, molecular motion can be measured by performing model correlation analysis on multiple spacetime trajectories. Motion characterized in this way may include, but is not limited to, the fraction of immobile molecules defined by a two-state model fitting (“…”). f 结合 ”).
[0066] As used herein, the term "motion" encompasses changes in the direction of a target's travel, as well as changes in its speed and duration (increases or decreases). Therefore, in some embodiments, tracking motion may include determining that the target is not moving, for example, when the target is in or substantially in a static binding state. As described above, this motion can be characterized in a variety of ways, including but not limited to quantifying (a) the diffusion coefficients of multiple spatiotemporal trajectories obtained from the maximum likelihood estimator; (b) the geometric mean posterior diffusion coefficients of multiple spatiotemporal trajectories; (c) the median of the jump length distributions of multiple spatiotemporal trajectories; (d) the third quartile of the jump length distributions of multiple spatiotemporal trajectories; (e) the median radius of gyration of multiple spatiotemporal trajectories; (f) the mean posterior diffusion coefficients of multiple spatiotemporal trajectories; (g) the median bond angle of multiple spatiotemporal trajectories; (i) the spatiotemporal trajectory lengths of multiple spatiotemporal trajectories; (j) the anisotropic decay time; (k) the state occupancy obtained by inference; (l) the spatial range of detection; (m) the number and wavelength of the conjugated fluorescent tags; (n) the occupancy rate of different diffusion states obtained from the state array; and / or (o) the polarization of the conjugated fluorescent tags.
[0067] As used herein, the term "spatiotemporal trajectory" refers to a set of spatial coordinates linked in time to the observed position of a molecule. In some implementations, multiple spatiotemporal trajectories can be constructed algorithmically by linking multiple molecules whose positions are determined at consecutive time points. In some implementations, when no other feasible links exist, multiple spatiotemporal trajectories can be conservatively constructed by linking only points within a fixed search radius. In some implementations, multiple spatiotemporal trajectories can be constructed probabilistically.
[0068] In some implementations, molecular motion can be quantified by analyzing changes in the rotational motion of molecules at consecutive time points. For example, but not by limitation, motion characterized in this way can be determined as a measurement of fluorescence polarization. Fluorescence polarization is a measurement of the change in the dipole moment orientation of a fluorescent molecule (e.g., coupled to a target or test molecule) over the time interval between an absorption event and an emission event. For example, but not by limitation, if a fluorophore is excited with polarized light, a slowly rotating molecule containing that fluorophore will emit more light that retains its original polarization than a rapidly rotating molecule. Therefore, by measuring fluorescence polarization, it is possible to determine the rotational motion of the target or test molecule and use this information to calculate the measurement result of the rotational motion.
[0069] In some embodiments, the measurement of the rotational motion described herein is calculated as a function of the anisotropic decay time. The system described herein allows the detection of the anisotropic decay time and can use strategies known in the art, such as those outlined in "Time-Dependent Anisotropy Decays" (Lakowicz, JR (ed.) Principles of Fluorescence Spectroscopy. Springer, Boston, MA. https: / / doi.org / 10.1007 / 978-0-387-46312-4_11), which is incorporated herein by reference in its entirety. In some embodiments, the measurement of the rotational motion described herein is calculated as a function of the intensity change of fluorescence polarization. The system described herein allows the detection of the intensity change of fluorescence polarization, which can then be calculated using strategies known in the art. In some embodiments, the measurement of the rotational motion described herein is calculated as a function of the relaxation time of rotational diffusion. The system described herein allows the detection of the intensity change of the relaxation time of rotational diffusion, which can then be calculated using strategies known in the art.
[0070] In some embodiments, the motion of a target molecule can be quantified by analyzing conformational changes at consecutive time points. In some embodiments, motion characterized in this way may include, but is not limited to, measurements of changes in the secondary, tertiary, and quaternary structures of the target protein, such as folding and unfolding processes and / or the remodeling of the target protein's internal conformation.
[0071] In some embodiments, molecular motion can be quantified by analyzing changes in intermolecular binding of target molecules at consecutive time points. In some embodiments, motion characterized in this way may include, but is not limited to, measurements of homologous or heterologous binding events, such as oligomerization processes.
[0072] As used herein, detected motion (including, but not limited to, any change in motion) can occur in response to any environmental or other factor (e.g., the presence of the test molecule). For example, but not as a limitation, motion or lack thereof can be induced by: (A) the addition of molecules; (B) changes in temperature; (C) changes in oxygen concentration, such as the introduction of hypoxic conditions; (D) mechanical stress; (E) changes in pH; (F) changes in light exposure (e.g., increases or decreases in intensity); (G) changes in solution composition, such as changes in viscosity and flow rate; and / or (H) changes in electrical or ionic stimulation.
[0073] As used herein, the term "multiple" refers to a number greater than one. In some embodiments, the term "multiple target molecules" refers to a number greater than one target molecule. For example, but not by limitation, "multiple target molecules" can include at least about 10, at least about 50, at least about 100, at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, at least about 1000, at least about 5,000, at least about 10,000, at least about 50,000, at least about 100,000, at least about 500,000, or at least about 1,000,000 target molecules. In some embodiments, the term "multiple test molecules" refers to a number greater than one test molecule. For example, but not as a limitation, multiple test molecules may include at least about 10, at least about 50, at least about 100, at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, at least about 1000, at least about 5,000, at least about 10,000, at least about 50,000, at least about 100,000, at least about 500,000, or at least about 1,000,000 test molecules.
[0074] As used herein, “intrinsically disordered protein” (IDP) or “intrinsically disordered region” (IDR) refers to protein and peptide fragments of various lengths that do not exist in a stable folded structural form. These structures can be defined under physiological conditions using classic structural biology tools such as X-ray crystallography and electron microscopy. See, for example, Uversky and Dunker, 2010 Biochimica et Biophysica Acta (1804: 1231-1264) (doi:10.1016 / j.bbapap.2010.01.017) and van der Lee et al., 2014 Chemical Reviews (114:6589-6631) (doi:10.1021 / cr400525m). As used herein, the term "high-throughput" in connection with the compositions, methods, and systems described herein refers to the ability to rapidly process multiple samples. For example, but not as a limitation, the high-throughput compositions, methods, and systems described herein can be configured to utilize a variety of sample processing plates, including 6-well plates, 12-well plates, 24-well plates, 48-well plates, 96-well plates, 384-well plates, 1536-well plates, or other multi-well plates capable of accommodating any number of separated samples. Furthermore, in some embodiments, the high-throughput compositions, methods, and systems of this disclosure can be configured to utilize robotic sample and plate processing, as well as other computer-controlled sample and plate processing strategies. In some embodiments, high-throughput systems include, but are not limited to, microfluidic flow chambers. In some embodiments, high-throughput methods include, but are not limited to, the use of microfluidic flow chambers.
[0075] 2. Molecules This disclosure provides a high-throughput method for characterizing individual target molecules in cell-free systems. In some embodiments, this disclosure provides a high-throughput method for characterizing individual target molecules in the presence of test molecules in a cell-free system. In some embodiments, the target molecule and / or test molecule to be analyzed by this disclosure can be any chemically defined entity.
[0076] In some embodiments, the target molecule and / or test molecule may be an organic molecule less than about 10 kDa, less than about 5 kDa, less than about 1 kDa, less than about 250 Da, or less than about 100 Da. In some embodiments, the target molecule and / or test molecule may be an inhibitor or an agonist. For example, but not as a limitation, the target molecule and / or test molecule may be a kinase inhibitor, such as a tyrosine kinase inhibitor.
[0077] In some embodiments, the target molecule and / or test molecule is a protein. In some embodiments, the target molecule and / or test molecule is a protein comprising a naturally occurring, such as wild-type, amino acid sequence or fragment thereof. In some embodiments, the target molecule and / or test molecule is a fusion of two or more proteins or fragments thereof. In some embodiments, the target molecule and / or test molecule is a protein comprising one or more artificial, i.e., non-naturally occurring amino acid sequences. In some embodiments, the target molecule and / or test molecule is a protein comprising naturally and / or non-naturally modified proteins, such as lipoprotein conjugates, glycoproteins, and artificially modified proteins, such as dye-conjugated proteins and drug-conjugated proteins (including antibody-drug conjugates). In some embodiments, proteins that can be analyzed by the methods of this disclosure may include at least about 20, at least about 30, at least about 40, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, at least about 100, at least about 200, at least about 300, at least about 400, at least about 500, at least about 1,000, at least about 5,000, at least about 10,000, at least about 15,000, at least about 20,000, or at least about 30,000 amino acids. In some embodiments, proteins that can be analyzed using the high-throughput methods of this disclosure include any protein, including but not limited to proteins containing one or more disulfide bonds, including multi-chain polypeptides containing one or more inter-chain and / or intra-chain disulfide bonds, and multi-chain polypeptides without intra-chain disulfide bonds.
[0078] In some embodiments, the target protein and / or test protein of this disclosure may be a signaling protein, such as a protein hormone, cytokine, kinase, phosphatase, receptor, or other enzyme or transcription factor. In some embodiments, the target protein and / or test protein of this disclosure is a receptor. In some embodiments, the target protein and / or test protein of this disclosure is an enzyme. In some embodiments, the target protein and / or test protein of this disclosure is a contractile protein. In some embodiments, the target protein and / or test protein of this disclosure is a structural protein. In some embodiments, the target protein and / or test protein of this disclosure is a storage protein. In some embodiments, the target protein and / or test protein of this disclosure is a transport protein. In some embodiments, the target protein and / or test protein of this disclosure is an ion channel. In some embodiments, the target protein and / or test protein of this disclosure is an antibody or antibody fragment.
[0079] In some embodiments, the target protein and / or test protein may include one or more disordered domains. For example, but not by limitation, the target protein and / or test protein may include at least one polypeptide fragment lacking a stable three-dimensional structure. In some embodiments, the target protein and / or test protein may include one or more structural domains and one or more disordered domains. In some embodiments, the target protein and / or test protein may not include structured domains. Non-limiting examples of proteins containing disordered domains include glucocorticoid receptors, growth hormone receptors, cell tumor antigen p53, T cell surface glycoprotein CD4, SHC converting protein 1, estrogen receptors, vitamin D3 receptors, cyclin-H, serine / threonine protein kinase pim-1, aryl hydrocarbon receptors, androgen receptors, cryptochrome-2, T cell surface glycoprotein CD3 δ chain, sulfotransferase 2B1, DNA repair protein RAD52 homologs, huntingtin-interacting protein K, and Ras-associated protein Ral-A. Additional non-limiting examples of proteins containing disordered domains are disclosed in the databases and references listed in Uversky and Dunker 2010 Biochimica et Biophysica Acta (1804: 1231-1264) (doi:10.1016 / j.bbapap.2010.01.017) and van der Lee et al., 2014 Chemical Reviews (114:6589-6631) (doi:10.1021 / cr400525m), the full text of which is disclosed herein by reference.
[0080] In some embodiments, the target molecule and / or test molecule is a peptide. For example, but not as a limitation, peptides that can be analyzed by the methods of this disclosure may include about 2, about 5, about 10, about 15, about 20, about 25, about 30, about 35, or about 40 amino acids. In some embodiments, the target molecule and / or test molecule is a peptide containing non-natural amino acids or other modifications.
[0081] In some embodiments, the target molecule and / or test molecule is a nucleic acid. In some embodiments, the nucleic acid may have a defined sequence. In some embodiments, the nucleic acid includes: (A) ribonucleic acid (RNA), including, for example, modified RNA; (B) deoxyribonucleic acid (DNA), including, for example, modified DNA; and (C) a combination of (A) and (B). In some embodiments, the nucleic acid includes one or more artificial nucleic acids, including, for example, morpholinonucleotides, locked nucleic acids (LNAs), peptide nucleic acids (PNAs), and xeno nucleic acids (XNAs). In some embodiments, the nucleic acid will be a single-stranded or double-stranded small interfering ribonucleic acid (e.g., double-stranded siRNA), antisense oligonucleotides, ribozymes, microRNAs, or aptamers. In some embodiments, the nucleic acid molecule may be linear or circular. In some embodiments, the nucleic acid may contain naturally occurring or non-naturally occurring nucleotides. Non-limiting examples of non-naturally occurring nucleotides include modified nucleotide bases having a derived sugar or phosphate backbone linked or chemically modified residues.
[0082] In some embodiments, the target molecule and / or test molecule is a carbohydrate. In some embodiments, the carbohydrate may be a monosaccharide (e.g., glucose, fructose, xylose, ribose, and galactose), a disaccharide (e.g., sucrose), or an oligosaccharide or polysaccharide (e.g., cellulose and starch).
[0083] In some embodiments, the target molecule and / or test molecule is a lipid. For example, but not by limitation, lipids can be triglycerides, phospholipids, and / or sterols.
[0084] In some embodiments, the target molecule and / or test molecule is a component comprising a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts, or animal extracts. In some embodiments, the bacterial extracts, cell extracts, tissue extracts, plant extracts, or animal extracts are lysates. In some embodiments, the target molecule and / or test molecule is a component comprising a mixture of serum, blood, and other biological samples. In some embodiments, the target molecule and / or test molecule is a component comprising a mixture of one or more buffer solutions and / or glycerol.
[0085] In some implementations, the target molecule can be a wild-type form of the target molecule, for example, the target molecule can be a protein that is in the wild-type form.
[0086] In some embodiments, the target molecule may be a modified form of the target molecule. For example, but not limited to, the modified form of the target molecule may be a mutant form of the target molecule. For example, but not limited to, the target molecule may be a protein that is a mutant form of the protein. In some embodiments, the mutant form of the protein, compared to the wild type of the protein, includes at least one amino acid substitution (e.g., at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten or more amino acid substitutions). In some embodiments, the modified target molecule may be a post-translational modified form of the target protein. In some embodiments, post-translational modifications include, but are not limited to, glycosylation, acetylation, phosphorylation, methylation, glycosylation, and lipidation. Additional non-limiting examples of post-translational modifications are disclosed in Ramazi and Zahiri, Database (Oxford):baab012 (2021), the entire contents of which are disclosed herein by reference in their entirety. In some embodiments, the modified target molecule may be a protein containing non-natural amino acids. In some embodiments, the modified target molecule may be a protein containing artificially modified non-natural amino acids. In some embodiments, the modified target molecule may comprise conjugates, such as protein conjugates, like fusion proteins and proteins operatively linked to non-protein compositions.
[0087] In some embodiments, the target molecule is a homolog of the target molecule. In some embodiments, the target molecule is a direct homolog of the target molecule. In some embodiments, the target molecule is a paralog of the target molecule.
[0088] In some embodiments, the target molecule and / or test molecule may be present in a mixture of molecules, such as in a mixture with a defined composition. For example, but not as a limitation, the target molecule may be present in a mixture (e.g., a sample) comprising one or more different target molecules, such as one or more target proteins, one or more target peptides, one or more target organic molecules less than 1 kDa, one or more target carbohydrates, one or more target lipids, one or more target nucleic acids, one or more target proteins, one or more target peptides, one or more target organic molecules less than 1 kDa, one or more target carbohydrates, one or more target lipids, and / or one or more target nucleic acids. In some embodiments, the sample or mixture may include a first target molecule and a second target molecule. In some embodiments, the first target molecule and the second target molecule are different kinds of target molecules. In some embodiments, the first target molecule and the second target molecule are target molecules in the same or different conformational states. In some embodiments, the distinction between the first target molecule and the second target molecule is achieved by a difference in their labeling, such as a difference in fluorescent labeling. In some embodiments, more than two target molecules are analyzed, such as three or more target molecules. In some embodiments, the target molecules may be labeled. For example, but not as a limitation, the target molecules may be fluorescently labeled, for example, for detection using the exemplary methods of this disclosure. In some embodiments, target molecules can be labeled by adding fluorescent proteins or tags that promote fluorescent labeling. Non-limiting examples of such fluorescent proteins include: green fluorescent protein (GFP), Venus, monomeric infrared fluorescent protein (mIFP), long Stokes shift monomeric orange (LssmOrange), labeled red fluorescent protein 657 (TagRFP657), monomeric orange 2 (mOrange2), monomeric apple (mApple), sapphire, monomeric labeled blue fluorescent protein (mTagBFP2), tdTomato, monomeric cherry (mCherry), enhanced yellow fluorescent protein (EYFP), monomeric cerulean 3 (mCerulean3), and enhanced green fluorescent protein (EGFP). Non-limiting examples of tags that promote fluorescent labeling include: Halo tags, SNAP tags, CLIP tags, TMP tags, and SunTag. In some embodiments, target molecules can be labeled with fluorescent artificial materials, such as polystyrene beads, quantum dots, and / or nanodiamonds, to emit fluorescent signals. In some embodiments, the target molecule may be tagged with common tags used for recombinant protein expression, non-limiting examples including His tags, GST tags, FLAG tags, HA tags, and Avi tags. In some embodiments, the target molecule may be biotinylated and tagged with avidin and its derivatives.In some embodiments, the target molecule can be labeled via a ligand, non-limiting examples including natural or non-natural ligands that can bind to a protein or tag. In some embodiments, the target molecule can be labeled via an antibody. In some embodiments, the target molecule can be labeled via a chemical reaction, non-limiting examples including NHS-mediated conjugation and maleimide-mediated conjugation. In some embodiments, the target molecule can be labeled via a chemical reaction specific to an incorporated non-natural amino acid. In some embodiments, the target molecule can be labeled via non-specific absorption. In some embodiments, the target molecule can be labeled by conjugation with synthetic nanomaterials or polymers.
[0089] Alternatively or additionally, the test molecules can be labeled. For example, but not as a limitation, the test molecules can be fluorescently labeled, for example, for detection using the exemplary methods of this disclosure. In some embodiments, the test molecules can be labeled via fluorescent proteins. Non-limiting examples of such fluorescent proteins include: green fluorescent protein (GFP), Venus, monomeric infrared fluorescent protein (mIFP), long Stokes shift monomeric orange (LssmOrange), labeled red fluorescent protein 657 (TagRFP657), monomeric orange 2 (mOrange2), monomeric apple (mApple), sapphire, monomeric labeled blue fluorescent protein (mTagBFP2), tdTomato, monomeric cherry (mCherry), enhanced yellow fluorescent protein (EYFP), monomeric cerulean 3 (mCerulean3), and enhanced green fluorescent protein (EGFP). Non-limiting examples of tags that can facilitate fluorescent labeling include: Halo tags, SNAP tags, CLIP tags, TMP tags, and SunTag. In some embodiments, the test molecule can be labeled with fluorescent artificial materials, such as polystyrene beads, quantum dots, and / or nanodiamonds, to emit a fluorescent signal. In some embodiments, the test molecule can be labeled via a ligand, with non-limiting examples including natural or non-natural ligands. In some embodiments, the test molecule can be labeled via an antibody. In some embodiments, the test molecule can be labeled via a chemical reaction, with non-limiting examples including NHS-mediated conjugation and maleimide-mediated conjugation. In some embodiments, the test molecule can be labeled via non-specific absorption. In some embodiments, the test molecule can be labeled by conjugation with synthetic nanomaterials or polymers.
[0090] In some embodiments, the target molecule and / or test molecule can be purified. For example, but not as a limitation, the target molecule and / or test molecule can be purified from at least some of the components initially generated or associated with it. In some embodiments, the purified target molecule and / or purified test molecule is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99% pure. For example, but not as a limitation, the target and / or test protein or peptide can be purified from the cell (and its components) expressing it. In some embodiments, the target molecule and / or test molecule can be partially purified. In some embodiments, the target molecule and / or test molecule can be a partially purified extract from a biological sample. In some embodiments, the target molecule and / or test molecule can be a crude extract from a biological sample. In some embodiments, the target molecule and / or test molecule can be a crude biological sample, with non-limiting examples including cell culture media, saliva, blood, serum, and other bodily fluids. In some embodiments, the extract is a lysate (e.g., cell or tissue lysate).
[0091] 3. SMT method for biophysical analysis This disclosure provides methods, such as high-throughput methods, for analyzing single molecules in cell-free samples. In some embodiments, this disclosure provides methods for determining the motion of a target molecule. In some embodiments, the motion of the target molecule is performed by tracking the target molecule over time to provide measurements of multiple spatiotemporal trajectories and / or rotational motions. Such motion can be performed with or without other sample components, such as test molecules or specific sample solutions.
[0092] In some implementations, the motion of the target molecule is determined by analyzing multiple spatiotemporal trajectories and / or measurements of rotational motion detected by the methods described herein. For example, but not as a limitation, such analysis can resolve motions determined to be: (a) diffusion coefficients of multiple spatiotemporal trajectories obtained from maximum likelihood estimates; (b) geometrically mean posterior diffusion coefficients of said multiple spatiotemporal trajectories; (c) the median of the jump length distributions of said multiple spatiotemporal trajectories; (d) the median radius of gyration of said multiple spatiotemporal trajectories; (e) the mean posterior diffusion coefficients of said multiple spatiotemporal trajectories; (f) the mean square displacements of said multiple spatiotemporal trajectories; (g) the median bond angles of said multiple spatiotemporal trajectories; (i) the spatiotemporal trajectory lengths of said multiple spatiotemporal trajectories; (j) the anisotropic decay time; (k) the state occupancy obtained by inference; (l) the spatial range of detection; (m) the number and wavelength of conjugated fluorescent tags; (n) the occupancy rates of different diffusion states obtained from the state array; and / or (o) the polarization of the conjugated fluorescent tags.
[0093] The sensitivity of the currently disclosed method provides observation of changes in the motion of the target molecule compared to the motion of a reference target molecule. In some embodiments, the motion of the reference target molecule can be the motion of the target molecule in the absence of a test molecule. In some embodiments, the motion of the reference target molecule can be the motion of the target molecule in the presence of a reference solution. In some embodiments, the motion of the reference target molecule can be the motion of a target molecule in a different form than the target molecule analyzed by the method of this disclosure. In some embodiments, the motion of the reference target molecule can be the motion of a target molecule in the same form as the target molecule analyzed by the method of this disclosure.
[0094] In some embodiments, the motion of the target molecule is determined as a diffusion coefficient associated with the target molecule. In some embodiments, the motion (e.g., diffusion coefficient) of the target molecule determined by the methods of this disclosure (e.g., high-throughput methods) can be used to identify the target molecule in cell-free samples and / or to identify interactions between the target molecule and other molecules, such as test molecules or other solution components.
[0095] In some embodiments, the motion of the target molecule and the motion of the reference target molecule are determined as the diffusion coefficient. In some embodiments, the variation in the diffusion coefficient between the target molecule and the reference target molecule is at least about 0.001%. For example, but not as a limitation, the variation in the diffusion coefficient observed by the disclosed methods is at least about 0.001%, at least about 0.005%, at least about 0.01%, at least about 0.05%, at least about 0.1%, at least about 0.5%, at least about 1%, at least about 1.5%, at least about 2%, at least about 2.5%, at least about 3%, at least about 3.5%, at least about 4%, at least about 4.5%, at least about 5%, at least about 5.5%, at least about 6%, at least about 6.5%, at least about 7%, at least about 7.5%, at least about 8%, at least about 8.5%, at least about 9%, at least about 9.5%, or at least about 10%. In some embodiments, the variation in the diffusion coefficient compared to the reference diffusion coefficient is at least about 0.001%. In some embodiments, the variation in the diffusion coefficient compared to the reference diffusion coefficient is at least about 0.005%. In some embodiments, the diffusion coefficient changes by at least about 0.01% compared to a reference diffusion coefficient. In some embodiments, the diffusion coefficient changes by at least about 0.05% compared to a reference diffusion coefficient. In some embodiments, the diffusion coefficient changes by at least about 0.1% compared to a reference diffusion coefficient. In some embodiments, the diffusion coefficient changes by at least about 0.5% compared to a reference diffusion coefficient. In some embodiments, the diffusion coefficient changes by at least about 1% compared to a reference diffusion coefficient. In some embodiments, the diffusion coefficient changes by at least about 2% compared to a reference diffusion coefficient. In some embodiments, the diffusion coefficient changes by at least about 3% compared to a reference diffusion coefficient. In some embodiments, the diffusion coefficient changes by at least about 4% compared to a reference diffusion coefficient. In some embodiments, the diffusion coefficient changes by at least about 5% compared to a reference diffusion coefficient. In some embodiments, the diffusion coefficient changes by at least about 6% compared to a reference diffusion coefficient. In some embodiments, the diffusion coefficient changes by at least about 7% compared to a reference diffusion coefficient. In some embodiments, the diffusion coefficient changes by at least about 8% compared to a reference diffusion coefficient. In some embodiments, the diffusion coefficient changes by at least about 9% compared to a reference diffusion coefficient. In some implementations, the diffusion coefficient varies by at least about 10% compared to the reference diffusion coefficient.
[0096] In some embodiments, the expected diffusion coefficients of the target molecule and the test molecule are estimated. In some embodiments, for each frame rate, the diffusion coefficients of the target molecule and / or the test molecule are measured using optimized tracking settings (e.g., search radius). In some embodiments, the diffusion coefficient measured for each molecule using optimized tracking settings is used to fit an estimated Stokes radius for each molecule under experimental conditions. In some embodiments, the estimated Stokes radius is used to estimate the expected diffusion coefficients of the target molecule and the test molecule. In some embodiments, a comprehensive tracking model is used to estimate the expected diffusion coefficients of the target molecule and the test molecule. In some embodiments, the comprehensive tracking model considers skip cutoff, tracking error, and other effects. In some embodiments, a comprehensive tracking model and the estimated Stokes radius are used to estimate the expected diffusion coefficients of the target molecule and the test molecule.
[0097] 3.1 Analyze the form of the target molecule This disclosure provides methods, such as high-throughput methods, for analyzing the motion of target molecules to determine their form. As used herein, “form” is not limited to the three-dimensional conformation of the target molecule, but encompasses additional options. For example, but not as a limitation, a target molecule may present in multiple forms depending on its properties; for instance, a protein target molecule may have a wild-type form, but may also have one or more modified forms, including but not limited to mutant forms, post-translational modified forms, alternative splicing forms, or conjugated forms. For example, but not as a limitation, the methods disclosed herein may allow determination of whether a target molecule is a post-translational modified form of a target molecule (e.g., a post-translational modified form of a target protein), whether a target molecule is an alternatively spliced form of a target molecule (e.g., an alternatively spliced form of a target protein), whether a target molecule has a specific conformation (e.g., an open conformation or a closed conformation of a target protein), a wild-type form of a target molecule (e.g., a wild-type form of a target protein), a mutant form of a target molecule (e.g., a mutant form of a target protein), a homolog of a target molecule (e.g., a homolog of a target protein), an ortholog of a target molecule (e.g., an ortholog of a target protein), a paralog of a target molecule (e.g., a paralog of a target protein), or an artificially modified form of a target molecule (e.g., an artificially modified form of a target protein).
[0098] In some embodiments, methods for analyzing the motion of target molecules to determine the form of the target molecule (e.g., high-throughput methods) may include comparing the motion of the target molecule with the motion of a reference target molecule. In some embodiments, the reference target molecule may be a different form of the target molecule being analyzed. In some embodiments, the reference target molecule may be the same form as the target molecule being analyzed.
[0099] In some embodiments, a method for determining the form of a target molecule may include: (a) tracking a plurality of target molecules in a cell-free sample over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (b) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the target molecule; and (c) comparing the motion of the target molecule obtained in (b) with the motion of a reference target molecule, wherein the motion of the reference target molecule is a form of motion of the target molecule; wherein: (i) a change in the motion of the target molecule compared to the motion of the reference target molecule indicates that the target molecule has a different form than the reference target molecule; or (ii) no change in the motion of the target molecule compared to the motion of the reference target molecule indicates that the target molecule has the same form as the reference target molecule. In some embodiments, the duration and / or reversibility of the change in the motion of the target molecule indicates that the target molecule has a different form than the reference target molecule. In some embodiments, the duration of the change in the motion of the target molecule indicates that the target molecule has a different form than the reference target molecule. In some implementations, the reversibility of the motion change of the target molecule, compared to the reversibility of the motion change of the reference target molecule, indicates that the target molecule has a different form than the reference target molecule.
[0100] In some embodiments, the motion of a reference target molecule compared to the motion of the target molecule can correspond to the motion of the reference target molecule, which is measured when the reference target molecule exists in a form different from that of the target molecule analyzed by the methods of this disclosure. For example, but not as a limitation, the motion of the reference target molecule can be measured under conditions in which the reference target molecule exists in a conformation different from that of the target molecule to which its motion is compared. In some embodiments, the motion of the reference target molecule corresponds to the motion of the reference target molecule when it is in the same form as that of the target molecule analyzed by the methods of this disclosure.
[0101] 3.2 Analysis of the interaction between target molecules and test solution This disclosure also provides methods for analyzing the movement of target molecules in a test solution, such as high-throughput methods. In some embodiments, the test solution is a solution of known composition. In some embodiments, a cell-free sample contains the test solution. In some embodiments, the test solution is a biological sample obtained from a subject. In some embodiments, biological samples of varying purity levels contain the test solution.
[0102] In some embodiments, the test solution includes reagents for altering the conformational and / or oxidative or charge state of the target molecule. In some embodiments, the test solution includes reagents for altering the conformational state of the target molecule (e.g., the target protein).
[0103] In some embodiments, the test solution contains one or more of the following: salts (e.g., sodium, magnesium, and calcium), buffers (e.g., acetate, citrate, bistris, carbonate, CAPS, TAPS, N,N-bis(2-hydroxyethyl)glycine, tris, tris(hydroxymethyl)methylglycine, TAPSO, HEPES, TES, MOPS, PIPES, cacodylate, SSC, MES, succinic acid, or phosphate), amino acids, acids, bases, surfactants, detergents (e.g., SDS, Triton X-100, or Tween-20), chelating agents (e.g., ethylenediaminetetraacetic acid, phosphonates, or citrate), preservatives, antibiotics, alcohols (e.g., methanol, ethanol, propanol, or isopropanol), reducing compounds, dissociating agents, viscosity modifiers, oxidizing compounds, dyes, or biomolecules (e.g., ATP, GTP, NADPH, nucleic acids, proteins, enzymes (e.g., RNase or proteinase K)).
[0104] In some embodiments, the test solution includes a reagent that reduces the structural stability of the target molecule. In some embodiments, the test solution includes a dissociating agent. Non-limiting examples of dissociating agents include n-butanol, ethanol, acetone, acetonitrile, guanidine chloride, lithium perchlorate, lithium acetate, magnesium chloride, phenol, 2-propanol, sodium dodecyl sulfate, thiourea, and urea. In some embodiments, the dissociating agent is guanidine chloride. In some embodiments, the dissociating agent is urea. In some embodiments, the dissociating agent is acetone. In some embodiments, the dissociating agent is acetonitrile.
[0105] In some embodiments, the test solution contains a reagent that accounts for the viscosity of the solution, such as a viscosity agent. In some embodiments, the viscosity agent is glycerin. In some embodiments, the viscosity agent (e.g., glycerin) is present in the solution at the following concentrations: about 1% v / v or higher, about 2% v / v or higher, about 5% v / v or higher, about 10% v / v or higher, about 15% v / v or higher, about 20% v / v or higher, about 25% v / v or higher, about 30% v / v, about 35% v / v or higher, about 40% v / v or higher, about 45% v / v or higher, about 50% v / v or higher, about 55% v / v or higher, about 60% v / v or higher, about 65% v / v or higher, about 70% v / v or higher, about 75% v / v or higher, about 80% v / v or higher, about 85% v / v or higher, about 90% v / v or higher, or about 95% v / v or higher.
[0106] In some embodiments, the test solution contains a gradient. In some embodiments, the gradient is a temperature gradient, a chemical gradient, or a combination thereof. In some embodiments, the gradient is a temperature gradient; for example, the solution may include a gradient from higher to lower temperatures. In some embodiments, the temperature gradient is formed using a laser. In some embodiments, the gradient is a chemical gradient; for example, the solution may include a gradient from higher to lower chemical concentrations.
[0107] In some embodiments, the test solution comprises at least two phases. In some embodiments, the at least two phases comprise two liquid phases. In some embodiments, the at least two phases comprise a liquid phase and a solid phase. For example, but not as a limitation, the test solution may comprise two liquid phases comprising an aqueous phase and an oil phase. Alternatively, the test solution may comprise two or more aqueous phases. In some embodiments, the test solution comprises a liquid phase and a solid phase, wherein the liquid phase is an aqueous phase and the solid phase is a precipitate. In some embodiments, the test solution comprises a liquid phase and a solid phase, wherein the liquid phase is an aqueous phase and the solid phase is an aggregate. In some embodiments, the test solution comprises cells or other solid particles. In some embodiments, the methods of this disclosure allow for the determination of the movement of target molecules at and / or across the interface between the two phases of the solution.
[0108] In some embodiments, the test solution actively flows through the interrogation area of the equipped device. For example, but not limited to, the flow of the test solution can be controlled by a flow-through microfluidic chip. In some embodiments, the flow is controlled using a peristaltic pump or a syringe pump. In some embodiments, the microfluidic chip contains one or more channels, one or more inlets, one or more outlets, and one or more interrogation areas. In some embodiments, the microfluidic chip is composed of glass and / or polymers, but is not limited thereto. In some embodiments, the microfluidic flow profile is controlled by sheath flow, but is limited thereto.
[0109] In some embodiments, the test solution is a homogeneous solution. For example, but not as a limitation, the test solution may have a homogeneous composition. In some embodiments, the concentration of a component, such as a chemical substance or reagent as illustrated herein, is consistent throughout the solution. In some embodiments, the concentration of a viscosity agent (e.g., glycerin) is consistent throughout the test solution.
[0110] In some embodiments, the method of this disclosure includes: (a) tracking a plurality of target molecules in a test solution over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (b) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the target molecules in the test solution; and (c) comparing the motion of the target molecules obtained in (b) with the motion of a reference target molecule, wherein the motion of the reference target molecule is the motion of the target molecule in a reference solution; wherein: (i) a change in the motion of the target molecule compared to the motion of the reference target molecule indicates that the target molecule is affected by the test solution; or (ii) no change in the motion of the target molecule compared to the motion of the reference target molecule indicates that the target molecule is not affected by the test solution.
[0111] In some embodiments, the comparison in step (c) further includes comparing the duration and / or reversibility of the motion change of the target molecule with the duration and / or reversibility of the motion change of a reference target molecule. For example, but not as a limitation, the duration of the motion change of the target molecule indicates that the target molecule is affected by the test solution compared to the duration of the motion change of the reference target molecule. In some embodiments, the reversibility of the motion change of the target molecule indicates that the target molecule is affected by the test solution compared to the reversibility of the motion change of the reference target molecule.
[0112] In some embodiments, the method of this disclosure includes: (a) tracking a plurality of target molecules in a test solution over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (b) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the target molecules in the test solution; and (c) comparing the motion of the target molecules obtained in (b) with the motion of a reference target molecule, wherein the motion of the reference target molecule is the motion of the target molecule in a reference solution; wherein: the comparison in step (c) is used to determine the properties of the test solution. In some embodiments, the comparison in step (c) further includes comparing the duration and / or reversibility of the motion change of the target molecules with the duration and / or reversibility of the motion change of the reference target molecule.
[0113] In some embodiments, the defining property of the test solution is pH, ion concentration, organic molecule concentration, or viscoelasticity. In some embodiments, viscoelasticity is viscosity. In some embodiments, the properties of the test solution are used to diagnose a disease in the subject. In some embodiments, the disease is cancer.
[0114] In some embodiments, the reference solution may be a solution having the same composition as the test solution. In some embodiments, the reference solution may be a solution having the same composition as the test solution, except for one component, such as a viscosity agent or a release agent. In some embodiments, the reference solution may be a solution having a different composition than the test solution. In some embodiments, the reference solution may be a second biological sample obtained from the subject.
[0115] In some embodiments, the interaction between the target protein and the test solution leads to a conformational change in the target molecule. In some embodiments, the interaction between the target protein and the test solution is reversible. In some embodiments, the interaction between the target protein and the test solution is irreversible. In some embodiments, the conformational change in the target molecule leads to a change in the temperature stability of the target molecule.
[0116] 3.3 Analysis of the interaction between the target molecule and the test molecule Intermolecular interactions are an important aspect of biomolecular function. For example, but not as a limitation, these key interactions include antibody-antigen, enzyme-coenzyme, enzyme-cofactor, enzyme-substrate, enzyme-allosteric / orthotropic regulator, ligand-receptor, ligand-co-receptor, protein-protein, protein-DNA, protein-RNA, protein-lipid, protein-cell surface, protein-virus particle, and protein-nanoparticle interactions. This disclosure provides methods for identifying interactions between target molecules and test molecules, including high-throughput methods. In some embodiments, these methods include detecting direct or indirect interactions between target molecules and test molecules.
[0117] In some embodiments, methods for identifying interactions between target molecules and test molecules (e.g., high-throughput methods) include: (a) contacting a cell-free sample containing a plurality of target molecules with a plurality of test molecules; (b) tracking the plurality of target molecules over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (c) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the target molecules in the presence of the test molecules; and (d) comparing the motion of the target molecules obtained in (c) with the motion of a reference target molecule, wherein the motion of the reference target molecule is the motion of the target molecule in the absence of the test molecules; wherein a change in the motion of the target molecule compared to the motion of the reference target molecule indicates an interaction between the target molecule and the test molecule. In some embodiments, the duration and / or reversibility of the change in the motion of the target molecule indicates an interaction between the target molecule and the test molecule, compared to the duration and / or reversibility of the change in the motion of the reference target molecule. In some embodiments, the interaction between the target molecule and the test molecule is reversible. In some embodiments, the interaction between the target molecule and the test molecule is irreversible. In some implementations, the interaction between the target protein and the test molecule leads to the oligomerization of the target protein.
[0118] In some embodiments, the methods of this disclosure (e.g., high-throughput methods) allow for the identification of interactions between a target molecule and a test molecule that induce conformational changes in the target molecule. For example, but not as a limitation, the methods of this disclosure can be used to analyze a library of test molecules to identify test molecules that cause conformational changes in the target molecule. For example, but not as a limitation, the methods of this disclosure can identify test molecules that bind allosterically to the target molecule. In some embodiments, the methods of this disclosure can identify test molecules that bind normally to the target molecule. In some embodiments, these methods may include: (a) contacting a cell-free sample containing a plurality of target molecules with a plurality of test molecules, wherein each sample is contacted with a different test molecule; (b) tracking the plurality of said target molecules in each sample over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (c) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the target molecules in the presence of test molecules; and (d) comparing the motion of said target molecules obtained in (c) with the motion of a reference target molecule, wherein the motion of the reference target molecule is the motion of the target molecule in the presence of a test molecule that does not induce a conformational change in said target molecule; wherein the change in the motion of the target molecule, compared to the motion of the reference target molecule, indicates an interaction between the target molecule and a test molecule that induces a conformational change in the target molecule. In some embodiments, the duration and / or reversibility of the change in the motion of the target molecule indicates an interaction between the target molecule and a test molecule that induces a conformational change in the target molecule, compared to the duration and / or reversibility of the change in the motion of the reference target molecule. In some embodiments, the conformational change of the target molecule leads to a change in the temperature stability of the target molecule.
[0119] This disclosure also includes methods for determining the dose response of a target molecule to a test molecule, such as high-throughput methods. For example, but not as a limitation, the method may include: (a) contacting a plurality of cell-free samples containing a plurality of said target molecules with said test molecules, wherein the plurality of cell-free samples are contacted with a series of test molecule doses; (b) in the presence of said series of test molecules, tracking the plurality of said target molecules over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (c) in the presence of said series of test molecules, analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions of the target molecules to determine the motion of the target molecules at each dose of the test molecules; (d) comparing the motions of the target molecules obtained in (c) at different test molecule doses to determine the dose response of the target molecules to said test molecules.
[0120] This disclosure also includes methods (e.g., high-throughput methods) for determining differences in the dose responses of two target molecules to test molecules, these methods comprising: (a) contacting a first plurality of cell-free samples containing a plurality of first target molecules with test molecules, wherein the first plurality of cell-free samples are contacted with a series of test molecule doses; (b) in the presence of the series of test molecule doses, tracking the plurality of target molecules over time to provide measurements of a first plurality of spatiotemporal trajectories and / or rotational motions; and (c) in the presence of the series of test molecule doses, analyzing the plurality of spatiotemporal trajectories and / or rotational motions of the target molecules. The motion of the target molecule is measured to determine the motion of the first target molecule at each dose of the test molecule; (d) the motion of the target molecule obtained in step (c) at different doses of the test molecule is compared to determine the dose response of the target molecule to the test molecule; (e) steps (a)-(d) are repeated with a second target molecule to determine the dose response of the second target molecule to the test molecule; and (f) the dose response of the first target molecule is compared with the dose response of the second target molecule to determine the difference between the responses of the first and second target molecules to the test molecule. In some embodiments, more than two target molecules, such as three target molecules, can be analyzed.
[0121] In some embodiments, this disclosure provides methods, such as high-throughput methods, for identifying interactions between test molecules and target proteins containing disordered structural domains. In some embodiments, the target protein does not contain structured structural domains. In some embodiments, these methods include: (a) contacting a cell-free sample containing a plurality of target proteins with a plurality of test molecules; (b) tracking the plurality of said target proteins over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (c) analyzing the measurements of said plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of said target proteins in the presence of said test molecules; and (d) comparing the motion of said target proteins obtained in (c) with the motion of a reference target protein, wherein the motion of said reference target protein is the motion of said target protein in the absence of said test molecules; wherein, compared with the motion of said reference target protein, a change in the motion of said target protein containing said disordered structural domains indicates an interaction between said target protein containing said disordered structural domains and said test molecule. In some embodiments, the duration and / or reversibility of the motion change of a target protein containing a disordered domain indicates the interaction between the target protein containing the disordered domain and the test molecule, compared to the duration and / or reversibility of the motion change of a reference target protein. In some embodiments, the interaction between the target protein containing the disordered domain and the test molecule is reversible. In some embodiments, the interaction between the target protein containing the disordered domain and the test molecule is irreversible. In some embodiments, a decrease in the diffusion coefficient of a target protein containing a disordered domain, compared to the diffusion coefficient of a reference target protein, indicates the interaction between the target protein containing the disordered domain and the test molecule. In some embodiments, an increase in the diffusion coefficient of a target protein containing a disordered domain, compared to the diffusion coefficient of a reference target protein, indicates the interaction between the target protein containing the disordered domain and the test molecule.
[0122] This disclosure also provides methods for identifying test molecules capable of distinguishing at least two target molecules, such as high-throughput methods. In some embodiments, these methods include: (a) contacting a cell-free sample containing a plurality of first target molecules with a plurality of test molecules; (b) tracking the plurality of first target molecules over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (c) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the first target molecules in the presence of the test molecules; (d) contacting a cell-free sample containing a plurality of second target molecules with a plurality of test molecules; (e) tracking the plurality of second target molecules over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (f) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the second target molecules in the presence of the test molecules; and (g) comparing the motions of the target molecules obtained in (c) and (f); wherein the changes in the motions of the first and second target molecules indicate that the test molecules are capable of distinguishing the two target molecules. In some embodiments, the distinction between the first target molecule and the second target molecule is achieved through differences in their fluorescent labels. In some embodiments, more than two target molecules can be analyzed, such as three target molecules. For example, but not as a limitation, the method may also include contacting a cell-free sample containing a plurality of third target molecules with a plurality of test molecules; tracking the plurality of said third target molecules over time to provide measurements of a third plurality of spatiotemporal trajectories and / or rotational motions; analyzing the measurements of said third plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of said third target molecules in the presence of said test molecules; and comparing the motion of said third target molecules with the motion obtained in (c) and (f); wherein the change in the motion of said third target molecules relative to the first target molecule and the second target molecule indicates that the test molecules are able to distinguish the three target molecules.
[0123] This disclosure also provides methods for identifying test molecules capable of distinguishing at least two target molecules, such as high-throughput methods. In some embodiments, these methods include: (a) contacting a cell-free sample containing a plurality of first target molecules and a plurality of second target molecules with a plurality of said test molecules; (b) tracking the plurality of first target molecules over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (c) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the first target molecules in the presence of said test molecules; (d) tracking the plurality of second target molecules over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (e) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the second target molecules in the presence of said test molecules; and (f) comparing the motions of the first target molecules and the second target molecules obtained in (c) and (f); wherein the changes in the motions of the first target molecules and the second target molecules indicate that the test molecules are capable of distinguishing the two target molecules.
[0124] 3.4 Single-molecule fluorescence polarization This disclosure also provides methods for characterizing the molecular dynamics of a target molecule by utilizing the orientation-related fluorescence properties of a fluorophore sufficiently firmly attached to the target molecule. In some embodiments, the disclosed methods include detecting changes in the orientation and rotational degrees of freedom of the fluorophore during oligomer formation. In some embodiments, the disclosed methods include detecting how conformational changes affect the orientation and dynamics of a fluorophore attached to a specific site within the molecule. In some embodiments, the disclosed methods include characterizing dynamic structural transitions, such as protein folding-unfolding events or nucleic acid conformational changes. In some embodiments, the disclosed methods include time-resolved anisotropy measurements and polarization-sensitive imaging techniques combined with advanced optical control. In some embodiments, the disclosed methods include (a) time-correlated single-photon counting (TCSPC), (b) step-scan pump-probe techniques, (c) ultralong-lived fluorophores, and / or (d) advanced optical techniques.
[0125] In some embodiments, TCSPC is used to detect the arrival time of a single photon with picosecond precision. In some embodiments, TCSPC comprises a 2D TCSPC via a single-photon avalanche diode (SPAD) array and a photon counting module. In some embodiments, TCSPC is used to resolve dynamics on the nanosecond scale. In some embodiments, TCSPC is used in conjunction with a polarization-sensitive readout to study the rapid rotational dynamics and short fluorescence lifetimes characteristic of many biological fluorophores. In some embodiments, TCSPC is used to distinguish different fluorophore states and / or orientations.
[0126] In some embodiments, step-scan pump-probe technology includes modulating the polarization of the excitation and probe light, and the resulting fluorescence emission over time provides insights into the orientation / rotation and dynamics of the fluorophore. In some embodiments, step-scan pump-probe technology includes measuring polarization-dependent and time-dependent fluorescence loss dynamics using step-scan pump-probe spectroscopic microscopy. In some embodiments, step-scan pump-probe technology is used for optical filtering of subgroups with different molecular sizes, orientations, or dynamics, and / or for studying the dynamics of systems in which the fluorophore orientation changes rapidly after excitation (e.g., in protein dynamics or structural changes in membranes).
[0127] In some embodiments, ultralong-lived fluorophores exhibit fluorescence lifetimes longer than typical fluorescence decay times. In some embodiments, ultralong-lived fluorophores exhibit fluorescence lifetimes several microseconds longer than typical fluorescence decay times. In some embodiments, ultralong-lived fluorophores exhibit fluorescence lifetimes several nanoseconds longer than typical fluorescence decay times. In some embodiments, ultralong-lived fluorophores are used to significantly extend depolarization times beyond typical fluorescence times. Non-limiting examples of ultralong-lived fluorophores are carbon dots, quantum dots, and nanodiamonds. In some embodiments, ultralong-lived fluorophores are used to measure rotational dynamics and depolarization processes over extended timescales.
[0128] In some embodiments, advanced optics techniques are used for precise spatial manipulation and control of the polarization state of light. In some embodiments, advanced optics techniques include wobbling anisotropy and polarization filtering. In some embodiments, advanced optics techniques include advanced optical methods involving phase and polarization control. In some embodiments, advanced optics techniques are used to achieve high-precision polarization-dependent measurements.
[0129] 4. Systems for biophysical analysis 4.1 Image Acquisition System In some implementations, SMT workflows, such as the htSMT workflow, can be used to implement various aspects of the current subject, where such workflows are combined with systems for image acquisition. For example, such image acquisition can combine imaging of samples to generate a series of images and / or videos. In some embodiments, an exemplary image acquisition system includes: a light source configured to emit light relayed by one or more optical elements in an optical repeater configured to shape the light emitted from the light source to form a shaped beam such that the shaped beam has uniform intensity along a longer dimension of a linear shape; an optical element, such as a galvanometer, configured to translate the shaped beam and may be located before or after the optical repeater configured to form the shaped beam such that the shaped beam has uniform intensity along a longer dimension of a linear shape; and one or more optical elements, such as a dichroic mirror (2-100), configured to guide the shaped beam to an objective lens, whereby a portion of a sample plane is illuminated by the tilted beam, resulting in light emission (e.g., fluorescence emission) from the sample, which is focused by the objective lens and passes through a series of optical elements, such as lenses and emission filters, to reach the image acquisition system.
[0130] In some embodiments, a microscope system for performing the methods of this disclosure may include (a) a stage for supporting a cell-free sample, wherein the cell-free sample contains a target molecule (e.g., a fluorescent molecule); (b) a light source for emitting a light beam capable of inducing a light-based response from the target molecule (e.g., a fluorescent molecule) in the cell-free sample; (c) an objective lens for focusing the light beam onto the cell-free sample in a sample plane, wherein the target molecule (e.g., a fluorescent molecule) in the sample is placed in a field of view in the sample plane; (d) a detector device for monitoring the light-based response from the target molecule (e.g., a fluorescent molecule) over a period of time (e.g., in the presence of a test molecule); (e) a memory; and (f) a processor in communication with the memory and the detector device. In some embodiments, the processor is capable of determining the diffusion coefficient of the target molecule (e.g., a fluorescent molecule) and comparing it with a reference diffusion coefficient. In some embodiments, the processor is capable of determining the diffusion coefficient of the target molecule (e.g., a fluorescent molecule) in the presence of a test molecule. In some embodiments, the reference diffusion coefficient is the diffusion coefficient of the target molecule (e.g., a fluorescent molecule) in the absence of a test molecule.
[0131] 4.2 Light Source In some embodiments, the system of this disclosure includes a light source configured to emit light. In some embodiments of the image acquisition system disclosed herein, the light source may be configured to emit light of a single wavelength. In some embodiments of the image acquisition system disclosed herein, the light source may be configured to emit light of two, three, four, five, or more individual wavelengths. In some embodiments, the wavelength of the light emitted by the light source is predetermined. For example, but not as a limitation, the wavelength may be predetermined such that the emitted light induces fluorescence emission when irradiating a sample, such as a sample containing fluorescent molecules (e.g., fluorescent target molecules and / or fluorescent test molecules). In some embodiments, the wavelengths used in relation to the methods described herein will be in the range of 400 nm to 900 nm. In some embodiments, the light source will emit light with wavelengths between 400 nm and 408 nm, between 550 nm and 565 nm, or between 638 nm and 650 nm. In some non-limiting embodiments, the light source is configured to include three lasers with nominal center wavelengths of 405 nm, 560 nm, and 640 nm, which may vary within the absorption band of the fluorophore used. In some implementations, a 560 nm wavelength is used to excite dyes (e.g., JF549) linked to HaloTag or SortaseTag. In other cases, 642 nm or 646 nm wavelengths are used to excite dyes (e.g., JF549) linked to HaloTag. 646 ).
[0132] In some non-limiting embodiments, the light source is used to catalyze photochemical reactions. For example, but not as a limitation, the wavelength and illumination intensity can cause chemical bonds to break. As an additional example, but not as a limitation, the wavelength and illumination intensity can induce a nonradiative dark state (i.e., "photobleaching of molecules"). As an additional example, but not as a limitation, the wavelength and illumination intensity can induce radiative or nonradiative energy transfer between fluorophores within the sample.
[0133] In some embodiments of the image acquisition system described herein, the light source may be configured to deliver a predetermined amount of power to the back focal plane of the objective lens. For example, but not limited to, the light source may deliver more than 10 mW of power for certain wavelengths (e.g., 405 nm) and / or more than 150 mW of power for other wavelengths (e.g., 640 nm). Alternatively or additionally, in the case where the light source comprises three lasers emitting at wavelengths of 405 nm, 560 nm, and 640 nm, respectively, the light source may be configured to deliver a predetermined amount of power to the back focal plane of the objective lens. For example, but not limited to, 405 nm may be configured to deliver >10 mW; 560 nm may be configured to deliver >150 mW; and 640 nm may be configured to deliver >50 mW.
[0134] In some embodiments of the image acquisition system described herein, the light source is configured to emit pulsed light. For example, but not limited to, the light source may be configured to emit radio-flicker pulsed light. In some embodiments of the image acquisition system described herein, the light source is configured to emit pulsed light synchronously with the start of image acquisition. In some non-limiting embodiments, the light source will pulse at specific time intervals according to the number of frames captured per second. For example, but not limited to, in a 200 frames per second (FPS) mode, the laser is turned on for 4 milliseconds and off for 1 millisecond. In some embodiments of the SMT workflow, the light source is configured to change from 90% power to 10% power in less than about 0.4 milliseconds. In some embodiments of the SMT workflow, the light source is configured to change from 90% power to 10% power in less than about 0.2 milliseconds. In some embodiments, the light source will be configured to achieve 200, 400, 600, or 800 FPS.
[0135] In some embodiments of the image acquisition system disclosed herein, single-mode fiber can be used to emit light from the light source and guide the light to an optical repeater. Alternatively, multimode fiber can be used in some embodiments of the image acquisition system disclosed herein. For example, but not as a limitation, the multimode fiber can be configured to have a predetermined shape for sample illumination.
[0136] In some embodiments of the image acquisition system described herein, such as systems configured for high-throughput sample analysis, the light source may be configured to exhibit low power output drift. In some embodiments, this low-drift configuration improves the consistency of sample processing to facilitate high-throughput analysis. For example, but not as a limitation, this low-drift power output configuration maintains the power output within variations of approximately 0% to approximately 15%, approximately 0% to approximately 10%, approximately 10%, approximately 9%, approximately 8%, approximately 7%, approximately 6%, approximately 5%, approximately 4%, approximately 3%, approximately 2%, or approximately 1%.
[0137] In some implementations, such low-drift power output is configured to maintain power output within approximately 0% to approximately 15%, approximately 0% to approximately 10%, approximately 10%, approximately 9%, approximately 8%, approximately 7%, approximately 6%, approximately 5%, approximately 4%, approximately 3%, approximately 2%, or approximately 1% variation in ambient temperature (room temperature) (e.g., 17°C + / - 5°C). In some implementations, this is achieved by using temperature sensors and / or closed-loop heaters to maintain a stable temperature of the internal light source (e.g., laser engine), thereby reducing output power drift. For example, but not as a limitation, a thermally insulated housing design can be used to protect the light source from ambient temperature fluctuations. Alternatively or alternatively, the closed-loop heater can be strategically placed in a specific location in the system, such as a fiber optic coupler, to reduce output drift. Alternatively or alternatively, a water jacket and / or cooler can be used to reduce heat buildup in the laser head. In addition, these thermal controls, used alone or in combination, can shorten the preheating time to reach stable operating conditions and maintain a more stable internal operating temperature when the laser is turned off and on.
[0138] 4.3 Optical Components and Sample Illumination In some embodiments, this disclosure includes a light source configured to emit light, which is relayed by one or more optical elements in an optical repeater configured to shape the light emitted from the light source to form a shaped beam. Specific optical elements implemented in any particular optical repeater can be selected and configured to produce a beam of appropriate shape and provide appropriate translation of the beam.
[0139] In some non-limiting embodiments of the optical repeater in the currently disclosed image acquisition system, the optical repeater will include one or more lenses and / or other optical elements. For example, but not as a limitation, the selection and orientation of the lenses and other optical elements in the optical repeater will be configured to appropriately shape the beam directed at the sample. In some non-limiting embodiments, the optical repeater will include optical elements for collimating the emitted light from the light source, such as collimators. Alternatively or additionally, the optical repeater will include additional optical elements, such as Powell lenses or other elements suitable for generating a beam fan, one or more cylindrical lenses, one or more slits for adjusting the beam range, one or more achromatic lenses and / or one or more mirrors, one or more of which may be galvanometers capable of translating light. Specific properties of the optical elements will be predetermined to produce a beam of appropriate shape. For example, but not as a limitation, the SMT of this disclosure can achieve a uniform horizontal FOV and a uniform vertical FOV. This uniformity of the horizontal and vertical FOV contrasts with other strategies that provide a non-uniform horizontal FOV and / or a non-uniform vertical FOV.
[0140] To achieve uniform horizontal and vertical FOV, the optical repeater of the SMT system described herein includes optical elements or components capable of generating a beam that elongates along the X-plane and narrows along the Y-plane, wherein the beam has uniform intensity along the longer dimension of the linear shape. In some non-limiting embodiments, the optical repeater of the SMT system described herein will include a Powell lens to shape the beam to have uniform intensity along the longer dimension of the linear shape. The optical repeater of the SMT system described herein may include additional or alternative optical elements or components to shape the beam to have uniform intensity along the longer dimension of the linear shape. For example, but not as a limitation, the optical repeater of the SMT system described herein may include diffractive elements or components configured to shape the beam to have uniform intensity along the longer dimension of the linear shape.
[0141] In some non-limiting embodiments of optical repeaters in currently disclosed image acquisition systems, the optical repeater will include one or more optical elements or components configured to translate a beam of light relative to the sample plane of the sample to be analyzed, for example, in a direction orthogonal to the longer dimension of the beam. For example, but not as a limitation, such optical elements or components configured to translate the beam of light relative to the sample plane of the sample to be analyzed may include galvanometers or piezoelectric elements configured to translate the beam. Alternatively or additionally, such optical elements or components configured to translate the beam of light relative to the sample plane of the sample to be analyzed may include computer-controlled motors. In some embodiments, the optical elements or components configured to translate the beam may be located before or after optical elements or components (e.g., Powell lenses) configured to shape the beam to have uniform intensity along the longer dimension of its linear shape.
[0142] In some embodiments, the system includes an optical relay station configured to shape light emitted by a light source to form a shaped beam, which is then guided by an optical element (e.g., a dichroic mirror) configured to direct the shaped beam to an objective lens, thereby illuminating the sample plane with the tilted beam.
[0143] In some non-limiting embodiments of the image acquisition system of this disclosure, the objective guides a tilted beam of light onto the plane of the sample to be analyzed. In some non-limiting embodiments of the image acquisition system of this disclosure, the objective is a water immersion objective. Using a water immersion objective enables high-throughput sample analysis by eliminating the oil associated with using an oil immersion objective, thus allowing for higher image quality and less distortion. The presence of oil is problematic in automated systems where it can spread to components, including optical elements that may become contaminated from contact with oil. Water immersion objectives offer better refractive index matching for imaging aqueous samples. In some non-limiting embodiments, the objective is a 60 x 1.27 NA water immersion objective (Nikon). In some embodiments of the workflow described herein, the water immersion objective is heated by a heating element. For example, such a heating element would maintain the water immersion objective at a temperature sufficient to avoid causing temperature changes in the sample contained in the sample plate.
[0144] 4.4. Image Acquisition In some non-limiting embodiments of the image acquisition system disclosed herein, the objective lens is also used to focus fluorescence emitted by the sample in response to illumination provided by a tilting beam. In some non-limiting embodiments, the objective lens focuses the fluorescence emission through an emission filter, such as a bandpass emission filter matched to the spectrum of the observed fluorophore and mounted in a high-speed filter wheel (Finger Lakes Instruments), and collects it by a detector device. In some non-limiting embodiments, the objective lens-focused fluorescence emission is directed to an optical repeater before being collected by the detector device. For example, but not as a limitation, such an optical repeater may include one or more lenses and one or more additional optical elements, such as elements configured to reject additional scattered light before collection by the detector device. In some non-limiting embodiments, the objective lens-focused fluorescence emission is directed by another dichroic mirror to split the emission across multiple regions of the detector. In some non-limiting embodiments, the objective lens-focused fluorescence emission is directed by another dichroic mirror to split the emission across multiple detectors.
[0145] In some non-limiting embodiments of the image acquisition system disclosed herein, the detector device is configured to synchronize detection with the translation of the tilted beam on the sample plane. For example, but not as a limitation, the detector device may be a CMOS camera, such as a back-illuminated CMOS camera (Hamamatsu Fusion BT).
[0146] In some implementations of the image acquisition system of this disclosure, a CMOS camera may be operated such that a series of SMT frames are collected for each field of view. For example, but not as a limitation, 1-20,000 SMT frames, 1-15,000 SMT frames, 1-10,000 SMT frames, 1-5,000 SMT frames, 1-1,000 SMT frames, 2-500 SMT frames, 5-250 SMT frames, 10-200 SMT frames, 100-200 SMT frames, or 200 SMT frames are collected per field of view. In some embodiments, the CMOS camera may be configured to operate at a frame rate of about 0.5 to about 2000 Hz. In some embodiments, the CMOS camera may be configured to operate at a frame rate of 0.5 to 1000 Hz, or in some embodiments at a frame rate of 200 Hz. In some embodiments, the CMOS camera may be configured to operate at a frame rate of 100 Hz to 1250 Hz. For example, but not by limitation, some SMT implementations may operate at 200 Hz. In some embodiments, some SMT implementations may operate at 400 Hz. In some embodiments, some SMT implementations may operate at 800 Hz. In some embodiments, some SMT implementations may operate at 1000 Hz. In some embodiments, some SMT implementations may operate at 1200 Hz. In some embodiments, some SMT implementations may operate at 1250 Hz. In some embodiments, some SMT implementations may operate at 1400 Hz. In some embodiments, some SMT implementations may operate at 1600 Hz. In some embodiments, some SMT implementations may operate at 1800 Hz. In some embodiments, some SMT implementations may operate at 2000 Hz. In some implementations, certain SMT implementations may operate at frame rates of approximately 100 Hz or higher, approximately 200 Hz or higher, approximately 400 Hz or higher, approximately 600 Hz or higher, approximately 800 Hz or higher, approximately 1000 Hz or higher, approximately 1200 Hz or higher, approximately 1400 Hz or higher, approximately 1600 Hz or higher, or approximately 1800 Hz or higher. In some implementations, certain SMT implementations may operate at a frame rate of up to approximately 1200 Hz. In some implementations, certain SMT implementations may operate at a frame rate of up to approximately 1400 Hz. In some implementations, certain SMT implementations may operate at a frame rate of up to approximately 1600 Hz. In some implementations, certain SMT implementations may operate at a frame rate of up to approximately 1800 Hz. In some implementations, certain SMT implementations may operate at a frame rate of up to approximately 2000 Hz. In some implementations, the CMOS camera will be configured to achieve 200, 400, or 800 FPS.
[0147] In certain non-limiting embodiments of the image acquisition system disclosed herein, the detector device is configured to transmit a signal with each frame to trigger other elements of the imaging system. For example, but not as a limitation, the detector device may trigger illumination from a light source to collect fluorescence emission associated with a stroboscopic laser pulse. For example, but not as a limitation, such fluorescence emission collection is associated with frames of 10 to 100 ms and stroboscopic laser pulses of 2 ms. In some embodiments, fluorescence emission collection is associated with stroboscopic laser pulses of about 0.1 to about 1 ms. In some embodiments, fluorescence emission collection is associated with stroboscopic laser pulses of about 0.2 to about 1 ms, about 0.3 to about 1 ms, about 0.4 to about 1 ms, about 0.1 to about 0.9 ms, about 0.1 to about 0.8 ms, about 0.1 to about 0.7 ms, about 0.1 to about 0.6 ms, about 0.1 to about 0.5 ms, about 0.1 to about 0.4 ms, about 0.2 to about 0.6 ms, about 0.2 to about 0.5 ms, about 0.2 to about 0.4 ms, or about 0.3 to about 0.5 ms. In some embodiments, fluorescence emission collection is associated with stroboscopic laser pulses of about 0.1 to about 0.6 ms. In some embodiments, fluorescence emission collection is associated with stroboscopic laser pulses of about 0.1 to about 0.5 ms. In some embodiments, fluorescence emission collection is associated with stroboscopic laser pulses of about 0.2 to about 0.4 ms. In some embodiments, fluorescence emission collection is associated with stroboscopic laser pulses of about 0.2 ms. In some implementations, fluorescence emission collection is associated with a stroboscopic laser pulse of approximately 0.4 ms.
[0148] In some embodiments, the imaging acquisition system may be configured to acquire a predetermined field of view (FOV), such as a detected FOV. In some embodiments, the FOV (e.g., the detected FOV) may have a size of about 150 μm to about 250 μm in a first dimension and a size of about 100 μm to about 210 μm in a second dimension. In some embodiments, the FOV (e.g., the detected FOV) may have a size of about 200 µm to about 250 µm in a first dimension and a size of about 150 µm to about 210 µm in a second dimension, or the FOV (e.g., the detected FOV) may have a size of about 225 µm to about 250 µm in a first dimension and a size of about 175 µm to about 210 µm in a second dimension. For example, but not as a limitation, the FOV (e.g., the detected FOV) may have a size of about 250 μm in a first dimension and a size of about 190 μm in a second dimension, for example, as disclosed in Example 1.
[0149] In some embodiments, a certain percentage of FOV (e.g., detected FOV) provides usable data. In some embodiments, at least 75% FOV, at least 80% FOV, at least 85% FOV, at least 90% FOV, at least 95% FOV, at least 96% FOV, at least 97% FOV, at least 98% FOV, at least 99% FOV, or 100% FOV provide usable data. In some embodiments, at least 75% FOV (e.g., detected FOV) provides usable data. In some embodiments, at least 80% FOV (e.g., detected FOV) provides usable data. In some embodiments, at least 85% FOV (e.g., detected FOV) provides usable data. In some embodiments, at least 90% FOV (e.g., detected FOV) provides usable data. In some embodiments, at least 95% FOV (e.g., detected FOV) provides usable data. In some embodiments, at least 96% FOV (e.g., detected FOV) provides usable data. In some embodiments, at least 97% of the FOV (e.g., the detected FOV) provides usable data. In some embodiments, at least 98% of the FOV (e.g., the detected FOV) provides usable data. In some embodiments, at least 99% of the FOV (e.g., the detected FOV) provides usable data. In some embodiments, 100% of the FOV (e.g., the detected FOV) provides usable data. In some embodiments, a percentage equal to or greater than about 75% of the FOV provides usable data; for example, a percentage equal to or greater than about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% of the FOV provides usable data. In some embodiments, a certain percentage of the FOV (e.g., the detected FOV) achieves sufficient laser illumination to track protein motion. For example, but not by limitation, at least 75% FOV, at least 80% FOV, at least 85% FOV, at least 90% FOV, at least 95% FOV, at least 96% FOV, at least 97% FOV, at least 98% FOV, at least 99% FOV, or 100% FOV achieves sufficient laser illumination to track protein motion. In some embodiments, at least 75% FOV (e.g., the detected FOV) achieves sufficient laser illumination to track protein motion. In some embodiments, at least 80% FOV (e.g., the detected FOV) achieves sufficient laser illumination to track protein motion.In some embodiments, at least 85% of the FOV (e.g., the detected FOV) achieves sufficient laser illumination to track protein motion. In some embodiments, at least 90% of the FOV (e.g., the detected FOV) achieves sufficient laser illumination to track protein motion. In some embodiments, at least 95% of the FOV (e.g., the detected FOV) achieves sufficient laser illumination to track protein motion. In some embodiments, at least 96% of the FOV (e.g., the detected FOV) achieves sufficient laser illumination to track protein motion. In some embodiments, at least 97% of the FOV (e.g., the detected FOV) achieves sufficient laser illumination to track protein motion. In some embodiments, at least 98% of the FOV (e.g., the detected FOV) achieves sufficient laser illumination to track protein motion. In some embodiments, at least 99% of the FOV (e.g., the detected FOV) achieves sufficient laser illumination to track protein motion. In some embodiments, 100% of the FOV (e.g., the detected FOV) achieves sufficient laser illumination to track protein motion. In some implementations, a FOV of about 75% or greater achieves sufficient laser illumination to track protein motion. For example, a FOV of about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% achieves sufficient laser illumination to track protein motion.
[0150] In some implementations, the imaging acquisition system can be configured to acquire a predetermined image size for each frame, referred to herein as the Region of Interest (ROI). In some implementations, the ROI will vary depending on the frame rate used. For example, at 200 FPS, 2304x768 pixels would define the ROI, which corresponds to 248.832 x 82.944 µm in the sample plane. 2 At 400 FPS, 2304 x 432 pixels will define the ROI, which is equivalent to 248.832 x 46.6 µm in the sample plane. 2 At 800 FPS, 2304 x 192 pixels corresponds to 248.832 x 20.928 µm in the sample plane. 2 In some implementations, the imaging acquisition system can be configured to achieve 200, 400, or 800 FPS.
[0151] In some implementations, the imaging acquisition system may be configured to perform a predetermined scan rate at a predetermined frame rate. For example, but not by limitation, the scan rate may be 82.94 µm / 4 ms, which is equivalent to 20.7 µm / ms, or 2.07 cm / s. In some implementations, the imaging acquisition system will be configured to perform scan rates reaching 200, 400, 600, or 800 FPS.
[0152] In some implementations, the detector device can be used to collect fluorescence emission at multiple wavelengths. For example, but not as a limitation, fluorescence emission from additional fluorophores in the same field of view can be collected at the same frame rate or different frame rates to provide downstream registration of the SMT trajectory with other labeled components. Additional channels of the detector device can be used as needed to expand the number of fluorescence emissions captured simultaneously in the same field of view to provide downstream registration of the SMT trajectory with other cellular components (e.g., test molecules) within the sample.
[0153] 4.5 SMT Software This disclosure provides an example system for a high-throughput single-molecule imaging platform for measuring molecular motion in cell-free samples. Experiments can be performed to collect large amounts of data from multiple target molecules. Experiments may include applying various identifiers to the target molecules, such as tags that can subsequently fluoresce or be otherwise detected (e.g., using a laser or other light source). Samples forming part of such experiments can be organized into plates with multiple wells. Each well may have one or more associated fields of view (FOVs). The FOV may be located within or correspond to a single well. Image sequences can be generated for the FOVs to produce one or more films, which may include SMT films as well as non-SMT films. SMT films can be used to trace the path of a single labeled molecule (such as a protein), thereby generating multiple spatiotemporal trajectories. Each spatiotemporal trajectory may consist of multiple spots, which include the spatiotemporal coordinates of the labeled molecule at a specific time. Separately to, and in some cases in parallel with, tracking, the films can be used to identify molecules to generate masks by using machine learning and / or computer vision-based image segmentation. Masks are spatial regions within the generated FOVs through segmentation. Each mask may belong to a mask category.
[0154] In some implementations, tracking and segmentation data can be combined to generate multiple metrics relating to various aspects of the sample, such as the location of phase changes or other sample attributes. In other words, spatiotemporal trajectories (e.g., spatiotemporal trajectory data) can be combined with image segmentation data processed by machine learning and further analyzed using statistical / machine learning methods. The processing of the combined data can be used to generate metrics, such as hit scores relating to compounds and / or targets in the sample, which can be stored in a database structure.
[0155] This disclosure provides an exemplary data stream for a high-throughput single-molecule imaging platform for measuring protein motility in cell-free samples. Experimental specifications defining the experiment can be provided as data input via one or more clients. The experimental specifications can define various parameters of the experiment, such as staining agents, dyes, compounds, treatments, etc. In some embodiments, the imaging system (e.g., an imaging system) can capture image sequences that generate one or more SMT videos and / or non-SMT videos or segmented videos (e.g., videos) characterizing molecular motility. SMT videos can characterize the motility of a single fluorescent molecule and / or images containing a single fluorescent molecule. Segmented videos can include image sequences characterizing the motility of labeled molecules and / or their components.
[0156] SMT videos can be analyzed to perform molecular tracing-related operations, which may include detection, subpixel localization, and linking to identify spatiotemporal trajectories on individual images within the SMT video. More specifically, during detection, one or more points within the SMT video can be detected or recovered. Each point can be equipped with spatiotemporal coordinates. These spatiotemporal coordinates can be estimated using subpixel localization techniques. Linking can be performed on these points to ultimately identify the spatiotemporal trajectory.
[0157] As used in this paper, a link is a potential association between two points. Each link is directional, starting at one point and ending at another. A “correct link” connects two points generated by the same emitter in different frames; otherwise, the link is “incorrect.” One goal of the linking algorithm is to estimate which links are correct. The format of the links mentioned in this paper is as follows: This means that the link α begins with a spot. i And stop at the spots j Links must satisfy at least the following three constraints: (a) links advance in time, (b) links cannot connect two points that are more than a certain limit (referred to herein as the “search radius”), and (c) links cannot connect two points that are more than a certain limit in time (referred to herein as the “gap limit”). A point-link graph is a graph of points and links in an SMT movie. Points are the vertices of the graph, and links are the edges of the graph. Because links advance in time, a point-link graph is a directed acyclic graph. A match is a subset of links in a point-link graph such that no two links in the subset start or end at the same point. This paper uses a spatiotemporal trajectory 715 to refer to a continuous (end-to-end) sequence of links in the same match. Multiple spatiotemporal trajectories can be used to determine dynamic metrics. Such parameters may include properties of blobs that characterize blob motion. Such parameters may include one or more of the velocity, diffusion coefficient, or anomaly parameters for each blob. Point The dynamic parameters are referred to here as The set of dynamic parameters for all blobs in the blob link graph is referred to here as... .
[0158] Experimental information, such as dynamic metrics, image metrics, and any data from which any metric is derived (e.g., segmentation information), can be provided to a data repository for storage. Such a data repository can store, for example, any results of an experiment, such as dynamic metrics, image metrics, and / or any data from which any metric is derived. The data repository may include local persistence and / or a dedicated server accessible locally or via the cloud. The data repository may also store metadata associated with it and / or metadata associated with the experimental specifications. Experimental information (e.g., results and metadata from historical experiments) can be provided to the data repository via a repository application programming interface (API). The repository API may also interface with a web-based graphical user interface frontend that provides such information for display on a client.
[0159] Example dynamic metrics may also include state arrays. State arrays are a framework for learning interpretable dynamic models from SMT spatiotemporal trajectories and can be used to further understand the motion of target proteins. In some variations, state arrays can be generated / filled using segmentation information. State arrays can be used to quantify the relative occupancy of molecules in different conformations (e.g., open and closed). Fractional occupancy can be calculated by dividing the average value of each state array bin (weighted by the occupancy of each bin) by the total weighted average diffusion coefficient.
[0160] In some implementations, the computer-implemented environment may include an imaging system that interacts with a computing architecture to perform the various algorithms described herein. The imaging system may interface with one or more clients (e.g., via a web application with a graphical user interface). One or more clients may interface with one or more servers accessible over a network. One or more clients may host frame grabbers that capture images (e.g., videos) from a camera. These images may be temporarily stored on one or more clients and periodically transferred over the network to one or more servers for remote storage. One or more servers may also contain or have access to one or more data storage devices for storing data collected and / or extracted by the imaging system from samples. In some variations, the network may include or interface with one or more network storage arrays for storing data such as captured images (e.g., videos).
[0161] In some variations, the sample computing device architecture may be a client and / or server architecture, and some components described in the figure may be optional for the client and / or server. The bus may act as an information highway interconnecting other illustrated components of the hardware. A processing system labeled CPU (Central Processing Unit) (e.g., one or more computer processors / data processors on a given computer or multiple computers) performs the computations and logical operations required to execute the program. Optionally or additionally, a processing system labeled GPU (Graphics Processing Unit) (e.g., one or more computer processors / data processors on a given computer or multiple computers) performs the computations and logical operations required to execute the program. Non-transitory processor-readable storage media (such as read-only memory (ROM) and random access memory (RAM)) may communicate with the processing system and / or the processing system and may include one or more programming instructions for the operations specified herein. Optionally, the program instructions may be stored on a non-transitory computer-readable storage medium, such as a disk, optical disk, recordable storage device, flash memory, solid-state drive, or other physical storage medium.
[0162] In one instance, the disk controller may interface one or more optional removable or local storage devices with the system bus. The removable storage device may be an external or internal disk drive, a solid-state drive, or an external hard disk drive. The local storage device may be an internal hard disk and / or memory. As previously described, the various examples of removable storage, local storage, and the disk controller are optional devices. The system bus may also include at least one communication interface to allow communication with external devices (such as cloud storage and remote services) physically connected to the computing system or obtained externally via wired or wireless networks. In some cases, at least one communication interface 1024 includes or additionally incorporates a network interface.
[0163] In some variations, such as for a client, to provide interaction with the user, the subject matter described herein may be implemented on a computing device having a display device (e.g., an LCD (liquid crystal display) or LED (light-emitting diode) monitor) for displaying information obtained from the bus to the user via a display interface, and on an input device (such as a keyboard and / or pointing device (e.g., a mouse or trackball) and / or a touchscreen) through which the user provides input to the computer. Other types of input devices may also be used to provide interaction with the user; for example, feedback provided to the user may be any form of sensory feedback (e.g., visual feedback, auditory feedback via a microphone, or tactile feedback); and input from the user may be received in any form, including sound, speech, or tactile input. The input device and microphone may be coupled to the bus via an input device interface and transmit information via the bus. For example, the input device may be an imaging system configured with the ability to capture the image sequences described herein. A frame grabber may capture or grab individual frames from analog or digital data encapsulating the image sequences obtained from the bus. The frame grabber may include a memory capable of storing single or multiple frames. The frame grabber can also provide single or multiple frames to the bus for further storage, such as in local memory and / or removable memory.
[0164] One or more aspects or features of the subject matter described herein may be implemented in digital electronic circuits, integrated circuits, application-specific integrated circuits (ASICs), field-programmable gate arrays (FPGAs), computer hardware, firmware, software, and / or combinations thereof. These aspects or features may be implemented in one or more computer programs that can be executed and / or interpreted on a programmable system including at least one programmable processor, which may be dedicated or general-purpose, coupled to receive data and instructions from a storage system, at least one input device, and at least one output device, and to transmit data and instructions to the storage system, at least one input device, and at least one output device. The programmable system or computing system may include clients and servers. Clients and servers are typically geographically separated and typically interact via a communication network. The client-server relationship is created by computer programs running on their respective computers that establish a client-server relationship between them.
[0165] These computer programs, also referred to as programs, software, software applications, applications, components, or code, include machine instructions for a programmable processor and can be implemented using high-level procedural languages, object-oriented programming languages, functional programming languages, logic programming languages, and / or assembly / machine languages. As used herein, the term "machine-readable medium" means any computer program product, device, and / or apparatus for providing machine instructions and / or data to a programmable processor, such as, for example, disks, optical disks, memories, and programmable logic devices (PLDs), including machine-readable media that receive machine instructions in the form of machine-readable signals. The term "machine-readable signal" means any signal used to provide machine instructions and / or data to a programmable processor. Machine-readable media may store such machine instructions non-transitoryly, such as, for example, non-transitory solid-state memory or magnetic hard disks or any equivalent storage medium. Machine-readable media may alternatively or additionally store such machine instructions transiently, such as, for example, processor caches or other random access memory associated with one or more physical processor cores.
[0166] 5. Examples The subject matter of this disclosure will be better understood by referring to the following embodiments, which are merely examples of the subject matter and not limiting. This section describes the experimental materials and methods used to generate the specific non-limiting exemplary data disclosed in Embodiments 1-5 herein.
[0167] Protein expression and purification: The HaloTag expression vector (pH6HTN His6HaloTag® T7 vector) was purchased from Promega. The expression vector for the Halo-protein 1 fusion was constructed by inserting the sequence encoding protein 1 into the C-terminus of HaloTag, exactly after the TEV cleavage site. Both plasmids were transfected into *E. coli* BL21(DE3) and grown in LB medium at 37°C until an OD600 of 0.6–0.8 was reached, followed by overnight induction with 0.1 mM IPTG at 16°C. Cells were harvested by centrifugation and analyzed using BugBuster. ® Proteins were lysed using EMD Millipore extraction reagent and purified using the standard Ni-NTA method. The eluted proteins were further purified using a size exclusion column pre-equilibrated with a buffer containing (25 mM HEPES, pH 7.9, 100 mM KCl, 12.5 mM MgCl2, 0.1 mM EDTA, 10% glycerol, and 1 mM DTT). Combined peak fractions were quantified using NanoDrop, aliquoted, and rapidly frozen in liquid nitrogen for long-term storage at -80°C.
[0168] Protein 2 was subcloned into the pGEX4T-1 expression vector, positioned immediately after the thrombin cleavage site and followed by the TEV cleavage site. The plasmid was transfected into *E. coli* BL21(DE3) and grown in LB medium at 37°C until an OD600 of 0.6–0.8 was reached, followed by overnight induction with 0.1 mM IPTG at 16°C. Cells were harvested by centrifugation and analyzed using BugBuster. ® Proteins were lysed using EMD Millipore extraction reagent and purified via standard glutathione agarose beads. GST tags were removed by thrombin digestion followed by removal from size exclusion columns pre-equilibrated with buffer containing (25 mM HEPES, pH 7.5, 150 mM NaCl, and 1 mM TCEP). Combined peak fractions were quantified by NanoDrop, replenished to 10% v / v with glycerol, aliquoted, and rapidly frozen in liquid nitrogen for long-term storage at -80°C.
[0169] DNA encoding protein 3 and its mutant was cloned into the pET11a bacterial expression vector, which has an N-terminal 6x His tag followed by a TEV cleavage site and three additional glycine residues (leaving a "GGGG" sequence at the N-terminus after TEV cleavage). The sequenced plasmid was transformed into chemically competent *E. coli* (BL21DE3). After single-colony inoculation, the bacteria were grown in LB at 37°C until an OD600 of 0.6–0.8 was reached, with the addition of 0.5 mM IPTG to induce protein expression overnight at 16°C. The bacterial culture was resuspended in a buffer (25 mM HEPES, pH 8.0, 150 mM NaCl, 1 mM TCEP, 5% glycerol) with freshly replenished protease inhibitors, harvested, and mechanically sonicated before incubation with Ni-NTA affinity resin for intermittent purification. The protein was washed with buffer containing 45 mM imidazole and eluted with lysis buffer containing 300 mM imidazole. TEV protease was used overnight to cleave the affinity tag for subsequent reverse affinity purification to yield cleaved protein 3 and the protein 3 mutant. The final protein was further purified by size exclusion chromatography followed by buffer exchange (25 mM HEPES, pH 7.5, 150 mM NaCl). Peak fractions were combined, made up to 5% with glycerol, and stored at -80°C after rapid freezing in liquid nitrogen.
[0170] The protein sequence of protein 4 was subcloned into the pET17b vector with an N-terminal 6x His tag. Transformed (BL21-DE3) *E. coli* were grown in Turbo Broth at 37°C until an OD600 of 0.6 was reached. 0.1 mM MIPTG was added to induce protein expression again at room temperature for 4 hours. The harvested precipitate was lysed in buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM TCEP + 25 mM imidazole, 1 mM PMSF supplemented with benzonase nuclease and protease inhibitor) and loaded onto a Ni-NTA column pre-equilibrated with lysis buffer. Proteins were eluted with lysis buffer supplemented with 500 mM imidazole and subsequently injected into HiTrap Q-FF columns pre-equilibrated with buffer (50 mM HEPES, pH 8.0, 150 mM NaCl, 1 mMTCEP) and S75 Superdex size exclusion columns in buffer (50 mM HEPES, pH 8.0, 150 mM NaCl, 1 mMTCEP) for further purification. Peak fractions were combined, replenished to 5% with glycerol, and stored at -80°C after rapid freezing with liquid nitrogen.
[0171] The protein sequence encoding protein 5 was subcloned into the pFASTBAC1 insect expression vector, which has an N-terminal GST tag and TEV cleavage site, as well as C-terminal AviTag and StrepTag II affinity tags. This donor plasmid was then transformed into *E. coli* DH10Bac for bacmid integration and plated on Bluo-gal selection agar plates (Kan, Gen, Tet) for blue / white colony selection, with the correct gene insertion product verified by PCR. To generate baculovirus, bacmids were scaled up in LB and purified using a Bacmid Maxiprep kit (Machery-Nagel), pre-complexed with ExpiSf Expifectamine reagent (ThermoFisher Scientific), and transiently transfected into ExpiSf9 cells (ThermoFisher Scientific). The harvested baculovirus was then infected with ExpiSf9 cells at a 1:50 dilution to induce protein expression. Cell pellets were harvested and lysed at room temperature for at least 30 minutes using insect Popculture detergent (Millipore Sigma), diluted in lysis buffer (50 mM HEPE, pH 8.0, 500 mM NaCl, 1 mM EDTA, 1 mM TCEP, 1 mM PMSF supplemented with benzonase nuclease and protease inhibitors). After clarification of the lysates, soluble fractions were loaded onto StrepTactin affinity columns (IBABiosciences), MonoQ anion exchange columns (Cytiva), and S200 Superdex size exclusion columns (Cytiva) to remove aggregates and contaminants, and exchanged into buffer containing (50 mM HEPES, pH 8.0, 250 mM NaCl, 1 mM TCEP). The combined peak fractions were replenished to 10% with glycerol and stored at -80°C after rapid freezing in liquid nitrogen.
[0172] Protein markers: In a buffer containing 50 mM HEPES pH 7.4, 150 mM NaCl, 0.01% NP40 substitute, 0.5 mM EDTA, and 1 mM DTT, 10–60 µM of Halo-labeled protein was mixed with 100–200 µM of Halo-JF549 dye (Tocris or internally synthesized) and incubated at room temperature (23°C). oC) Incubate at room temperature for 15–30 minutes. Remove free dye using a size exclusion column pre-equilibrated with buffer (25 mM HEPES pH 7.9, 100 mM KCl, 12.5 mM MgCl2, 0.1 mM EDTA, 10% glycerol, and 1 mM DTT). Combined peak fractions are quantified by NanoDrop, aliquoted, and rapidly frozen in liquid nitrogen at -80°C. o Long-term storage at C.
[0173] For sorting enzyme-based enzymatic ligation, the N-terminus is cleaved via thrombin protease or TEV protease to expose free Gly residues for labeling. Then, labeling buffer (50 mM HEPE pH 7.5, 150 mM NaCl, 10 mM CalCl2) and 5 µM recombinant purified His-labeled sorting enzyme (SrtA) are applied. staph The product was incubated with a pentamutant (DOI: 10.1002 / cpps.38) and 10 moles of an excess (peptide donor to protein substrate) of LPETGG-JF549 peptide (JF549 conjugated to the N-terminus of peptide LPETGG, Elim Biopharm) dissolved in water. After incubation at room temperature for at least 30–60 minutes, the reactants were purified by magnetic separation using a DYNABEADS™ His tag and subsequently injected into a size exclusion column for further separation of the labeled product from the peptide-dye and exchange buffer (50 mM HEPES, pH 8.0, 150 mM NaCl, 1 mM TCEP). Absorbances at 549 nm and 280 nm were used to estimate labeling efficiency (40%–70%). The final product was replenished with glycerol to 10% v / v and stored at -80°C.
[0174] Single-molecule tracking and data analysis: The labeled proteins were diluted to 4–200 pM in a buffer containing (25 mM HEPES, pH 7.9, 100 mM KCl, 12.5 mM MgCl2, 0.1 mM EDTA, 1 mM DTT, 0.01% NP40, 0.3 mg / mL BSA) and supplemented to specific concentrations of glycerol and other additives, such as the specified dissociation agent. Based on the DMSO tolerance of each protein being tested, small molecule compounds (i.e., organic molecules less than 1 kDa) dissolved in DMSO were added to the reactants. 30 µL of each reactant was aliquoted onto 384-well glass-bottom CellVis plates for imaging under a single-molecule imaging microscope. The protein 1 peptide used to disrupt the protein 2–protein 1 interaction was custom-synthesized (Elim Biopharm) and supplemented as specified. The molecule MX used with protein 3 was custom-synthesized (CPC Scientific Inc.) and supplemented as specified. Pre-imaging incubation may amplify changes caused by the presence of liquid release agents and small molecule binders. These incubation steps were inserted into a specific experiment: 37°C for 1 hour, followed by 4°C for 3 days. Figure 4D ); 37℃ for 2 hours ( Figure 4E (middle image), 4℃ for 3 days, followed by 37℃ for 1 hour ( Figure 4E (bottom image); and room temperature (25℃) for 2 hours ( Figure 4F ).
[0175] At 200 Hz ( Figures 2A-3B and Figures 4B-6D ) or 800 Hz ( Figures 3C-3E Single-molecule tracking (SMT) images are obtained on an oblique line scanning (OLS) microscope. An exemplary OLS microscope is described in PCT / US2023 / 085589. Data is processed through a custom pipeline that manipulates the sequence of images produced by the microscope. In short, individual emitters are detected by applying a generalized log-likelihood ratio test to each 11x11 sub-window in the image, as described above. See the signal-to-noise ratio definition and quantization below. (Partial). Emitters are detected by identifying pixels with a log-likelihood ratio greater than 16. The detected emitters are localized to sub-pixel accuracy in a two-stage procedure. First, the sub-pixel location is estimated by calculating the maximum radially symmetric point. Second, this estimate is used to embed an iterative Levenberg-Marquardt fitting procedure into a 2D integral Gaussian within an 11x11 pixel sub-window centered on the detection.
[0176] A modification to the Sbalzerini hill-climbing algorithm can be used to link local emitters in a timely manner to generate spatiotemporal trajectories. This algorithm uses Gibbs sampling to estimate the uncertainty of data association. In SMT, lengths greater than 2.5 µm are prohibited. Figures 2A-3B and Figures 4B-6D ) or 1.5 µm ( Figures 3C-3E Links of more than two gap frames and links of more than two gap frames are used to limit association error.
[0177] Signal-to-noise ratio definition and quantization: Signal-to-noise ratio (SNR) is defined by the likelihood ratio of a hypothesis test comparing: the absence of a target, where the local image is modeled by the sum of constant offset and independent Gaussian noise; and the presence of a target, where the local image is modeled by the sum of a centered Gaussian peak (width known but amplitude unknown), independent Gaussian noise, and constant offset. SNR is expressed as: in: It is an image cropped to the current region of interest (ROI); It is the side length of the square ROI (in pixels); It is an inner product operator; It is a zero-mean detection kernel that matches the expected Gaussian target profile, and , where the ROI is summed; It is a uniform kernel (i.e., its value is 1 across the entire ROI).
[0178] Differential scanning fluorescence (DSF): Unlabeled protein 4 was diluted to 3 µM in buffer (25 mM HEPES, pH 7.4, 150 mM NaCl), with DMSO added alone to 0.5% (vector control) or the test compound diluted to 50 µM. The melting temperature (Tm) was measured using a Prometheus Panta NanoDSF instrument, and the data were processed using relevant software.
[0179] Fluorescence polarization (FP) measurement: 20 nM of protein 4 was mixed with 5 nM of FAM-labeled protein 6 peptide (which binds to the same site as molecule M3 on protein 4, with the C-terminus capped with amine, Elim Biopharm) in a buffer containing (10 mM HEPES pH 7.5, 150 mM NaCl, 50 mM EDTA, 0.005% Tween 20, 0.1 mg / ml BSA, and 1 mM DTT). The compound was supplemented with 0.2% DMSO. The signal was measured in 384-well plates using an EnVision 2013 plate reader (Perkin Elmer). The half-maximum inhibition (IC50) was determined using Prism software (GraphPad).
[0180] Measurement of spatiotemporal trajectories: When reporting the number of spatiotemporal trajectories, singlet states (spatiotemporal trajectories with 1 detection) are excluded because they do not contribute information to most dynamic estimations.
[0181] The average diffusion coefficient was calculated using the mean square displacement method. D est = MSD 2D / 4 t This estimate is expected to be passed. σ loc 2 / t The diffusion coefficient will be overestimated, among which σ loc 2 It is the variance of the 1D positioning error, and t It is the frame interval.
[0182] To distinguish spatiotemporal trajectories under various dynamic states, diffusion coefficients and localization error values were inferred using a state array (a variational Bayesian procedure based on Dirichlet process mixing) and the coefficients of a Brownian mixing model on a grid. The mixing components were selected with 100 logarithmic intervals between 0.01 and 100 µm. 2 The diffusion coefficients range from 0.02 to 0.08 per second. µ The Cartesian product of the positioning error values m (1D standard deviation). Occupation is reported as the average posterior probability marginalized across all positioning error values for each diffusion coefficient. To make inference tractable, inference is restricted to 10,000 spatiotemporal trajectories randomly sampled from each aperture.
[0183] Single-population bias estimation is performed using analytical computation that captures the probabilities of erroneous links and truncation of jump length distributions due to a finite search radius. The spatially uniform distribution allows estimation of the probability of erroneous links based on observed emitter concentration and nearest-neighbor linking models. This probabilistic analysis also allows characterization of the erroneous link jump length distribution. Single-population bias estimation incorporates these erroneous link artifacts and the prohibition of observations of jump lengths greater than the search radius. Figure 6A As shown, these deviation expressions are used to improve the accuracy of diffusion coefficient estimation.
[0184] Empirical estimation of link accuracy: To estimate the accuracy of the linking algorithm, a bootstrapping procedure was used. The detection results from the first and second halves of the film were superimposed, and the tracking algorithm was run on the resulting detection set without knowing the source of each detection. This resulted in a generated link score, where individual detections were merged from different halves of the film. Since this score does not account for erroneous links between detections within the same half of the film, nor for the effects of photobleaching, it forms the lower bound for the link error rate (ERLB).
[0185] 5.1. Example 1: SMT can distinguish subtle differences in proteins through movement. This embodiment illustrates the use of the methods of this disclosure to distinguish target proteins by analyzing their motility. This embodiment further demonstrates that the methods of this disclosure can be used to measure the diffusion properties of purified proteins in solution.
[0186] As described by the Stokes-Einstein equations, particle motion depends on temperature, the viscosity of the medium, and the effective hydration radius of the particle. For example, size, shape, surface chemical / physical characteristics, and interactions with the surrounding medium can all contribute to and influence the effective hydration radius, which in turn can affect the motion of target molecules under certain conditions (e.g., temperature and medium). Therefore, tracking particle motion can provide valuable information about their structural and functional properties.
[0187] To verify that the SMT system can reliably measure protein motility in solution, viscosity was adjusted using incremental concentrations of glycerol to measure JF. 549Diffusion of labeled HisHalo. His-Halo was diluted to 50 pM in imaging buffer consisting of 25 mM HEPES pH 7.4, 150 mM NaCl, 1 mM DTT, 0.03% (w / v) BSA, and 0.01% NP-40, with glycerol levels ranging from 0% to 40%. The dilution was transferred to 384-well plates, which were incubated at 37°C for 15 min prior to OLS imaging. Each concentration was captured in replicates of 22–44 wells, with 4 FOVs obtained per well at 200 frames / second. Glycerol titrations were performed on both plates using the same protein formulation. Viscosity calculations were performed. Figure 6A and Figure 6B As shown, the diffusion coefficient is estimated from the tracking results and corrected using an analytical expression for tracking bias, resulting in a close match with the theoretical value predicted by the Stokes-Einstein equation.
[0188] Further experiments were performed to confirm that the SMT system could be used to distinguish proteins. HaloTag and HaloTag fused with a peptide from protein 1 (referred to in this paper as "Halo-protein 1") were expressed and purified. Figure 1A The diffusion of HaloTag and Halo-protein 1 was measured at 37°C in the presence of different glycerol concentrations.
[0189] To estimate the expected diffusion coefficients, dynamic light scattering (DLS) was used to determine the hydration radii of HaloTag and Halo-protein 1 in aqueous solution (50 mM HEPES, pH 7.5, 150 mM NaCl), and the radii were determined to be 2.39 nm and 3.09 nm, respectively. Based on the estimate for HaloTag using public resource (52.14.70.9 / Run_hullrad.html), this value is largely consistent, giving a hydration radius of 2.14 nm for the core domain of the HaloTag protein. Minor differences, not limited by any particular theory, may be due to the presence of unstructured tail sequences in the purified protein used in this experiment. Another resource (www.met.reading.ac.uk / ~sws04cdw / viscosity_calc.html) was used to estimate the dynamic viscosity of glycerol, which was 0.00093 N*s / m for 10% v / v and 30% v / v glycerol, respectively. 2 and 0.00185 N*s / m 2 When the Boltz constant is 1.38E -23 Under these conditions, at a temperature of 37°C, the expected diffusion coefficients of HaloTag in 10% and 30% glycerol are 102.1 µm and 102.1 µm, respectively.2 / s and 51.3 µm 2 / s.
[0190] like Figure 1B As shown, when HaloTag was measured at 200 frames per second (FPS) under SMT conditions, the diffusion coefficients of HaloTag at 10% and 30% glycerol were determined to be 52.4 and 34.2 µm, respectively. 2 / s, which is slower overall than expected. Figure 1B , column "theoretical (µm) 2 / s), estimating the radius. However, increasing the frame rate leads to measurements closer to theoretically expected results. Similar results were observed with Halo-protein 1 ( Figure 1B The column “Measured SMT (µm)” 2 / s), constant tracking settings”). The discrepancy between the SMT measurement results and the theoretical values can still be attributed to two sources. First, when the tracking settings (e.g., search radius) are optimized for each frame rate, better measurements of the diffusion coefficient are obtained ( Figure 1B (Last column). Secondly, the Stokes radius, or hydration radius, of the protein is strongly dependent on the medium. The measured diffusion coefficient can be used with optimized tracing settings to fit the estimated Stokes radius under our experimental conditions. The Stokes radius of HaloTag was estimated to be 3.6 nm, and the Stokes radius of HaloTag-protein 1 was estimated to be 4.2 nm. Using these radii, we give... Figure 1B , column "theoretical (µm) 2 / s), the theoretical value in the fitted Stokes radius. Finally, in Figure 6B The corrections applied in the model (based on a comprehensive tracking model that considers jump cutoff, tracking error, and other effects) can be used to estimate the diffusion coefficient we will measure in our determination, giving our estimated Stokes radius. Figure 1B "Corrected prediction (µm)" 2 / s), based on the fitted radius. The values in the "Corrected Prediction" and "SMT Measurement, Optimized Tracking Settings" columns are very consistent.
[0191] Figure 1CA plot of the mean diffusion coefficients of HaloTag and Halo-protein 1 with a - / + 98% confidence interval relative to the number of fields of view (FOV) used for calculation is provided as a guide for data collection. Interestingly, despite the two proteins being very similar, the SMT technique was able to distinguish them under every test condition. This suggests that small changes in the amino acid sequence of a protein have an effect on its motion (e.g., due to alterations in its hydration radius and interactions with surrounding molecules) sufficient to enable the SMT to detect these types of subtle changes. Furthermore, despite the inherent difficulties in generating the spatiotemporal trajectories of rapidly diffusing proteins in solution, measurements using the currently disclosed method are validated by demonstrating a strong overall agreement between experimental measurements and corresponding Stokes-Einstein theory.
[0192] 5.2. Example 2: SMT can identify protein-protein interactions. This embodiment illustrates the use of the methods disclosed herein to identify the interaction between a protein and its ligand.
[0193] The direct application of the SMT method disclosed in this paper is to detect protein-protein interactions; for example, if a labeled protein binds to a significantly sized partner body, the motility of the labeled protein will be significantly reduced. It has been well demonstrated that the N-terminus of protein 1 binds to protein 2 with high affinity. To determine whether SMT can be used to identify protein-protein interactions, the interaction between Halo-protein 1 (41.5 kD) and recombinant protein 2 (85.6 kD) was analyzed.
[0194] GST-protein 2 (dimeric protein 2) was prepared via bacterial expression as described above. The GST tag was removed by thrombin cleavage and purified by SEC to obtain monomeric protein 2. His-Halo-protein 1 (1-53) was prepared via bacterial expression as described above, and then... 549 Labeled and purified via SEC. Final concentration was determined by gel band intensity imaged on the Cy3 channel of an ImageQuant 800 via Nanodrop.
[0195] Halo-protein 1 and protein 2 were diluted to final concentrations of 40 pM and 30 nM, respectively, in imaging buffer (25 mM HEPES-K pH=7.6, 0.1 M EDTA pH=8.0, 12.5 mM magnesium chloride, 100 mM potassium chloride, 0.2 mM PMSF, 1 mM DTT, 0.3 mg / ml BSA, 0.01% NP40, and 30% glycerol, pH=7.9). The compounds were printed onto 384 Cell Vis glass plates via Echo 655, and protein 2 was incubated at room temperature for 10 min before adding Halo-protein 1. Protein solutions were dispensed using Integra VIAFLO. The plates were then incubated at 37°C for 2 h before imaging.
[0196] It was found that in the presence of 30% glycerol, the titration of protein 2 gradually slowed the diffusion of Halo-protein 1 (from approximately 29.2 µm). 2 / s to approximately 19.4 µm 2 / s, measured at 40 pM) Figure 2A and Figure 6C ).like Figure 2A and Figure 6C As shown, the concentration-dependent diffusion of Halo-protein 1 decreased with increasing concentration of monovalent protein 2. Given the differences in buffer composition and measurement temperature, the apparent kD of 0.9 nM was largely consistent with previous reports. Furthermore, when titrating the divalent form of protein 2, the diffusion shift of Halo-protein 1 reached 15.08 µm. 2 The minimum value was found at / s, while upon addition of monovalent protein 2, the shift reached 19.39 µm. 2 / s. Furthermore, when free, unlabeled protein 1 peptide was titrated into a mixture of 40 pM Halo-protein 1 and 30 nM protein 2, the diffusion of Halo-protein 1 was reversed in a dose-dependent manner, indicating competitive destruction ( Figure 2B and Figure 6D ).
[0197] To demonstrate the applicability of the currently disclosed method in drug discovery, tests were conducted on small molecule inhibitors and protein 1 competitive peptide alterations JF. 549 The ability of the labeled protein 1-protein 2 complex to move. A known protein 2 inhibitor (molecule B1) can increase JF in a dose-dependent manner. 549 The diffusion of labeled protein 1, with the greatest effect similar to that of competitive peptides ( Figure 6D ).
[0198] As these data demonstrate, SMT measurements of protein diffusion can detect protein-protein interactions and protein-ligand interactions, as well as the inhibition of such interactions by competitive ligands in solution, with potential sensitivity in the picomolar range.
[0199] The relevance of the published method was demonstrated by capturing the interaction between two proteins (protein 1 and protein 2). The ability to utilize the published method was also demonstrated by monitoring the disruption of this protein interaction by competitive peptides and small molecule inhibitors, indicating that its application could be in drug discovery. The currently published method requires purified proteins at picomolar concentrations, enabling the development of assays for difficult-to-purify proteins and sensitivity for measuring sub-nanomolar affinity. It is hypothesized that ligand interactions can alter protein diffusion in ways other than those caused by disruption of protein-protein interactions, including ligand-induced confirmatory changes, changes in protein stability, and perhaps more subtle changes in the protein hydration layer, leading to small but measurable variations in diffusion.
[0200] 5.3. Example 3: Detection of protein conformational changes Many enzymes are allosterically regulated, meaning that effectors bind to sites other than the enzyme's active site, whereby the effector modulates enzyme function by inducing structural / conformal changes. Such changes can affect diffusion by altering the overall shape and surface characteristics (chemical properties and topology) of proteins, which in turn affect their effective hydration radius and interactions with surrounding solution molecules. To test this feasibility, protein 3 can be used as a model. Protein 3 is a phosphatase known to undergo conformational changes during its active cycle. In its resting state, it is largely in a more closed, inactive state. Upon binding to an activating peptide, it reverts to a more open and active conformation. Cancer cells often exploit this mechanism to gain a proliferative advantage by mutating key amino acid residues that regulate this process. One example is a protein 3 mutant that primarily results in an open and active conformation.
[0201] Because fluorescent tags can contribute to the overall motility signature of target proteins in certain situations, various protein labeling methods can be utilized. The HaloTag method is a convenient autocatalytic approach, but it requires the addition of a relatively large module of approximately 40 kDa. As an alternative, sorterase labeling requires much smaller linkages, with the final product consisting of only about 6 amino acid residues, allowing small peptides linked to the fluorophore to be conjugated by the sorterase. Both methods offer flexibility in the size and shape of the final labeled protein for SMT. SMT was used to compare the diffusion of sorterase-labeled protein 3 and protein 3 mutants.
[0202] Significant differences in their overall average diffusion were observed, with protein 3 being approximately 32 μm. 2 / s, while the protein 3 mutant is approximately 42 μm. 2 / s ( Figure 3A When state arrays were used to estimate the occupancy of these proteins in different diffusion states, protein 3 and the protein 3 mutant were observed to exist in two states, one with a peak diffusion coefficient of approximately 30 µm. 2 / s, and the other is about 100 µm 2 / s ( Figure 3C Protein 3 is mainly expressed as 30 µm. 2 The / s state exists, and the mutant shows a more comparable occupancy rate in these two states, but at 100 µm 2 Slightly more in the / s state. It is worth noting that in SMT, the faster state is always undersampled, so the protein 3 mutant may exist mainly in the faster state, but through the state array, the occupancy of the two states appears to be more equal than their actual occupancy.
[0203] This results in an overall average diffusion coefficient of protein 3 of approximately 32 µm. 2 / s, while the overall average diffusion coefficient of the mutant is higher (42 µm). 2 This also leads to the assumption that it has approximately 30 µm ( / s). 2 A peak diffusion coefficient of / s represents a closed state, while a peak diffusion coefficient of approximately 100 µm represents a closed state. 2 The peak diffusion coefficient of / s represents the open state, and both protein 3 and protein 3 mutant exist as a balance between these two states.
[0204] The effective hydration radii of protein 3 and its mutant have previously been reported as 2.62 and 2.92 nm, respectively, suggesting that the diffusion of the protein 3 mutant should be about 10% slower based solely on radius. Because the opposite trend was observed, there are other factors besides the pure hydration radius that contribute to the diffusion behavior of these proteins, which could be further used to understand their structure and function.
[0205] To confirm that the diffusion changes induced by the mutation directly reflect the conformational changes, compounds (molecules M1 and M2) that have been reported to convert protein 3 mutants back to the wild-type conformation were titrated. Indeed, a dose-dependent reversal was observed at the population level. Figure 3B Furthermore, the rank of the two tested compounds was consistent with that reported in the literature. This experiment demonstrates the effectiveness of using SMT to detect organic molecules smaller than 1 kDa that bind to proteins, and to explore structural results.
[0206] To further confirm the detectability of conformational changes in protein 3, and to observe the effects of molecule M1 and another molecule MX through state arrays, two populations were observed representing two known conformations of protein 3. Figure 3C Molecular MX is a binding pocket interactor (rather than an allosteric interactor like molecule M1) and biases protein 3 and its mutants towards a conformation closer to the dominant (i.e., open) conformation of the protein 3 mutant. In a dose-dependent manner, molecule MX does indeed shift the occupancy of protein 3 from a dominant slower state to a dominant faster state, consistent with the slower state representing the dominant (closed) conformation of protein 3 and the faster state representing the dominant (open) state of the protein 3 mutant. Similarly, in a dose-dependent manner, molecule M1 shifts the occupancy of the protein 3 mutant more towards the slower state, consistent with its known activity of biasing the protein 3 mutant towards a conformation closer to protein 3. The reverse is not true – molecule MX has minimal effect on the relative state occupancy of the protein 3 mutant, while molecule M1 actually biases protein 3 even more towards the slower state.
[0207] State arrays offer a superior method for quantifying the relative occupancy of each conformation in dose-titration experiments. Calculating the “closed fraction” (for protein 3) or “open fraction” (for protein 3 mutants) as a function of molecule MX or M1 concentrations provides a larger signal window than simply viewing the overall average diffusion coefficient. Figure 3D and Figure 3B (Compared). Here, by using 10 to 50 µm 2 / s (for closed systems) or 50 to 200 µm 2 / s (for open) state array intervals averaged (weighted by occupancy of each interval) divided by 10-200 µm 2 The fractional occupancy of each state is determined by the total weighted average diffusion coefficient within a range of / s. The error is the standard error of repeatability.
[0208] Finally, it was demonstrated that this technique can be used to identify molecules that distinguish between these two conformational states. Through state array analysis, it was found that in the presence of a constant concentration of molecule M1 (which biases protein 3 towards the slower state), a higher concentration of molecule MX is required than when molecule MX is added alone to shift the occupancy of protein 3 to the faster state. Figure 3EThis indicates that molecule M1 is selectively stabilizing the slower state. It is noteworthy that molecules M1 and MX bind to different sites (allosteric versus binding pocket), therefore this is not a competitive effect. Consistent with this, even in the presence of molecule M1, at the highest concentration of molecule MX, the fraction of protein 3 in the blocked state stabilizes at 0.7, significantly higher than the 0.2 fraction at the highest dose in the absence of molecule M1. Since the effect of molecule M1 is not entirely reversible, molecule MX does not compete with molecule M1.
[0209] 5.4. Example 4: Detection of binding to proteins with rigid structures This embodiment illustrates the use of the methods disclosed herein to analyze the interaction between proteins and organic molecules smaller than 1 kDa.
[0210] Many protein-ligand interactions do not lead to significant changes in the three-dimensional (3D) structure. While conventional organic molecular drugs are typically in the range of 250 Da to 1 kDa, this represents only a few percent or less of the mass of many proteins. Given the limited overall mass increase from such ligand binding to a protein, the effect of this binding on the protein's hydration layer is likely minimal, and therefore detecting such interactions using SMT can be challenging. For example, recombinant expression of protein 4, a well-characterized organic molecular binding molecule M3, was selected for analysis. Unlike protein 3 mutants, the binding of protein 4 to its organic molecular ligand caused almost no change in the protein's 3D structure. Figure 4A SortaseTags were ligated to proteins and labeled with the JF549 fluorophore, and diffusion was tracked in the presence of DMSO (vector control) or molecule M3. The presence of molecule M3 did not cause any significant change in protein diffusion. Figure 4B ).
[0211] In searching for buffer conditions that might allow for the detection of the binding of organic molecules smaller than 1 kDa to protein 4 by diffusion measurements, analysis was conducted on dissociative agents known to destabilize protein structures, such as acetone, acetonitrile, DMSO, guanidine salts, and urea. Figures 4C-4D Unbound by theory, it is hypothesized that ionizing agents can partially unfold proteins, leading to one or more intermediate or unfolded states, and that the presence of organic molecular binders can potentially make one structure more stable than others. Given that these structures will be expected to have different effective hydration radii, they are expected to lead to differentiated diffusion. As shown ( Figures 4C-4D Under various conditions, different test liquid agents increased the difference between the DMSO control (without molecule M3) and the molecule M3-treated samples, with acetone, acetonitrile, urea, and guanidine salts being more significant than DMSO.
[0212] To analyze the effects of various experimental conditions, the concentration of the dissociative agent was titrated within a series of concentration ranges. Similar to... Figures 4C-4D The observations shown, when in Figure 4E A general trend of reduced diffusion was also observed during titration with urea, guanidine salts, and acetone. Without being limited to a specific theory, one explanation is that protein unfolding leads to an increase in the effective hydration radius, thereby reducing diffusion. Additionally, at certain concentrations, urea and guanidine salts provided conditions that distinguished the diffusion of protein 4 treated with DMSO and molecule M3, where the dynamic windows were larger; more specifically, urea at 6–7 M and guanidine salts at approximately 1 M. Figure 4E The overall trend is that molecule M3 leads to increased diffusion, consistent with the assumption that it stabilizes protein structure and reduces unfolding. Unlike the smooth transition with urea, guanidine titration resulted in a significant decrease in diffusion of DMSO-treated proteins at approximately 1 M. The complexity of this titration curve suggests that additional factors are influencing the diffusion of the tested proteins, and new insights into the diffusion state of the tested proteins are possible by adjusting the buffer composition.
[0213] To test whether this method is applicable to structure-activity-relationship (SAR) analysis, a series of dose titrations of molecular M3 analogs against protein 4 were performed in the presence of 6 M urea. Figure 4F Upon addition of these compounds, a gradual increase in the diffusion of protein 4 was observed, and apparent EC50 was measured to compare their potency. These compounds were also characterized using other conventional assays, such as fluorescence polarization (FP, measuring the displacement of fluorescently labeled probes bound to the same pocket) and differential scanning fluorometry (DSF, measuring protein unwinding / unwinding), commonly used in SAR analysis. The order of potency measured by SMT largely followed that of FP, and molecules with higher potency as measured by SMT generally exhibited a greater increase in melting temperature (Tm) as measured by DSF. The results indicate that SMT is indeed suitable for SAR analysis.
[0214] 5.5. Example 5: Tracing the diffusion of inherently disordered regions This embodiment illustrates the use of the methods disclosed herein to analyze the interactions of proteins containing intrinsically disordered regions (IDRs) with other molecules (e.g., organic molecules less than 1 kDa).
[0215] The human proteome comprises a continuum of proteins / domains, from structured to unstructured. Integral domains (IDRs) are abundant within this continuum and play a crucial role in biology. However, due to their lack of stable structure, IDRs are unsuitable for routine biophysical methods such as crystallography and electron microscopy. Compared to other proteins / domains with relatively stable tertiary structures, IDRs typically exist in an ensemble of interchangeable conformations. Because these conformational changes can lead to variations in the effective hydration radius of a protein, proteins containing IDRs are readily analyzed for motion-focused approaches, and tracing these motions can provide insights into the conformational profile of the IDR, including how it relates to the protein's biological function.
[0216] Protein 5 was analyzed as a model of IDR, and its secondary structure was reported to be largely missing. The movement of protein 5 labeled with JF549 via the SortaseTag at the N-terminus was tracked, and its diffusion coefficient was determined. Molecule M4 was reported as a covalently modified protein 5 that binds to it. A gradual increase in protein 5 diffusion was observed upon titration of the compound. Figure 5 Unrestricted by any particular theory, these results indicate variations in the interactions between protein 5 and buffer components, such as the direct interaction between the protein and molecule M4. Therefore, SMT provides a novel tool for studying IDR and its interactions with ligands.
[0217] 5.6. Examples 6: Single-molecule fluorescence polarization This example illustrates the use of single-molecule fluorescence polarization to leverage the orientation-dependent fluorescence properties of fluorophores sufficiently robustly bound to target biomolecules, thereby enabling the characterization of the latter's molecular dynamics. This method (complemented by translational single-molecule tracking (SMT)) provides insights into molecular size, conformational changes, and binding dynamics in diverse microenvironments. While translational SMT is influenced by factors beyond molecular size, such as local conditions (e.g., viscosity, matrix-like or cell boundaries, and microfluidic flow), single-molecule fluorescence polarization operates independently of the molecular environment at its initial approximation. Single-molecule fluorescence polarization can capture temporal dynamics through spatiotemporal correlation functions and provide valuable information about molecular size and changes due to binding and conformational events.
[0218] method: Several methods can be used to perform single-molecule fluorescence polarization: (1) time-correlated single-photon counting (TCSPC), (2) step-scan pump-probe technique, (3) ultra-long lifetime fluorophores, and (4) advanced optical techniques.
[0219] Time-correlated single-photon counting (TCSPC), performed by detecting the arrival time of a single photon with picosecond precision, allows for accurate measurements of fluorescence lifetime, which can be crucial for resolving dynamics at the nanosecond scale. TCSPC achieves extremely high temporal resolution using 2D TCSPC via a single-photon avalanche diode (SPAD) array and a photon counting module. This method, used in conjunction with a polarization-sensitive readout, is well-suited for studying the rapid rotational dynamics and short fluorescence lifetimes characteristic of many biological fluorophores. It enhances the ability to distinguish different fluorophore states or orientations.
[0220] Step-scan pump-probe technology modulates the polarization of excitation and probe light, and the resulting fluorescence emission over time provides insights into the orientation / rotation and dynamics of the fluorophore. Step-scan pump-probe technology uses step-scan pump-probe spectroscopic microscopy to measure polarization-dependent and time-dependent fluorescence loss dynamics. It can be used for optical filtering of subgroups with different molecular sizes, orientations, or dynamics, and for studying the dynamics of systems in which fluorophore orientation changes rapidly after excitation (such as in protein dynamics or structural changes in membranes).
[0221] Ultralong-lived fluorophores exhibit fluorescence lifetimes significantly longer than typical organic fluorophores (e.g., several nanoseconds to several microseconds or longer). Ultralong-lived fluorophores (e.g., carbon dots, quantum dots, nanodiamonds) can be used to significantly extend depolarization times beyond typical fluorescence lifetimes. They can be used to measure rotational dynamics and depolarization processes over extended timescales, enabling the study of slow molecular motion or mobility-constrained environments.
[0222] Advanced optical techniques (e.g., stress-engineered optics) enable precise spatial manipulation and control of the polarization state of light, which is crucial for techniques such as wobbling anisotropy and polarization filtering. Advanced optical techniques include advanced optical methods involving phase and polarization control. These techniques enable high-precision polarization-related measurements, allowing the extraction of detailed information about fluorophore orientation and dynamics.
[0223] discuss: At the single-molecule and single-photon levels, single-molecule fluorescence polarization utilizes fluorescence properties controlled by the alignment of transition dipole moments of the fluorophore. For common fluorophores (such as JF549, based on rhodamine), absorption and emission probabilities are related to the orientation of the fluorophore relative to the polarization of incident light (known as fluorescence anisotropy). This phenomenon (which is influenced by rotational dynamics within the excited-state lifetime of the molecule) provides temporal contrast for revealing molecular size, intermolecular and intramolecular dynamics, and binding events.
[0224] Current camera-based translational SMT faces challenges because its integration time (>20 µs) is significantly longer than typical fluorescence lifetimes (<100 ns) and rotational dynamics (<100 ns). To address this issue, the time-averaged fluorescence intensity correlation (i.e., wobbling anisotropy) under specific polarization can be measured using the method described in this paper.
[0225] In the case of oligomerization, single-molecule fluorescence polarization provides contrast by detecting changes in fluorophore orientation and rotational degrees of freedom during oligomer formation. This contrast arises from the anisotropy of fluorescence emission as the monomer transitions to the oligomeric state.
[0226] Furthermore, single-molecule fluorescence polarization reveals how conformational changes affect the orientation and dynamics of fluorophores attached to specific sites within the molecule. This capability enables the characterization of dynamic structural transitions, such as protein folding-unfolding events or nucleic acid conformational changes, with extremely high sensitivity and spatial resolution.
[0227] Key methods include time-resolved anisotropy measurements, which track changes in fluorescence polarization over time to reveal the dynamics of oligomer formation, dissociation, and intramolecular conformation. Polarization-sensitive imaging techniques, combined with advanced optical control, facilitate the spatial mapping of these events in complex biological environments.
[0228] Single-molecule fluorescence polarization enables the characterization of oligomerization processes and intramolecular conformational dynamics at a level of detail that is difficult to achieve with ensemble averaging methods. This method not only provides insights into the stoichiometry and structural dynamics of biomolecules but also offers a means to correlate these dynamics with functional changes in biological systems. Ultimately, single-molecule fluorescence polarization can reveal the complexity of molecular assembly pathways and dynamic structural changes, and advance our understanding of biological functions and disease mechanisms.
[0229] 6. Exemplary Implementation Scheme A. This disclosure provides a method for identifying the interaction between a target molecule and a test molecule, comprising: (a) contacting a cell-free sample containing a plurality of said target molecules with a plurality of said test molecules; (b) tracking the plurality of said target molecules over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (c) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the target molecules in the presence of said test molecules; and (d) comparing the motion of the target molecules obtained in (c) with the motion of a reference target molecule, wherein the motion of the reference target molecule is the motion of the target molecules in the absence of said test molecules; wherein the change in the motion of the target molecules compared to the motion of the reference target molecule indicates the interaction between the target molecules and the test molecules.
[0230] A1. The method described in A, wherein the method is a high-throughput method.
[0231] A2. The method as described in A or A1, wherein the motion change is calculated as a change in: (a) the diffusion coefficient obtained from the maximum likelihood estimator; (b) the geometrically mean posterior diffusion coefficient; (c) the median of the jump length distribution; (d) the third quartile of the jump length distribution; (e) the median radius of gyration; (f) the mean posterior diffusion coefficient; (g) the mean square displacement; (h) the median bond angle; (i) the spatiotemporal trajectory length; (j) the anisotropic decay time; (k) the spatial range of the probe; (l) the number and wavelength of the concatenated fluorescent markers; (m) the occupancy of different diffusion states obtained from the state array; (n) the polarization of the concatenated fluorescent markers; or (o) the state occupancy obtained by inference.
[0232] A3. The method as described in any one of A to A2, wherein the change in motion is calculated as a change in the diffusion coefficient.
[0233] A4. The method of any one of A to A3, wherein an increase or decrease in the motion of the target molecule compared to the motion of the reference target molecule indicates an interaction between the target molecule and the test molecule.
[0234] A5. The method of any one of A to A4, wherein the target molecule is an organic molecule less than 1 kDa.
[0235] A6. The method of any one of A to A5, wherein the target molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
[0236] A7. The method as described in A6, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
[0237] A8. The method as described in A6 or A7, wherein the protein comprises disordered domains.
[0238] A9. The method as described in A8, wherein the protein does not contain structured domains.
[0239] A10. The method as described in A6, wherein the peptide is a ligand.
[0240] A11. The method of any one of A to A4, wherein the target molecule is a nanomaterial.
[0241] A12. The method of any one of A to A4, wherein the target molecule is a synthetic polymer.
[0242] A13. The method of any one of A to A12, wherein the test molecule is an organic molecule less than 1 kDa.
[0243] A14. The method of any one of A to A13, wherein the test molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
[0244] A15. The method as described in A14, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
[0245] A16. The method as described in A14 or A15, wherein the protein comprises disordered domains.
[0246] A17. The method as described in A16, wherein the protein does not contain structured domains.
[0247] A18. The method as described in A14, wherein the peptide is a ligand.
[0248] A19. The method of any one of A to A12, wherein the test molecule is a nanomaterial.
[0249] A20. The method of any one of A to A12, wherein the test molecule is a synthetic polymer.
[0250] A21. The method of any one of A to A20, wherein the target molecule is labeled.
[0251] A22. The method of any one of A to A21, wherein the target molecule is fluorescently labeled.
[0252] A23. The method of any one of A to A22, wherein the test molecule is labeled.
[0253] A24. The method of any one of A to A23, wherein the test molecule is fluorescently labeled.
[0254] A25. The method of any one of A to A24, wherein the change in the motion of the target molecule compared to the motion of the reference target molecule indicates a direct or indirect interaction between the target molecule and the test molecule.
[0255] A26. The method of any one of A to A25, wherein the interaction between the target molecule and the test molecule results in a conformational change of the target molecule.
[0256] A27. The method of any one of A to A25, wherein the interaction between the target molecule and the test molecule results in an increase in the mass of the target molecule.
[0257] A28. The method of any one of A to A27, wherein the cell-free sample comprises a solution.
[0258] A29. The method as described in A28, wherein the solution comprises a liquid release agent, a carrier, a viscosity agent, or a combination thereof.
[0259] A30. The method as described in A29, wherein the solution contains a viscosity agent.
[0260] A31. The method as described in A30, wherein the viscosity agent comprises glycerin.
[0261] A32. The method as described in A31, wherein the solution contains at least about 30% glycerol.
[0262] A33. The method of any one of A28 to A32, wherein the solution comprises a temperature gradient, a chemical gradient, at least two phases, or a combination thereof.
[0263] A34. The method of any one of A to A33, wherein the volume of the cell-free sample is from about 0.1 µl to about 100 µl.
[0264] A35. The method of any one of A to A34, wherein the change in motion is measured as the change in the diffusion coefficient of the target molecule compared to the diffusion coefficient of the reference target molecule, and the change is at least about 0.001%, at least about 0.005%, at least 0.01%, at least about 0.05%, at least about 0.1%, at least about 0.5%, at least about 1%, at least about 1.5%, at least about 2%, or at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10%.
[0265] A36. The method of any one of A to A35, wherein the duration of the motion change of the target molecule indicates the interaction between the target molecule and the test molecule compared to the duration of the motion change of the reference target molecule.
[0266] A37. The method of any one of A to A36, wherein the reversibility of the motion change of the target molecule indicates the interaction between the target molecule and the test molecule, compared with the reversibility of the motion change of the reference target molecule.
[0267] A38. The method of any one of A to A37, wherein the interaction between the target molecule and the test molecule results in the oligomerization of the target molecule.
[0268] A39. The method of any one of A to A38, wherein the interaction between the target molecule and the test molecule is reversible.
[0269] A40. The method of any one of A to A39, wherein the interaction between the target molecule and the test molecule is irreversible.
[0270] A41. The method of any one of A to A40, wherein the target molecule and / or the test molecule is a component of a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts or animal extracts.
[0271] A42. The method as described in A41, wherein the bacterial extract, the cell extract, the tissue extract, the plant extract, or the animal extract is a lysate.
[0272] A43. The method of any one of A to A42, wherein the target molecule and / or the test molecule is a component of a mixture of serum, blood and other biological samples.
[0273] A44. The method of any one of A to A43, wherein the target molecule and / or the test molecule is a component of a mixture of buffer and glycerol.
[0274] A45. The method of any one of A to A44, wherein the target molecule and / or the test molecule is labeled with a fluorescent protein.
[0275] A46. The method of any one of A to A45, wherein the target molecule and / or the test molecule is labeled by conjugation of synthetic nanomaterials or polymers.
[0276] A47. The method of any one of A to A46, wherein the target molecule and / or the test molecule is labeled with a fluorescent protein.
[0277] A48. The method of any one of A to A47, wherein the plurality of target molecules are conjugated with a plurality of fluorescent labels.
[0278] A49. The method of any one of claims A to A48, wherein the target molecule and / or the test molecule is labeled by conjugation with synthetic nanomaterials or polymers.
[0279] A50. The method of any one of A to A49, wherein the interaction between the target molecule and the test molecule results in a change in the temperature stability of the target molecule.
[0280] B. This disclosure provides a method for identifying the interaction between a test molecule and a target protein comprising a disordered domain, comprising: (a) contacting a cell-free sample comprising a plurality of said target proteins with a plurality of said test molecules; (b) tracking the plurality of said target proteins over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (c) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the target proteins in the presence of said test molecules; and (d) comparing the motion of said target proteins obtained in (c) with the motion of a reference target protein, wherein the motion of the reference target protein is the motion of the target protein in the absence of said test molecules; wherein a change in the motion of the target protein comprising the disordered domains compared to the motion of the reference target protein indicates an interaction between the target protein comprising the disordered domains and the test molecule.
[0281] B1. The method described in B, wherein the method is a high-throughput method.
[0282] B2. The method as described in B or B1, wherein the motion change is calculated as a change in: (a) the diffusion coefficient obtained from the maximum likelihood estimator; (b) the geometrically mean posterior diffusion coefficient; (c) the median of the jump length distribution; (d) the third quartile of the jump length distribution; (e) the median radius of gyration; (f) the mean posterior diffusion coefficient; (g) the mean square displacement; (h) the median bond angle; (i) the spatiotemporal trajectory length; (j) the anisotropic decay time; (k) the spatial range of the probe; (l) the number and wavelength of the concatenated fluorescent markers; (m) the occupancy of different diffusion states obtained from the state array; (n) the polarization of the concatenated fluorescent markers; or (o) the state occupancy obtained by inference.
[0283] B3. The method as described in any one of B to B2, wherein the change in motion is calculated as a change in the diffusion coefficient.
[0284] B4. The method of any one of B to B3, wherein an increase or decrease in the motion of the target protein containing the disordered domain, compared to the motion of the reference target protein, indicates an interaction between the target protein containing the disordered domain and the test molecule.
[0285] B5. The method of any one of B to B4, wherein the target protein comprising the disordered domain is selected from the group consisting of antibodies, receptors and enzymes.
[0286] B6. The method of any one of B to B5, wherein the target protein comprising the disordered domain does not contain a structured domain.
[0287] B7. The method of any one of B to B6, wherein the test molecule is an organic molecule less than 1 kDa.
[0288] B8. The method of any one of B to B7, wherein the test molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
[0289] B9. The method as described in B8, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
[0290] B10. The method as described in B8 or B9, wherein the protein comprises a disordered domain.
[0291] B11. The method as described in B10, wherein the protein does not contain structured domains.
[0292] B12. The method as described in B8, wherein the peptide is a ligand.
[0293] B13. The method of any one of B to B12, wherein the target protein comprising the disordered domain is labeled.
[0294] B14. The method of any one of B to B13, wherein the target protein comprising the disordered domain is fluorescently labeled.
[0295] B15. The method of any one of B to B14, wherein the test molecule is labeled.
[0296] B16. The method of any one of B to B15, wherein the test molecule is fluorescently labeled.
[0297] B17. The method of any one of B to B16, wherein the change in the motion of the target protein containing the disordered domain, compared to the motion of the reference target protein, indicates a direct or indirect interaction between the target protein containing the disordered domain and the test molecule.
[0298] B18. The method of any one of B to B17, wherein the interaction between the target protein and the test molecule, comprising the disordered domain, results in a conformational change of the target protein.
[0299] B19. The method of any one of B to B17, wherein the interaction between the target protein and the test molecule, comprising the disordered domain, results in an increase in the mass of the target protein.
[0300] B20. The method of any one of B to B19, wherein the cell-free sample comprises a solution.
[0301] B21. The method as described in B20, wherein the solution contains a viscosity agent.
[0302] B22. The method as described in B20 or B21, wherein the solution comprises a liquid release agent, a carrier, a viscosity agent, or a combination thereof.
[0303] B23. The method as described in B22, wherein the viscosity agent comprises glycerin.
[0304] B24. The method as described in B23, wherein the solution contains at least about 30% glycerol.
[0305] B25. The method of any one of B20 to B24, wherein the solution comprises a temperature gradient, a chemical gradient, at least two phases, or a combination thereof.
[0306] B26. The method of any one of B to B25, wherein the volume of the cell-free sample is from about 0.1 µl to about 100 µl.
[0307] B27. The method of any one of B to B26, wherein the change in motion is measured as the change in the diffusion coefficient of the target protein compared to the diffusion coefficient of the reference target protein, and the change is at least about 0.001%, at least about 0.005%, at least 0.01%, at least about 0.05%, at least about 0.1%, at least about 0.5%, at least about 1%, at least about 1.5%, at least about 2%, or at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10%.
[0308] B28. The method of any one of B to B27, wherein the duration of the motion change of the target protein comprising the disordered domain indicates the interaction between the target protein and the test molecule, compared to the duration of the motion change of the reference target protein.
[0309] B29. The method of any one of B to B28, wherein the reversibility of the motion change of the target protein containing the disordered domain, compared with the reversibility of the motion change of the reference target protein, indicates the interaction between the target protein and the test molecule.
[0310] B30. The method of any one of B to B29, wherein the interaction between the target protein and the test molecule of the disordered domain results in the oligomerization of the target protein.
[0311] B31. The method of any one of B to B30, wherein the interaction between the target protein comprising the disordered domain and the test molecule is reversible.
[0312] B32. The method of any one of B to B31, wherein the interaction between the target protein comprising the disordered domain and the test molecule is irreversible.
[0313] B33. The method of any one of B to B32, wherein the target protein of the disordered domain and / or the test molecule is a component of a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts or animal extracts.
[0314] B34. The method as described in B33, wherein the bacterial extract, the cell extract, the tissue extract, the plant extract, or the animal extract is a lysate.
[0315] B35. The method of any one of B to B34, wherein the target protein comprising the disordered domain and / or the test molecule is a component of a mixture of serum, blood, and other biological samples.
[0316] B36. The method of any one of B to B35, wherein the target protein of the disordered domain and / or the test molecule are components of a mixture of buffer and glycerol.
[0317] B37. The method of any one of B to B36, wherein the target protein and / or the test molecule is labeled with a fluorescent protein.
[0318] B38. The method of any one of B to B37, wherein the target protein and / or the test molecule is labeled by conjugation of synthetic nanomaterials or polymers.
[0319] B39. The method of any one of B to B38, wherein the conformational change of the target protein results in a change in the temperature stability of the target protein.
[0320] C. This disclosure provides a method for analyzing target molecules in a test solution, comprising: (a) tracking a plurality of said target molecules in the test solution over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (b) analyzing the measurements of said plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of said target molecules in the test solution; and (c) comparing the motion of said target molecules obtained in (b) with the motion of a reference target molecule, wherein the motion of said reference target molecule is the motion of said target molecule in a reference solution; wherein: (i) a change in the motion of said target molecule compared to the motion of said reference target molecule indicates that said target molecule is affected by said test solution; or (ii) no change in the motion of said target molecule compared to the motion of said reference target molecule indicates that said target molecule is not affected by said test solution.
[0321] C1. The method as described in C, wherein the method is a high-throughput method.
[0322] C2. The method as described in C or C1, wherein the motion change is calculated as a change in: (a) the diffusion coefficient obtained from the maximum likelihood estimator; (b) the geometrically mean posterior diffusion coefficient; (c) the median of the jump length distribution; (d) the third quartile of the jump length distribution; (e) the median radius of gyration; (f) the mean posterior diffusion coefficient; (g) the mean square displacement; (g) the median bond angle; (i) the spatiotemporal trajectory length; (j) the anisotropic decay time; (k) the spatial range of the probe; (l) the number and wavelength of the concatenated fluorescent markers; (m) the occupancy of different diffusion states obtained from the state array; (n) the polarization of the concatenated fluorescent markers; or (o) the state occupancy obtained by inference.
[0323] C3. The method as described in any one of C to C2, wherein the change in motion is calculated as a change in the diffusion coefficient.
[0324] C4. The method as described in any one of C to C3, wherein the target molecule is an organic molecule with a value of less than 1 kDa.
[0325] C5. The method of any one of C to C4, wherein the target molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
[0326] C6. The method as described in C5, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
[0327] C7. The method as described in C5 or C6, wherein the protein comprises a disordered domain.
[0328] C8. The method as described in C7, wherein the protein does not contain structured domains.
[0329] C9. The method as described in C5, wherein the peptide is a ligand.
[0330] C10. The method as described in any one of C to C3, wherein the target molecule is a nanomaterial.
[0331] C11. The method of any one of C to C3, wherein the target molecule is a synthetic polymer.
[0332] C12. The method of any one of C to C11, wherein the target molecule is labeled.
[0333] C13. The method of any one of C to C12, wherein the target molecule is fluorescently labeled.
[0334] C14. The method of any one of C to C13, wherein the test solution contains a liquid release agent.
[0335] C15. The method as described in C14, wherein the dissociating agent is urea.
[0336] C16. The method of any one of C to C15, wherein the test solution contains a viscosity agent.
[0337] C17. The method as described in C16, wherein the viscosity agent is glycerin.
[0338] C18. The method of any one of C to C17, wherein the test solution comprises a gradient.
[0339] C19. The method as described in C17, wherein the gradient is a temperature gradient, a chemical gradient, or a combination thereof.
[0340] C20. The method of any one of C to C19, wherein the test solution comprises at least two phases or a combination thereof.
[0341] C21. The method of any one of C to C20, wherein the interaction between the target protein and the test solution results in a conformational change of the target molecule.
[0342] C22. The method of any one of C to C21, wherein the duration of the motion change of the target molecule indicates that the target molecule is affected by the test solution, compared with the duration of the motion change of the reference target molecule.
[0343] C23. The method of any one of C to C22, wherein the reversibility of the motion change of the target molecule indicates that the target molecule is affected by the test solution, compared with the reversibility of the motion change of the reference target molecule.
[0344] C24. The method of any one of C to C23, wherein the interaction between the target molecule and the test solution is reversible.
[0345] C25. The method of any one of C to C24, wherein the interaction between the target molecule and the test solution is irreversible.
[0346] C26. The method of any one of C to C25, wherein the target molecule and / or the reference target molecule is a component of a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts or animal extracts.
[0347] C27. The method as described in C26, wherein the bacterial extract, the cell extract, the tissue extract, the plant extract, or the animal extract is a lysate.
[0348] C28. The method of any one of C to C27, wherein the target molecule and / or the reference target molecule is a component of a mixture of serum, blood and other biological samples.
[0349] C29. The method of any one of C to C28, wherein the target molecule and / or the reference target molecule is a component comprising a mixture of one or more buffer solutions and glycerol.
[0350] C30. The method of any one of C to C29, wherein the target molecule and / or the reference target molecule is labeled with a fluorescent protein.
[0351] C31. The method of any one of C to C30, wherein the target molecule and / or the reference target molecule is labeled by conjugation of synthetic nanomaterials or polymers.
[0352] D. This disclosure provides a method for determining the form of a target molecule, comprising: (a) tracking a plurality of said target molecules in a cell-free sample over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (b) analyzing said plurality of spatiotemporal trajectories and / or rotational motion measurements to determine the motion of said target molecules; and (c) comparing the motion of said target molecules obtained in (b) with the motion of a reference target molecule, wherein the motion of said reference target molecule is a form of motion of said target molecule; wherein: (i) a change in the motion of said target molecule compared to the motion of said reference target molecule indicates that said target molecule has a different form than said reference target molecule; or (ii) no change in the motion of said target molecule compared to the motion of said reference target molecule indicates that said target molecule has the same form as said reference target molecule.
[0353] D1. The method described in D, wherein the method is a high-throughput method.
[0354] D2. The method as described in D or D1, wherein the motion change is calculated as a change in: (a) the diffusion coefficient obtained from the maximum likelihood estimator; (b) the geometric mean posterior diffusion coefficient; (c) the median of the jump length distribution; (d) the third quartile of the jump length distribution; (e) the median radius of gyration; (f) the mean posterior diffusion coefficient; (h) the mean square displacement; (i) the median bond angle; (j) the spatiotemporal trajectory length; (j) the anisotropic decay time; (k) the spatial range of the probe; (l) the number and wavelength of the concatenated fluorescent markers; (m) the occupancy of different diffusion states obtained from the state array; (n) the polarization of the concatenated fluorescent markers; or (o) the state occupancy obtained by inference.
[0355] D3. The method as described in any one of D to D2, wherein the change in motion is calculated as a change in the diffusion coefficient.
[0356] D4. The method of any one of D to D3, wherein the target molecule is an organic molecule less than 1 kDa.
[0357] D5. The method of any one of D to D4, wherein the target molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
[0358] D6. The method as described in D5, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
[0359] D7. The method as described in D5 or D6, wherein the protein comprises a disordered domain.
[0360] D8. The method as described in D7, wherein the protein does not contain structured domains.
[0361] D9. The method as described in D5, wherein the peptide is a ligand.
[0362] D10. The method as described in any one of D to D3, wherein the target molecule is a nanomaterial.
[0363] D11. The method of any one of D to D3, wherein the target molecule is a synthetic polymer.
[0364] D12. The method of any one of D to D11, wherein the target molecule is labeled.
[0365] D13. The method of any one of D to D12, wherein the target molecule is fluorescently labeled.
[0366] D14. The method of any one of D to D13, wherein the cell-free sample comprises a solution.
[0367] D15. The method as described in D14, wherein the solution comprises a liquid release agent, a carrier, a viscosity agent, or a combination thereof.
[0368] D16. The method as described in D15, wherein the solution contains a dissociating agent.
[0369] D17. The method as described in D16, wherein the dissociating agent is urea.
[0370] D18. The method of any one of D14 to D17, wherein the solution comprises a viscosity agent.
[0371] D19. The method as described in D18, wherein the viscosity agent comprises glycerin.
[0372] D20. The method as described in D19, wherein the solution contains at least about 30% glycerol.
[0373] D21. The method of any one of D14 to D20, wherein the solution comprises a temperature gradient, a chemical gradient, at least two phases, or a combination thereof.
[0374] D22. The method of any one of D to D21, wherein the volume of the cell-free sample is from about 0.1 µl to about 100 µl.
[0375] D23. The method of any one of D to D22, wherein the change in motion is measured as the change in the diffusion coefficient of the target molecule compared to the diffusion coefficient of the reference target molecule, and the change is at least about 0.001%, at least about 0.005%, at least 0.01%, at least about 0.05%, at least about 0.1%, at least about 0.5%, at least about 1%, at least about 1.5%, at least about 2%, or at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10%.
[0376] D24. The method of any one of D to D23, wherein the form of the target molecule is a post-translational modified form of the target molecule.
[0377] D25. The method of any one of D to D23, wherein the form of the target molecule is the wild-type form of the target molecule.
[0378] D26. The method of any one of D to D23, wherein the form of the target molecule is a mutant form of the target molecule.
[0379] D27. The method of any one of D to D26, wherein the duration of the motion change of the target molecule indicates that the target molecule has a different form than the reference target molecule compared to the duration of the motion change of the reference target molecule.
[0380] D28. The method of any one of D to D27, wherein the reversibility of the motion change of the target molecule indicates that the target molecule has a different form than the reference target molecule, compared with the reversibility of the motion change of the reference target molecule.
[0381] D29. The method of any one of D to D28, wherein the target molecule and / or the reference target molecule is a component of a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts or animal extracts.
[0382] D30. The method as described in D29, wherein the bacterial extract, the cell extract, the tissue extract, the plant extract, or the animal extract is a lysate.
[0383] D31. The method of any one of D to D30, wherein the target molecule and / or the reference target molecule is a component of a mixture of serum, blood and other biological samples.
[0384] D32. The method of any one of D to D31, wherein the target molecule and / or the reference target molecule is a component of a mixture of buffer solution and glycerol.
[0385] D33. The method of any one of D to D32, wherein the target molecule and / or the reference target molecule is labeled with a fluorescent protein.
[0386] D34. The method of any one of D to D33, wherein the target molecule and / or the reference target molecule is labeled by conjugation of synthetic nanomaterials or polymers.
[0387] E. This disclosure provides a method for identifying a test molecule capable of distinguishing at least two target molecules, comprising: (a) contacting a cell-free sample containing a plurality of first target molecules with a plurality of said test molecules; (b) tracking the plurality of first target molecules over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (c) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the first target molecules in the presence of said test molecules; (d) contacting a cell-free sample containing a plurality of second target molecules with the plurality of said test molecules; (e) tracking the plurality of second target molecules over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (f) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the second target molecules in the presence of said test molecules; and (g) comparing the motions of the first target molecules and the motions of the second target molecules obtained in (c) and (f); wherein the changes in the motions of the first target molecules and the second target molecules indicate that the test molecule is capable of distinguishing the two target molecules.
[0388] E1. The method described in E, wherein the method is a high-throughput method.
[0389] E2. The method as described in E or E1, wherein the motion change is calculated as a change in: (a) the diffusion coefficient obtained from the maximum likelihood estimator; (b) the geometrically mean posterior diffusion coefficient; (c) the median of the jump length distribution; (d) the third quartile of the jump length distribution; (e) the median radius of gyration; (f) the mean posterior diffusion coefficient; (g) the mean square displacement; (h) the median bond angle; (i) the spatiotemporal trajectory length; (j) the anisotropic decay time; (k) the spatial range of the probe; (l) the number and wavelength of the concatenated fluorescent markers; (m) the occupancy of different diffusion states obtained from the state array; (n) the polarization of the concatenated fluorescent markers; or (o) the state occupancy obtained by inference.
[0390] E3. The method as described in any one of E to E2, wherein the change in motion is calculated as a change in the diffusion coefficient.
[0391] E4. The method of any one of E to E3, wherein the target molecule is an organic molecule less than 1 kDa.
[0392] E5. The method of any one of E to E4, wherein the target molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
[0393] E6. The method as described in E5, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
[0394] E7. The method as described in E5 or E6, wherein the protein comprises a disordered domain.
[0395] E8. The method as described in E7, wherein the protein does not contain structured domains.
[0396] E9. The method as described in E5, wherein the peptide is a ligand.
[0397] E10. The method of any one of E to E3, wherein the target molecule is a nanomaterial.
[0398] E11. The method of any one of E to E3, wherein the target molecule is a synthetic polymer.
[0399] E12. The method as described in any one of E to E11, wherein the test molecule is an organic molecule with a value of less than 1 kDa.
[0400] E13. The method of any one of E to E12, wherein the test molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
[0401] E14. The method as described in E13, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
[0402] E15. The method as described in E13 or E14, wherein the protein comprises a disordered domain.
[0403] E16. The method as described in E15, wherein the protein does not contain structured domains.
[0404] E17. The method as described in E13, wherein the peptide is a ligand.
[0405] E18. The method of any one of E to E17, wherein the target molecule is labeled.
[0406] E19. The method of any one of E to E18, wherein the target molecule is fluorescently labeled.
[0407] E20. The method of any one of E to E19, wherein the test molecule is labeled.
[0408] E21. The method of any one of E to E20, wherein the test molecule is fluorescently labeled.
[0409] E22. The method of any one of E to E21, wherein the first target molecule and the second target molecule are related target molecules.
[0410] E23. The method as described in E22, wherein at least one of the target molecules is the wild-type form of the target molecule.
[0411] E24. The method as described in E22, wherein at least one of the target molecules is a mutant form of the target molecule.
[0412] E25. The method as described in E22, wherein the first target molecule and the second target molecule are the target molecules in the same or different conformational states.
[0413] E26. The method as described in E22, wherein at least one of the target molecules is a post-translational modification of the target molecule.
[0414] E27. The method as described in E22, wherein the first target molecule and the second target molecule are homologs, orthologs, or paralogs.
[0415] E28. The method of any one of E to E21, wherein the first target molecule and the second target molecule are unrelated target molecules.
[0416] E29. The method of any one of E to E28, further comprising: contacting a cell-free sample containing a plurality of third target molecules with a plurality of test molecules; tracking the plurality of third target molecules over time to provide measurements of a third plurality of spatiotemporal trajectories and / or rotational motions; analyzing the measurements of the third plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the third target molecules in the presence of the test molecules; and comparing the motion of the third target molecules with the motion obtained in (c) and (f); wherein the change in the motion of the third target molecules relative to the first target molecules and the second target molecules indicates that the test molecules are able to distinguish the three target molecules.
[0417] E30. The method of any one of E to E29, wherein the duration of the motion changes of the first target molecule and the second target molecule indicates that the test molecule is able to distinguish between the two target molecules.
[0418] E31. The method of any one of E to E30, wherein the reversibility of the motion changes of the first target molecule and the second target molecule indicates that the test molecule is able to distinguish between the two target molecules.
[0419] E32. The method of any one of E to E31, wherein the first target molecule, the second target molecule and / or the test molecule are components of a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts or animal extracts.
[0420] E33. The method as described in E32, wherein the bacterial extract, the cell extract, the tissue extract, the plant extract, or the animal extract is a lysate.
[0421] E34. The method of any one of E to E33, wherein the first target molecule, the second target molecule and / or the test molecule are components of a mixture of serum, blood and other biological samples.
[0422] E35. The method of any one of E to E34, wherein the first target molecule, the second target molecule and / or the test molecule are components of a mixture of buffer solution and glycerol.
[0423] E36. The method of any one of E to E35, wherein the first target molecule, the second target molecule and / or the test molecule are labeled with a fluorescent protein.
[0424] E37. The method of any one of E to E36, wherein the first target molecule, the second target molecule and / or the test molecule are labeled by conjugation of synthetic nanomaterials or polymers.
[0425] E38. The method of any one of E to E37, wherein the first target molecule and the second target molecule are distinguished by the difference in their fluorescent labels.
[0426] F. This disclosure provides a method for identifying one or more test molecules that induce conformational changes in target molecules, comprising: (a) contacting a cell-free sample containing a plurality of said target molecules with a plurality of test molecules, wherein each sample is contacted with a different test molecule; (b) tracking the plurality of said target molecules in each sample over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (c) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the target molecules in the presence of each of the different test molecules; and (d) comparing the motion of the target molecules obtained in (c) with the motion of a reference target molecule, wherein the motion of the reference target molecule is the motion of the target molecule in the presence of a test molecule that does not induce conformational changes in the target molecule; wherein a change in the motion of the target molecule compared to the motion of the reference target molecule indicates an interaction between the target molecule and the one or more test molecules that induce conformational changes in the target molecule.
[0427] F1. The method described in F, wherein the method is a high-throughput method.
[0428] F2. The method as described in F or F1, wherein the motion change is calculated as a change in: (a) the diffusion coefficient obtained from the maximum likelihood estimator; (b) the geometrically mean posterior diffusion coefficient; (c) the median of the jump length distribution; (d) the third quartile of the jump length distribution; (e) the median radius of gyration; (f) the mean posterior diffusion coefficient; (g) the median bond angle; (i) the spatiotemporal trajectory length; (j) the anisotropic decay time; (k) the spatial range of the probe; (l) the number and wavelength of the concatenated fluorescent markers; (m) the occupancy of different diffusion states obtained from the state array; (n) the polarization of the concatenated fluorescent markers; or (o) the state occupancy obtained by inference.
[0429] F3. The method as described in any one of F to F2, wherein the change in motion is calculated as a change in the diffusion coefficient.
[0430] F4. The method of any one of F to F3, wherein the target molecule is an organic molecule less than 1 kDa.
[0431] F5. The method of any one of F to F3, wherein the target molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
[0432] F6. The method as described in F5, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
[0433] F7. The method as described in F5 or F6, wherein the protein comprises disordered domains.
[0434] F8. The method as described in F7, wherein the protein does not contain structured domains.
[0435] F9. The method as described in F5, wherein the peptide is a ligand.
[0436] F10. The method of any one of F to F3, wherein the target molecule is a nanomaterial.
[0437] F11. The method of any one of F to F3, wherein the target molecule is a synthetic polymer.
[0438] F12. The method of any one of F to F11, wherein the test molecule is an organic molecule less than about 1 kDa.
[0439] F13. The method of any one of F to F12, wherein the test molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
[0440] F14. The method as described in F13, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
[0441] F15. The method as described in F13 or F14, wherein the protein comprises a disordered domain.
[0442] F16. The method as described in F15, wherein the protein does not contain structured domains.
[0443] F17. The method as described in F13, wherein the peptide is a ligand.
[0444] F18. The method of any one of F to F17, wherein the target molecule is labeled.
[0445] F19. The method of any one of F to F18, wherein the target molecule is fluorescently labeled.
[0446] F20. The method as described in any one of F to F19, wherein the test molecule is labeled.
[0447] F21. The method of any one of F to F20, wherein the test molecule is fluorescently labeled.
[0448] F22. The method of any one of F to F21, wherein the cell-free sample comprises a solution.
[0449] F23. The method as described in F22, wherein the solution comprises a liquid release agent, a viscosity agent, or a combination thereof.
[0450] F24. The method as described in F23, wherein the viscosity agent comprises glycerin.
[0451] F25. The method as described in F24, wherein the solution contains at least about 30% glycerol.
[0452] F26. The method of any one of F22 to F25, wherein the solution comprises a temperature gradient, a chemical gradient, at least two phases, or a combination thereof.
[0453] F27. The method of any one of F to F26, wherein the volume of the sample is from about 0.1 µl to about 100 µl.
[0454] F28. The method of any one of F to F27, wherein the change in motion is measured as the change in the diffusion coefficient of the target molecule in the presence of a test molecule and in the presence of a reference test molecule that does not induce a confirmatory change, and the change is at least about 0.001%, at least about 0.005%, at least 0.01%, at least about 0.05%, at least about 0.1%, at least about 0.5%, at least about 1%, at least about 1.5%, at least about 2%, or at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10%.
[0455] F29. The method of any one of F to F28, wherein the duration of the motion change of the target molecule indicates the interaction between the target molecule and the one or more test molecules that induce conformational changes in the target molecule, compared to the duration of the motion change of the reference target molecule.
[0456] F30. The method of any one of F to F29, wherein the reversibility of the motion change of the target molecule indicates the interaction between the target molecule and the one or more test molecules that induce conformational changes in the target molecule, compared with the reversibility of the motion change of the reference target molecule.
[0457] F31. The method of any one of F to F30, wherein the interaction between the target molecule and the one or more test molecules is reversible.
[0458] F32. The method as described in any one of F to F31, wherein the interaction between the target molecule and the one or more test molecules is irreversible.
[0459] F33. The method of any one of F to F32, wherein the target molecule, the reference target molecule and / or the one or more test molecules are components of a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts or animal extracts.
[0460] F34. The method as described in F33, wherein the bacterial extract, the cell extract, the tissue extract, the plant extract, or the animal extract is a lysate.
[0461] F35. The method of any one of F to F34, wherein the target molecule, the reference target molecule and / or the one or more test molecules are components of a mixture of serum, blood and other biological samples.
[0462] F36. The method of any one of F to F35, wherein the target molecule, the reference target molecule and / or the one or more test molecules are components of a mixture of buffer and glycerol.
[0463] F37. The method of any one of F to F36, wherein the target molecule, the reference target molecule, and / or the one or more test molecules are labeled with a fluorescent protein.
[0464] F38. The method of any one of F to F37, wherein the target molecule, the reference target molecule and / or the one or more test molecules are labeled by conjugation of synthetic nanomaterials or polymers.
[0465] F39. The method of any one of F to F38, wherein the conformational change of the target molecule is related to a change in the temperature stability of the target molecule.
[0466] G. This disclosure provides a method for determining the dose response of a target molecule to a test molecule, comprising: (a) contacting a plurality of cell-free samples containing a plurality of said target molecules with said test molecules, wherein the plurality of cell-free samples are contacted with a series of test molecule doses; (b) in the presence of said series of test molecules, tracking the plurality of said target molecules over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (c) in the presence of said series of test molecules, analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions of the target molecules to determine the motion of the target molecules at each dose of the test molecules; and (d) comparing the motions of the target molecules obtained in step (c) at different test molecule doses to determine the dose response of the target molecules to said test molecules.
[0467] G1. This disclosure provides a method for determining the difference in dose response of two target molecules to a test molecule, comprising: (a) contacting a first plurality of cell-free samples containing a plurality of first target molecules with the test molecule, wherein the first plurality of cell-free samples are contacted with a series of test molecule doses; (b) in the presence of the series of test molecule doses, tracking the plurality of target molecules over time to provide measurements of a first plurality of spatiotemporal trajectories and / or rotational motions; (c) in the presence of the series of test molecule doses, analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions of the target molecules to determine the motion of the first target molecules at each concentration of the test molecule; (d) comparing the motions of the target molecules obtained in step (c) at different test molecule doses to determine the dose response of the target molecules to the test molecule; (e) repeating steps (a)-(d) with a second target molecule to determine the dose response of the second target molecule to the test molecule; and (f) comparing the dose response of the first target molecule with the dose response of the second target molecule to determine the difference in the response of the first target molecule and the second target molecule to the test molecule.
[0468] G2. The method as described in G or G1, wherein the method is a high-throughput method.
[0469] G3. The method as described in G or G1, wherein the motion is calculated as: (a) the diffusion coefficients of the plurality of spatiotemporal trajectories obtained from the maximum likelihood estimator; (b) the geometric mean posterior diffusion coefficients of the plurality of spatiotemporal trajectories; (c) the median of the jump length distributions of the plurality of spatiotemporal trajectories; (d) the third quartile of the jump length distributions of the plurality of spatiotemporal trajectories; (e) the median radius of gyration of the plurality of spatiotemporal trajectories; (f) the mean posterior diffusion coefficients of the plurality of spatiotemporal trajectories; (g) the mean square displacements of the plurality of spatiotemporal trajectories; (h) the median bond angles of the plurality of spatiotemporal trajectories; (i) the spatiotemporal trajectory lengths of the plurality of spatiotemporal trajectories; (j) the anisotropic decay time; (k) the spatial range of detection; (l) the number and wavelength of the concatenated fluorescent markers; (m) the occupancy of different diffusion states obtained from the state array; (n) the polarization of the concatenated fluorescent markers; or (o) the state occupancy obtained by inference.
[0470] G4. The method as described in any one of G to G3, wherein the motion is calculated as a diffusion coefficient.
[0471] G5. The method of any one of G to G4, wherein the target molecule is an organic molecule less than 1 kDa.
[0472] G6. The method of any one of G to G5, wherein the target molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
[0473] G7. The method as described in G6, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
[0474] G8. The method as described in G6 or G7, wherein the protein comprises a disordered domain.
[0475] G9. The method as described in G8, wherein the protein does not contain structured domains.
[0476] G10. The method as described in G6, wherein the peptide is a ligand.
[0477] G11. The method as described in any one of G to G4, wherein the target molecule is a nanomaterial.
[0478] G12. The method of any one of G to G4, wherein the target molecule is a synthetic polymer.
[0479] G13. The method of any one of G to G12, wherein the test molecule is an organic molecule less than 1 kDa.
[0480] G14. The method of any one of G to G13, wherein the test molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
[0481] G15. The method as described in G14, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
[0482] G16. The method as described in G14 or G15, wherein the protein comprises a disordered domain.
[0483] G17. The method as described in G16, wherein the protein does not contain structured domains.
[0484] G18. The method as described in G14, wherein the peptide is a ligand.
[0485] G19. The method as described in any one of G to G18, wherein the target molecule is labeled.
[0486] G20. The method of any one of G to G19, wherein the target molecule is fluorescently labeled.
[0487] G21. The method as described in any one of G to G20, wherein the test molecule is labeled.
[0488] G22. The method of any one of G to G21, wherein the test molecule is fluorescently labeled.
[0489] G23. The method of any one of G1 to G22, wherein the first target molecule and the second target molecule are related target molecules.
[0490] G24. The method as described in G23, wherein at least one of the target molecules is the wild-type form of the target molecule.
[0491] G25. The method as described in G23, wherein at least one of the target molecules is a mutant form of the target molecule.
[0492] G26. The method as described in G23, wherein the first target molecule and the second target molecule are the target molecules in the same or different conformational states.
[0493] G27. The method as described in G23, wherein at least one of the target molecules is a post-translational modified form of the target molecule.
[0494] G28. The method as described in G23, wherein the first target molecule and the second target molecule are homologs, orthologs, or paralogs.
[0495] G29. The method as described in G1, wherein the first target molecule and the second target molecule are unrelated target molecules.
[0496] G30. The method as described in G1, wherein the first cell-free sample and the second cell-free sample comprise a solution containing a dissociation agent, a carrier, a viscosity agent, or a combination thereof.
[0497] G31. The method as described in G30, wherein the solution contains a viscosity agent.
[0498] G32. The method as described in G31, wherein the viscosity agent comprises glycerin.
[0499] G33. The method as described in G32, wherein the solution contains at least about 30% glycerol.
[0500] G34. The method of any one of G30 to G33, wherein the solution comprises a temperature gradient, a chemical gradient, at least two phases or a combination thereof.
[0501] G35. The method of any one of G to G34, wherein comparing the motion of the target molecule obtained in step (c) at different test molecule doses further includes comparing the duration of the motion changes of the target molecule.
[0502] G36. The method of any one of G to G35, wherein comparing the motion of the target molecule obtained in step (c) at different test molecule doses further comprises comparing the reversibility of the motion changes of the target molecule.
[0503] G37. The method of any one of G to G36, wherein the interaction between the target molecule and the test molecule is reversible.
[0504] G38. The method of any one of G to G37, wherein the interaction between the target molecule and the test molecule is irreversible.
[0505] G39. The method of any one of G to G38, wherein the target molecule and / or the test molecule is a component of a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts or animal extracts.
[0506] G40. The method as described in G39, wherein the bacterial extract, the cell extract, the tissue extract, the plant extract, or the animal extract is a lysate.
[0507] G41. The method of any one of G to G40, wherein the target molecule and / or the test molecule is a component of a mixture of serum, blood and other biological samples.
[0508] G42. The method of any one of G to G41, wherein the target molecule and / or the test molecule is a component of a mixture of buffer and glycerol.
[0509] G43. The method of any one of G to G42, wherein the target molecule and / or the test molecule is labeled with a fluorescent protein.
[0510] G44. The method of any one of G to G43, wherein the target molecule and / or the test molecule is labeled by conjugation of synthetic nanomaterials or polymers.
[0511] G45. The method of any one of G to G44, wherein the first target molecule and the second target molecule are distinguished by the difference in their fluorescent labels.
[0512] G46. The method as described in any one of G to G45, wherein three or more target molecules are analyzed.
[0513] H. This disclosure provides a method for identifying a test molecule capable of distinguishing at least two target molecules, comprising: (a) contacting a cell-free sample containing a plurality of first target molecules and a plurality of second target molecules with a plurality of said test molecules; (b) tracking the plurality of first target molecules over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (c) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the first target molecules in the presence of said test molecules; (d) tracking the plurality of second target molecules over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (e) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the second target molecules in the presence of said test molecules; and (f) comparing the motions of the first target molecules and the motions of the second target molecules obtained in (c) and (f); wherein the changes in the motions of the first target molecules and the second target molecules indicate that the test molecule is capable of distinguishing the two target molecules.
[0514] H1. The method as described in H, wherein the method is a high-throughput method.
[0515] H2. The method as described in H or H1, wherein the motion change is calculated as a change in: (a) the diffusion coefficient obtained from the maximum likelihood estimator; (b) the geometrically mean posterior diffusion coefficient; (c) the median of the jump length distribution; (d) the third quartile of the jump length distribution; (e) the median radius of gyration; (f) the mean posterior diffusion coefficient; (g) the mean square displacement; (h) the median bond angle; (i) the spatiotemporal trajectory length; (j) the anisotropic decay time; (k) the spatial range of the probe; (l) the number and wavelength of the concatenated fluorescent markers; (m) the occupancy of different diffusion states obtained from the state array; (n) the polarization of the concatenated fluorescent markers; or (o) the state occupancy obtained by inference.
[0516] H3. The method as described in any one of H to H2, wherein the change in motion is calculated as a change in the diffusion coefficient.
[0517] H4. The method as described in H to H3, wherein the target molecule is an organic molecule with a value less than 1 kDa.
[0518] H5. The method as described in H to H4, wherein the target molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
[0519] H6. The method as described in H5, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
[0520] H7. The method as described in H5 or H6, wherein the protein comprises a disordered domain.
[0521] H8. The method as described in H7, wherein the protein does not contain structured domains.
[0522] H9. The method as described in H5, wherein the peptide is a ligand.
[0523] H10. The method as described in H to H3, wherein the target molecule is a nanomaterial.
[0524] H11. The method as described in H to H3, wherein the target molecule is a synthetic polymer.
[0525] H12. The method as described in any one of H to H11, wherein the test molecule is an organic molecule with a value of less than 1 kDa.
[0526] H13. The method of any one of H to H12, wherein the test molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
[0527] H14. The method as described in H13, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
[0528] H15. The method as described in H13 or H14, wherein the protein comprises a disordered domain.
[0529] H16. The method as described in H15, wherein the protein does not contain structured domains.
[0530] H17. The method as described in H13, wherein the peptide is a ligand.
[0531] H18. The method of any one of H to H17, wherein the target molecule is labeled.
[0532] H19. The method of any one of H to H18, wherein the target molecule is fluorescently labeled.
[0533] H20. The method as described in any one of H to H19, wherein the test molecule is labeled.
[0534] H21. The method as described in any one of H to H20, wherein the test molecule is fluorescently labeled.
[0535] H22. The method of any one of H to H21, wherein the first target molecule and the second target molecule are related target molecules.
[0536] H23. The method as described in H22, wherein at least one of the target molecules is the wild-type form of the target molecule.
[0537] H24. The method as described in H22, wherein at least one of the target molecules is a mutant form of the target molecule.
[0538] H25. The method as described in H22, wherein the first target molecule and the second target molecule are the target molecules in the same or different conformational states.
[0539] H26. The method as described in H22, wherein at least one of the target molecules is a post-translational modified form of the target molecule.
[0540] H27. The method as described in H22, wherein the first target molecule and the second target molecule are homologs, orthologs, or paralogs.
[0541] H28. The method of any one of H to H21, wherein the first target molecule and the second target molecule are unrelated target molecules.
[0542] H29. The method of any one of H to H28, further comprising: contacting a cell-free sample containing a plurality of third target molecules with a plurality of test molecules; tracking the plurality of third target molecules over time to provide measurements of a third plurality of spatiotemporal trajectories and / or rotational motions; analyzing the measurements of the third plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the third target molecules in the presence of the test molecules; and comparing the motion of the third target molecules with the motion obtained in (c) and (f); wherein the change in the motion of the third target molecules relative to the first target molecules and the second target molecules indicates that the test molecules are capable of distinguishing the three target molecules.
[0543] H30. The method as described in any one of H to H29, wherein the duration of the motion change of the first molecule, compared to the duration of the motion change of the second molecule, indicates that the test molecule is able to distinguish between the two target molecules.
[0544] H31. The method as described in any one of H to H30, wherein the reversibility of the motion change of the first molecule, compared with the reversibility of the motion change of the second molecule, indicates that the test molecule is able to distinguish between the two target molecules.
[0545] H32. The method of any one of H to H31, wherein the interaction between the target molecule and the test molecule is reversible.
[0546] H33. The method of any one of H to H32, wherein the interaction between the target molecule and the test molecule is irreversible.
[0547] H34. The method of any one of H to H33, wherein the first target molecule, the second target molecule and / or the test molecule are components of a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts or animal extracts.
[0548] H35. The method as described in H34, wherein the bacterial extract, the cell extract, the tissue extract, the plant extract, or the animal extract is a lysate.
[0549] H36. The method of any one of H to H35, wherein the first target molecule, the second target molecule and / or the test molecule are components of a mixture of serum, blood and other biological samples.
[0550] H37. The method of any one of H to H36, wherein the first target molecule, the second target molecule and / or the test molecule are components of a mixture of buffer solution and glycerol.
[0551] H38. The method of any one of H to H37, wherein the first target molecule, the second target molecule and / or the test molecule are labeled with a fluorescent protein.
[0552] H39. The method of any one of H to H38, wherein the first target molecule, the second target molecule and / or the test molecule are labeled by conjugation of synthetic nanomaterials or polymers.
[0553] I. This disclosure provides a method for analyzing a test solution containing a target molecule, comprising: (a) tracking a plurality of target molecules in the test solution over time to provide measurements of a plurality of spatiotemporal trajectories and / or rotational motions; (b) analyzing the measurements of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the target molecules in the test solution; and (c) comparing the motion of the target molecules obtained in (b) with the motion of a reference target molecule, wherein the motion of the reference target molecule is the motion of the target molecule in a reference solution; wherein: the comparison in step (c) is used to determine the properties of the test solution.
[0554] I1. The method described in I, wherein the method is a high-throughput method.
[0555] I2. The method as described in I or I1, wherein the motion of the target molecule is calculated as follows: (a) the diffusion coefficient obtained from the maximum likelihood estimate; (b) the geometrically mean posterior diffusion coefficient; (c) the median of the jump length distribution; (d) the third quartile of the jump length distribution; (e) the median radius of gyration; (f) the mean posterior diffusion coefficient; (g) the mean square displacement; (g) the median bond angle; (i) the spatiotemporal trajectory length; (j) the anisotropic decay time; (k) the spatial range of detection; (l) the number and wavelength of the conjugated fluorescent tags; (m) the occupancy of different diffusion states obtained from the state array; (n) the polarization of the conjugated fluorescent tags; or (o) the state occupancy obtained by inference.
[0556] I3. The method as described in any one of I to I2, wherein the change in motion is calculated as a change in the diffusion coefficient.
[0557] I4. The method of any one of I to I3, wherein the target molecule is an organic molecule less than 1 kDa.
[0558] 15. The method of any one of 1 to 14, wherein the target molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
[0559] I6. The method as described in I5, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
[0560] I7. The method as described in I5 or I6, wherein the protein comprises a disordered domain.
[0561] I8. The method as described in I7, wherein the protein does not contain structured domains.
[0562] I9. The method as described in I5, wherein the peptide is a ligand.
[0563] I10. The method of any one of I to I3, wherein the target molecule is a nanomaterial.
[0564] I11. The method of any one of I to I3, wherein the target molecule is a synthetic polymer.
[0565] I12. The method of any one of I to I11, wherein the target molecule is labeled.
[0566] I13. The method of any one of I to I12, wherein the target molecule is fluorescently labeled.
[0567] I14. The method of any one of I to I13, wherein the test solution comprises a dissociating agent.
[0568] I15. The method as described in I14, wherein the dissociating agent is urea.
[0569] I16. The method of any one of I to I15, wherein the test solution comprises a viscosity agent.
[0570] I17. The method as described in I16, wherein the viscosity agent is glycerin.
[0571] I18. The method of any one of I to I17, wherein the test solution comprises a gradient.
[0572] I19. The method as described in I18, wherein the gradient is a temperature gradient, a chemical gradient, or a combination thereof.
[0573] I20. The method of any one of I to I19, wherein the test solution comprises at least two phases or a combination thereof.
[0574] I21. The method of any one of I to I20, wherein the interaction between the target protein and the test solution results in a conformational change of the target molecule.
[0575] I22. The method of any one of I to I21, wherein the property of the test solution is pH, ion concentration, organic molecule concentration, or viscoelasticity.
[0576] I23. The method as described in I22, wherein the viscoelasticity is viscosity.
[0577] I24. The method of any one of I to I23, wherein the test solution is a biological sample obtained from the subject.
[0578] I25. The method of any one of I to I24, wherein the properties of the test solution are used to diagnose the disease of the subject.
[0579] I26. The method as described in any one of I to I25, wherein the disease is cancer.
[0580] I27. The method of any one of I to I26, wherein comparing the motion of the target molecule obtained in (b) with the motion of a reference target molecule further comprises comparing the duration of the motion change of the target molecule with the duration of the motion change of the reference target molecule.
[0581] I28. The method of any one of I to I27, wherein comparing the motion of the target molecule obtained in (b) with the motion of a reference target molecule further comprises comparing the reversibility of the change in motion of the target molecule with the reversibility of the change in motion of the reference target molecule.
[0582] I29. The method of any one of I to I28, wherein the interaction between the target molecule and the test solution is reversible.
[0583] I30. The method of any one of I to I29, wherein the interaction between the target molecule and the test solution is irreversible.
[0584] I31. The method of any one of I to I30, wherein the target molecule and / or the reference target molecule is a component of a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts or animal extracts.
[0585] I32. The method as described in I31, wherein the bacterial extract, the cell extract, the tissue extract, the plant extract, or the animal extract is a lysate.
[0586] I33. The method of any one of I to I32, wherein the target molecule and / or the reference target molecule is a component of a mixture of serum, blood and other biological samples.
[0587] I34. The method of any one of I to I33, wherein the target molecule and / or the reference target molecule is a component of a mixture of buffer solution and glycerol.
[0588] I35. The method of any one of I to I34, wherein the first target molecule, the second target molecule and / or the test molecule are labeled with a fluorescent protein.
[0589] I36. The method of any one of I to I35, wherein the first target molecule, the second target molecule and / or the test molecule are labeled by conjugation of synthetic nanomaterials or polymers.
[0590] J. The method as described in any one of A to I36, further comprising time-correlated single-photon counting.
[0591] J1. The method as described in any one of A to J, further comprising step-scan pump-probe spectroscopic microscopy.
[0592] J2. The method of any one of A to J1, wherein the target molecule and / or the test molecule is labeled with an ultralong-lifetime fluorophore.
[0593] J3. The method as described in any one of A to J2, further comprising advanced optical techniques.
[0594] J4. The method as described in any one of A to J3, further comprising oscillating anisotropy and / or polarization filtering.
[0595] J5. The method of any one of A to J4, wherein the motion change is calculated as a change in the polarization of the conjoined fluorescent marker, and wherein determining the change in the polarization of the conjoined fluorescent marker includes time-correlated single-photon counting.
[0596] J6. The method of any one of A to J5, wherein the motion change is calculated as a change in the polarization of the conjugated fluorescent label, and wherein determining the change in the polarization of the conjugated fluorescent label comprises step-scan pump-probe spectral microscopy.
[0597] J7. The method of any one of A to J6, wherein the target molecule and / or the test molecule is labeled with an ultralong-lifetime fluorophore.
[0598] J8. The method of any one of A to J7, wherein the motion change is calculated as a change in the polarization of the coupled fluorescent marker, and wherein determining the change in the polarization of the coupled fluorescent marker comprises advanced optical techniques.
[0599] J9. The method of any one of A to J8, wherein the motion change is calculated as a change in the polarization of the conjoined fluorescent marker, and wherein determining the change in the polarization of the conjoined fluorescent marker includes oscillating anisotropy and / or polarization filtering.
[0600] K. A system for performing the method as described in any one of A to J9.
[0601] K1. The system as described in K includes a microfluidic device.
[0602] * * * * * * * * Although the subject matter and its advantages have been described in detail, it should be understood that various changes, substitutions, and modifications can be made without depar...
Claims
1. A method for identifying the interaction between a target molecule and a test molecule, comprising: (a) Contacting a cell-free sample containing a plurality of the target molecules with a plurality of the test molecules; (b) Tracking multiple target molecules over time to provide measurements of multiple spatiotemporal trajectories and / or rotational motions; (c) Analyze the measurement results of the multiple spatiotemporal trajectories and / or rotational motions to determine the motion of the target molecule in the presence of the test molecule; as well as (d) The motion of the target molecule obtained in (c) is compared with the motion of a reference target molecule, wherein the motion of the reference target molecule is the motion of the target molecule in the absence of the test molecule; The change in the motion of the target molecule, compared to the motion of the reference target molecule, indicates the interaction between the target molecule and the test molecule.
2. The method of claim 1, wherein the method is a high-throughput method.
3. The method of claim 1 or 2, wherein the change in motion is calculated as the following change: (a) Diffusion coefficient obtained from the maximum likelihood estimator; (b) Geometric mean posterior diffusion coefficient; (c) The median of the jump length distribution; (d) The third quartile of the jump length distribution; (e) Median radius of gyration; (f) Mean posterior diffusion coefficient; (g) Mean square displacement; (h) Median bond angle; (i) Spatiotemporal trajectory length; (j) Anisotropic decay time; (k) The spatial range of the detection; (l) The number and wavelength of the conjugated fluorescent markers; (m) Occupancy rate of different diffusion states obtained from the state array; (n) Polarization of the conjugated fluorescent label; or (o) The state obtained through inference occupies.
4. The method of any one of claims 1 to 3, wherein the change in motion is calculated as a change in the diffusion coefficient.
5. The method of any one of claims 1 to 4, wherein an increase or decrease in the motion of the target molecule compared to the motion of the reference target molecule indicates an interaction between the target molecule and the test molecule.
6. The method of any one of claims 1 to 5, wherein the interaction between the target molecule and the test molecule is reversible or irreversible.
7. The method of any one of claims 1 to 6, wherein the duration and / or reversibility of the motion change of the target molecule indicates the interaction between the target molecule and the test molecule, compared with the duration and / or reversibility of the motion change of the reference target molecule.
8. The method of any one of claims 1 to 7, wherein the target molecule and / or the test molecule is a component comprising a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts, or animal extracts.
9. The method of claim 8, wherein the bacterial extract, the cell extract, the tissue extract, the plant extract, or the animal extract is a lysate.
10. The method of any one of claims 1 to 9, wherein the target molecule and / or the test molecule is a component of a mixture comprising serum, blood and / or other biological samples.
11. The method of any one of claims 1 to 10, wherein the target molecule and / or the test molecule is a component comprising a mixture of buffer and glycerol.
12. The method of any one of claims 1 to 11, wherein the target molecule and / or the test molecule is an organic molecule with a value of less than 1 kDa.
13. The method of any one of claims 1 to 12, wherein the target molecule and / or the test molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
14. The method of claim 13, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
15. The method of claim 13 or 14, wherein the protein comprises disordered domains and / or does not comprise structured domains.
16. The method of claim 13, wherein the peptide is a ligand.
17. The method of any one of claims 1 to 11, wherein the target molecule and / or the test molecule is a nanomaterial or a synthetic polymer.
18. The method of any one of claims 1 to 17, wherein the target molecule and / or the test molecule are labeled.
19. The method of any one of claims 1 to 18, wherein the target molecule and / or the test molecule are fluorescently labeled.
20. The method of any one of claims 1 to 19, wherein the target molecule and / or the test molecule is labeled with a fluorescent protein.
21. The method of any one of claims 1 to 20, wherein the plurality of target molecules and / or the plurality of test molecules are conjugated with a plurality of fluorescent labels.
22. The method of any one of claims 1 to 21, wherein the target molecule and / or the test molecule is labeled by conjugation with synthetic nanomaterials or polymers.
23. The method of any one of claims 1 to 22, wherein the change in the motion of the target molecule compared to the motion of the reference target molecule indicates a direct or indirect interaction between the target molecule and the test molecule.
24. The method of any one of claims 1 to 23, wherein the interaction between the target molecule and the test molecule results in a conformational change of the target molecule, an increase in the mass of the target molecule, a change in the temperature stability of the target molecule, and / or oligomerization of the target molecule.
25. The method of any one of claims 1 to 24, wherein the cell-free sample comprises a solution.
26. The method of claim 25, wherein the solution comprises a liquid release agent, a carrier, a viscosity agent, or a combination thereof.
27. The method of claim 26, wherein the viscosity agent comprises glycerin.
28. The method of claim 27, wherein the solution contains at least about 30% glycerol.
29. The method of any one of claims 25 to 28, wherein the solution comprises a temperature gradient, a chemical gradient, at least two phases, or a combination thereof.
30. The method of any one of claims 1 to 29, wherein the volume of the cell-free sample is from about 0.1 µl to about 100 µl.
31. The method of any one of claims 1 to 30, wherein the change in motion is measured as the change in the diffusion coefficient of the target molecule compared to the diffusion coefficient of the reference target molecule, and the change is at least about 0.001%, at least about 0.005%, at least 0.01%, at least about 0.05%, at least about 0.1%, at least about 0.5%, at least about 1%, at least about 1.5%, at least about 2%, or at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10%.
32. A method for identifying the interaction between a test molecule and a target protein containing a disordered domain, comprising: (a) Contact a cell-free sample containing a plurality of the target proteins with a plurality of the test molecules; (b) Tracking multiple target proteins over time to provide measurements of multiple spatiotemporal trajectories and / or rotational motions; (c) Analyze the measurements of the multiple spatiotemporal trajectories and / or rotational motions to determine the motion of the target protein in the presence of the test molecule; as well as (d) The motion of the target protein obtained in (c) is compared with the motion of a reference target protein, wherein the motion of the reference target protein is the motion of the target protein in the absence of the test molecule; The change in the motion of the target protein containing the disordered domain, compared to the motion of the reference target protein, indicates the interaction between the target protein containing the disordered domain and the test molecule.
33. The method of claim 32, wherein the method is a high-throughput method.
34. The method of claim 32 or 33, wherein the change in motion is calculated as the following change: (a) Diffusion coefficient obtained from the maximum likelihood estimator; (b) Geometric mean posterior diffusion coefficient; (c) The median of the jump length distribution; (d) The third quartile of the jump length distribution; (e) Median radius of gyration; (f) Mean posterior diffusion coefficient; (g) Mean square displacement; (h) Median bond angle; (i) Spatiotemporal trajectory length; (j) Anisotropic decay time; (k) The spatial range of the detection; (l) The number and wavelength of the conjugated fluorescent markers; (m) Occupancy rate of different diffusion states obtained from the state array; (n) Polarization of the conjugated fluorescent label; or (o) The state obtained through inference occupies.
35. The method of any one of claims 32 to 34, wherein the change in motion is calculated as a change in the diffusion coefficient.
36. The method of any one of claims 32 to 35, wherein an increase or decrease in the motion of the target protein containing the disordered domain, compared to the motion of the reference target protein, indicates an interaction between the target protein containing the disordered domain and the test molecule.
37. The method of any one of claims 32 to 36, wherein the interaction between the target protein comprising the disordered domain and the test molecule is reversible or irreversible.
38. The method of any one of claims 32 to 37, wherein the duration and / or reversibility of the motion change of the target protein containing the disordered domain indicates the interaction between the target molecule and the test molecule, compared with the duration and / or reversibility of the motion change of the reference target protein.
39. The method of any one of claims 32 to 38, wherein the target protein comprising the disordered domain and / or the test molecule is a component comprising a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts, or animal extracts.
40. The method of claim 39, wherein the bacterial extract, the cell extract, the tissue extract, the plant extract, or the animal extract is a lysate.
41. The method of any one of claims 32 to 40, wherein the target protein comprising the disordered domain and / or the test molecule is a component of a mixture of serum, blood, and other biological samples.
42. The method of any one of claims 32 to 41, wherein the target protein comprising the disordered domain and / or the test molecule is a component comprising a mixture of buffer and glycerol.
43. The method of any one of claims 32 to 42, wherein the target protein comprising the disordered domain is selected from the group consisting of antibodies, receptors, and enzymes.
44. The method of any one of claims 32 to 43, wherein the target protein comprising the disordered domain does not contain a structured domain.
45. The method of any one of claims 32 to 44, wherein the test molecule is an organic molecule with a value of less than 1 kDa.
46. The method of any one of claims 32 to 45, wherein the test molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
47. The method of claim 46, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
48. The method of claim 46 or 47, wherein the protein comprises disordered domains and / or does not comprise structured domains.
49. The method of claim 46, wherein the peptide is a ligand.
50. The method of any one of claims 32 to 49, wherein the target protein and / or the test molecule comprising the disordered domain are labeled.
51. The method of any one of claims 32 to 50, wherein the target protein and / or the test molecule comprising the disordered domain are fluorescently labeled.
52. The method of any one of claims 32 to 51, wherein the target protein and / or the test molecule is labeled with a fluorescent protein.
53. The method of any one of claims 32 to 52, wherein the target protein and / or the test molecule are labeled by conjugation of synthetic nanomaterials or polymers.
54. The method of any one of claims 32 to 53, wherein the change in the motion of the target protein containing the disordered domain, compared to the motion of the reference target protein, indicates a direct or indirect interaction between the target protein containing the disordered domain and the test molecule.
55. The method of any one of claims 32 to 54, wherein the interaction between the target protein of the disordered domain and the test molecule results in a conformational change of the target protein, a change in the temperature stability of the target protein, an increase in the mass of the target protein, and / or oligomerization of the target protein.
56. The method of any one of claims 32 to 55, wherein the cell-free sample comprises a solution.
57. The method of claim 56, wherein the solution comprises a liquid release agent, a carrier, a viscosity agent, or a combination thereof.
58. The method of claim 57, wherein the viscosity agent comprises glycerin.
59. The method of claim 58, wherein the solution contains at least about 30% glycerol.
60. The method of any one of claims 56 to 59, wherein the solution comprises a temperature gradient, a chemical gradient, at least two phases, or a combination thereof.
61. The method of any one of claims 32 to 60, wherein the volume of the cell-free sample is from about 0.1 µl to about 100 µl.
62. The method of any one of claims 32 to 61, wherein the motion change is measured as the change in the diffusion coefficient of the target protein compared to the diffusion coefficient of the reference target protein, and the change is at least about 0.001%, at least about 0.005%, at least 0.01%, at least about 0.05%, at least about 0.1%, at least about 0.5%, at least about 1%, at least about 1.5%, at least about 2%, or at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10%.
63. A method for analyzing target molecules in a test solution, comprising: (a) Tracking multiple target molecules in the test solution over time to provide measurements of multiple spatiotemporal trajectories and / or rotational motions; (b) Analyze the measurement results of the multiple spatiotemporal trajectories and / or rotational motions to determine the motion of the target molecules in the test solution; as well as (c) The motion of the target molecule obtained in (b) is compared with the motion of a reference target molecule, wherein the motion of the reference target molecule is the motion of the target molecule in a reference solution; Wherein: (i) the change in the motion of the target molecule compared to the motion of the reference target molecule indicates that the target molecule is affected by the test solution; Alternatively (ii) the fact that the motion of the target molecule does not change compared to the motion of the reference target molecule indicates that the target molecule is unaffected by the test solution.
64. The method of claim 63, wherein the method is a high-throughput method.
65. The method of claim 63 or 64, wherein the change in motion is calculated as the following change: (a) Diffusion coefficient obtained from the maximum likelihood estimator; (b) Geometric mean posterior diffusion coefficient; (c) The median of the jump length distribution; (d) The third quartile of the jump length distribution; (e) Median radius of gyration; (f) Mean posterior diffusion coefficient; (g) Mean square displacement; (g) Median bond angle; (i) Spatiotemporal trajectory length; (j) Anisotropic decay time; (k) The spatial range of the detection; (l) The number and wavelength of the conjugated fluorescent markers; (m) Occupancy rate of different diffusion states obtained from the state array; (n) Polarization of the conjugated fluorescent label; or (o) The state obtained through inference occupies.
66. The method of any one of claims 63 to 65, wherein the change in motion is calculated as a change in the diffusion coefficient.
67. The method of any one of claims 63 to 66, wherein the duration and / or reversibility of the motion change of the target molecule indicates that the target molecule is affected by the test solution, compared with the duration and / or reversibility of the motion change of the reference target molecule.
68. The method of any one of claims 63 to 67, wherein the target molecule and / or the reference target molecule is a component of a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts, or animal extracts.
69. The method of claim 68, wherein the bacterial extract, the cell extract, the tissue extract, the plant extract, or the animal extract is a lysate.
70. The method of any one of claims 63 to 69, wherein the target molecule and / or the reference target molecule are components of a mixture of serum, blood, and other biological samples.
71. The method of any one of claims 63 to 70, wherein the target molecule and / or the reference target molecule is a component comprising a mixture of buffer and glycerol.
72. The method of any one of claims 63 to 71, wherein the target molecule and / or the reference target molecule are organic molecules with a value of less than 1 kDa.
73. The method of any one of claims 63 to 72, wherein the target molecule and / or the reference target molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
74. The method of claim 73, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
75. The method of claim 73 or 74, wherein the protein comprises disordered domains and / or does not comprise structured domains.
76. The method of claim 73, wherein the peptide is a ligand.
77. The method of any one of claims 63 to 72, wherein the target molecule and / or the reference target molecule is a nanomaterial or a synthetic polymer.
78. The method of any one of claims 63 to 77, wherein the target molecule and / or the reference target molecule are labeled.
79. The method of any one of claims 63 to 78, wherein the target molecule and / or the reference target molecule are fluorescently labeled.
80. The method of any one of claims 63 to 79, wherein the target molecule and / or the reference target molecule is labeled with a fluorescent protein.
81. The method of any one of claims 63 to 80, wherein the target molecule and / or the reference target molecule is labeled by conjugation with synthetic nanomaterials or polymers.
82. The method of any one of claims 63 to 81, wherein the test solution comprises a liquid release agent and / or a viscosity agent.
83. The method of claim 82, wherein the liquid release agent is urea.
84. The method of claim 82 or 83, wherein the viscosity agent is glycerin.
85. The method of any one of claims 63 to 84, wherein the test solution comprises a gradient.
86. The method of claim 85, wherein the gradient is a temperature gradient, a chemical gradient, or a combination thereof.
87. The method of any one of claims 63 to 86, wherein the test solution comprises at least two phases or a combination thereof.
88. The method of any one of claims 63 to 87, wherein the interaction between the target molecule and the test solution results in a conformational change of the target molecule.
89. The method of any one of claims 63 to 88, wherein the interaction between the target molecule and the test solution is reversible or irreversible.
90. A method for determining the form of a target molecule, comprising: (a) Tracking multiple target molecules in cell-free samples over time to provide measurements of multiple spatiotemporal trajectories and / or rotational motions; (b) Analyze the measurement results of the multiple spatiotemporal trajectories and / or rotational motions to determine the motion of the target molecule; as well as (c) The motion of the target molecule obtained in (b) is compared with the motion of a reference target molecule, wherein the motion of the reference target molecule is a form of motion of the target molecule; Wherein: (i) the change in the motion of the target molecule compared to the motion of the reference target molecule indicates that the target molecule has a different form than the reference target molecule; or (ii) the lack of change in the motion of the target molecule compared to the motion of the reference target molecule indicates that the target molecule has the same form as the reference target molecule.
91. The method of claim 90, wherein the method is a high-throughput method.
92. The method of claim 90 or 91, wherein the change in motion is calculated as the following change: (a) Diffusion coefficient obtained from the maximum likelihood estimator; (b) Geometric mean posterior diffusion coefficient; (c) The median of the jump length distribution; (d) The third quartile of the jump length distribution; (e) Median radius of gyration; (f) Mean posterior diffusion coefficient; (g) Mean square displacement; (h) Median bond angle; (i) Spatiotemporal trajectory length; (j) Anisotropic decay time; (k) The spatial range of the detection; (l) The number and wavelength of the conjugated fluorescent markers; (m) Occupancy rate of different diffusion states obtained from the state array; (n) Polarization of the conjugated fluorescent label; or (o) The state obtained through inference occupies.
93. The method of any one of claims 90 to 92, wherein the change in motion is calculated as a change in the diffusion coefficient.
94. The method of any one of claims 90 to 93, wherein the duration and / or reversibility of the motion change of the target molecule indicates that the target molecule has a different form than the reference target molecule, compared to the duration and / or reversibility of the motion change of the reference target molecule.
95. The method of any one of claims 90 to 94, wherein the target molecule and / or the reference target molecule is a component of a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts, or animal extracts.
96. The method of claim 95, wherein the bacterial extract, the cell extract, the tissue extract, the plant extract, or the animal extract is a lysate.
97. The method of any one of claims 90 to 96, wherein the target molecule and / or the reference target molecule are components of a mixture of serum, blood, and other biological samples.
98. The method of any one of claims 90 to 97, wherein the target molecule and / or the reference target molecule is a component comprising a mixture of buffer and glycerol.
99. The method of any one of claims 90 to 98, wherein the target molecule and / or the reference target molecule is an organic molecule with a value of less than 1 kDa.
100. The method of any one of claims 90 to 99, wherein the target molecule and / or the reference target molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
101. The method of claim 100, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
102. The method of claim 100 or 101, wherein the protein comprises disordered domains and / or does not comprise structured domains.
103. The method of claim 100, wherein the peptide is a ligand.
104. The method of any one of claims 90 to 98, wherein the target molecule and / or the reference target molecule is a nanomaterial or a synthetic polymer.
105. The method of any one of claims 90 to 104, wherein the target molecule and / or the reference target molecule are labeled.
106. The method of any one of claims 90 to 105, wherein the target molecule and / or the reference target molecule are fluorescently labeled.
107. The method of any one of claims 90 to 106, wherein the target molecule and / or the reference target molecule is labeled with a fluorescent protein.
108. The method of any one of claims 90 to 107, wherein the target molecule and / or the reference target molecule are labeled by conjugation of synthetic nanomaterials or polymers.
109. The method of any one of claims 90 to 108, wherein the cell-free sample comprises a solution.
110. The method of claim 109, wherein the solution comprises a liquid release agent, a carrier, a viscosity agent, or a combination thereof.
111. The method of claim 110, wherein the liquid release agent is urea.
112. The method of claim 110 or 111, wherein the viscosity agent comprises glycerin.
113. The method of claim 112, wherein the solution contains at least about 30% glycerol.
114. The method of any one of claims 109 to 113, wherein the solution comprises a temperature gradient, a chemical gradient, at least two phases, or a combination thereof.
115. The method of any one of claims 90 to 114, wherein the volume of the cell-free sample is from about 0.1 µl to about 100 µl.
116. The method of any one of claims 90 to 115, wherein the change in motion is measured as the change in the diffusion coefficient of the target molecule compared to the diffusion coefficient of the reference target molecule, and the change is at least about 0.001%, at least about 0.005%, at least 0.01%, at least about 0.05%, at least about 0.1%, at least about 0.5%, at least about 1%, at least about 1.5%, at least about 2%, or at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10%.
117. The method of any one of claims 90 to 116, wherein the form of the target molecule is a post-translational modified form of the target molecule, a wild-type form of the target molecule, or a mutant form of the target molecule.
118. A method for identifying a test molecule capable of distinguishing at least two target molecules, comprising: (a) Contact a cell-free sample containing a plurality of first target molecules with a plurality of said test molecules; (b) Track multiple first target molecules over time to provide measurements of multiple spatiotemporal trajectories and / or rotational motions; (c) Analyze the measurement results of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the first target molecule in the presence of the test molecule; (d) Contact a cell-free sample containing multiple second target molecules with multiple test molecules; (e) Tracking multiple second target molecules over time to provide measurements of multiple spatiotemporal trajectories and / or rotational motions; (f) Analyze the measurement results of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the second target molecule in the presence of the test molecule; as well as (g) Compare the motions of the first target molecule and the second target molecule obtained in (c) and (f); The changes in the motion of the first target molecule and the second target molecule indicate that the test molecule can distinguish between the two target molecules.
119. The method of claim 118, wherein the method is a high-throughput method.
120. The method of claim 118 or 119, wherein the change in motion is calculated as the following change: (a) Diffusion coefficient obtained from the maximum likelihood estimator; (b) Geometric mean posterior diffusion coefficient; (c) The median of the jump length distribution; (d) The third quartile of the jump length distribution; (e) Median radius of gyration; (f) Mean posterior diffusion coefficient; (g) Mean square displacement; (h) Median bond angle; (i) Spatiotemporal trajectory length; (j) Anisotropic decay time; (k) The spatial range of the detection; (l) The number and wavelength of the conjugated fluorescent markers; (m) Occupancy rate of different diffusion states obtained from the state array; (n) Polarization of the conjugated fluorescent label; or (o) The state obtained through inference occupies.
121. The method of any one of claims 118 to 120, wherein the change in motion is calculated as a change in the diffusion coefficient.
122. The method of any one of claims 118 to 121, wherein the duration and / or reversibility of the motion changes of the first target molecule and the second target molecule indicate that the test molecule is able to distinguish between the two target molecules.
123. The method of any one of claims 118 to 122, wherein the first target molecule, the second target molecule and / or the test molecule are components of a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts or animal extracts.
124. The method of claim 123, wherein the bacterial extract, the cell extract, the tissue extract, the plant extract, or the animal extract is a lysate.
125. The method of any one of claims 118 to 124, wherein the first target molecule, the second target molecule and / or the test molecule are components of a mixture of serum, blood and other biological samples.
126. The method of any one of claims 118 to 125, wherein the first target molecule, the second target molecule and / or the test molecule are components comprising a mixture of buffer and glycerol.
127. The method of any one of claims 118 to 126, wherein the first target molecule, the second target molecule and / or the test molecule are organic molecules with a value of less than 1 kDa.
128. The method of any one of claims 118 to 127, wherein the first target molecule, the second target molecule and / or the test molecule are selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates and lipids.
129. The method of claim 128, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
130. The method of claim 128 or 129, wherein the protein comprises disordered domains and / or does not comprise structured domains.
131. The method of claim 128, wherein the peptide is a ligand.
132. The method of any one of claims 118 to 126, wherein the first target molecule, the second target molecule and / or the test molecule are nanomaterials or synthetic polymers.
133. The method of any one of claims 118 to 132, wherein the first target molecule, the second target molecule, and / or the test molecule are labeled.
134. The method of any one of claims 118 to 133, wherein the first target molecule, the second target molecule and / or the test molecule are fluorescently labeled.
135. The method of any one of claims 118 to 134, wherein the first target molecule, the second target molecule, and / or the test molecule are labeled with a fluorescent protein.
136. The method of any one of claims 118 to 135, wherein the first target molecule, the second target molecule, and / or the test molecule are labeled by conjugation of synthetic nanomaterials or polymers.
137. The method of any one of claims 118 to 136, wherein the first target molecule and the second target molecule are distinguished by the difference in their fluorescent labels.
138. The method of any one of claims 118 to 137, wherein the first target molecule and the second target molecule are related target molecules.
139. The method of claim 138, wherein at least one of the target molecules is a wild-type form of the target molecule; wherein at least one of the target molecules is a mutant form of the target molecule; and / or wherein at least one of the target molecules is a post-translational modified form of the target molecule.
140. The method of any one of claims 118 to 138, wherein the first target molecule and the second target molecule are target molecules in the same or different conformational states; wherein the first target molecule and the second target molecule are homologs, orthologs, or paralogs; and / or wherein the first target molecule and the second target molecule are unrelated target molecules.
141. The method of any one of claims 118 to 140, further comprising: A cell-free sample containing multiple third target molecules is brought into contact with multiple of the test molecules; Tracking multiple third target molecules over time to provide measurements of a third plurality of spatiotemporal trajectories and / or rotational motions; analyzing the measurements of the third plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the third target molecules in the presence of the test molecules; and comparing the motion of the third target molecules with the motions obtained in (c) and (f); wherein the change in the motion of the third target molecules relative to the first and second target molecules indicates that the test molecules are able to distinguish the three target molecules.
142. A method for identifying one or more test molecules that induce conformational changes in target molecules, comprising: (a) Contacting a cell-free sample containing a plurality of said target molecules with a plurality of test molecules, wherein each sample is contacted with a different test molecule; (b) Tracking multiple target molecules in each sample over time to provide measurements of multiple spatiotemporal trajectories and / or rotational motions; (c) Analyze the measurement results of the multiple spatiotemporal trajectories and / or rotational motions to determine the motion of the target molecule in the presence of each of the different test molecules; as well as (d) The motion of the target molecule obtained in (c) is compared with the motion of a reference target molecule, wherein the motion of the reference target molecule is the motion of the target molecule in the presence of a test molecule that does not induce a conformational change in the target molecule. The change in the motion of the target molecule, compared to the motion of the reference target molecule, indicates the interaction between the target molecule and one or more test molecules that induce conformational changes in the target molecule.
143. The method of claim 142, wherein the method is a high-throughput method.
144. The method of claim 142 or 143, wherein the change in motion is calculated as the following change: (a) Diffusion coefficient obtained from the maximum likelihood estimator; (b) Geometric mean posterior diffusion coefficient; (c) The median of the jump length distribution; (b) The third quartile of the jump length distribution; (c) Median radius of gyration; (d) Mean posterior diffusion coefficient; (f) Mean square displacement; (g) Median bond angle; (i) Spatiotemporal trajectory length; (j) Anisotropic decay time; (k) The spatial range of the detection; (l) The number and wavelength of the conjugated fluorescent markers; (m) Occupancy rate of different diffusion states obtained from the state array; (n) Polarization of the conjugated fluorescent label; or (o) The state obtained through inference occupies.
145. The method of any one of claims 142 to 144, wherein the change in motion is calculated as a change in the diffusion coefficient.
146. The method of any one of claims 142 to 145, wherein the conformational change of the target molecule is related to a change in the temperature stability of the target molecule.
147. The method of any one of claims 142 to 146, wherein the interaction between the target molecule and the one or more test molecules is reversible or irreversible.
148. The method of any one of claims 142 to 147, wherein the duration and / or reversibility of the motion change of the target molecule indicates the interaction between the target molecule and the one or more test molecules that induce conformational changes in the target molecule, compared with the duration and / or reversibility of the motion change of the reference target molecule.
149. The method of any one of claims 142 to 148, wherein the target molecule, the reference target molecule, and / or the one or more test molecules are components of a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts, or animal extracts.
150. The method of claim 149, wherein the bacterial extract, the cell extract, the tissue extract, the plant extract, or the animal extract is a lysate.
151. The method of any one of claims 142 to 150, wherein the target molecule, the reference target molecule, and / or the one or more test molecules are components of a mixture of serum, blood, and other biological samples.
152. The method of any one of claims 142 to 151, wherein the target molecule, the reference target molecule, and / or the one or more test molecules are components comprising a mixture of buffer and glycerol.
153. The method of any one of claims 142 to 152, wherein the target molecule, the reference target molecule, and / or the one or more test molecules are organic molecules with a value less than 1 kDa.
154. The method of any one of claims 142 to 153, wherein the target molecule, the reference target molecule, and / or the one or more test molecules are selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
155. The method of claim 154, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
156. The method of claim 154 or 155, wherein the protein comprises disordered domains and / or does not comprise structured domains.
157. The method of claim 154, wherein the peptide is a ligand.
158. The method of any one of claims 142 to 152, wherein the target molecule, the reference target molecule, and / or the one or more test molecules are nanomaterials or synthetic polymers.
159. The method of any one of claims 142 to 158, wherein the target molecule, the reference target molecule, and / or the one or more test molecules are labeled.
160. The method of any one of claims 142 to 159, wherein the target molecule, the reference target molecule, and / or the one or more test molecules are fluorescently labeled.
161. The method of any one of claims 142 to 160, wherein the target molecule, the reference target molecule, and / or the one or more test molecules are labeled with a fluorescent protein.
162. The method of any one of claims 142 to 161, wherein the target molecule, the reference target molecule, and / or the one or more test molecules are labeled by conjugation of synthetic nanomaterials or polymers.
163. The method of any one of claims 142 to 162, wherein the cell-free sample comprises a solution.
164. The method of claim 163, wherein the solution comprises a liquid release agent, a viscosity agent, or a combination thereof.
165. The method of claim 164, wherein the viscosity agent comprises glycerin.
166. The method of claim 165, wherein the solution contains at least about 30% glycerol.
167. The method of any one of claims 163 to 166, wherein the solution comprises a temperature gradient, a chemical gradient, at least two phases, or a combination thereof.
168. The method of any one of claims 142 to 167, wherein the volume of the sample is from about 0.1 µl to about 100 µl.
169. The method of any one of claims 142 to 168, wherein the motion change is measured as the change in the diffusion coefficient of the target molecule in the presence of a test molecule and in the presence of a reference test molecule that does not induce a conformational change, and the change is at least about 0.001%, at least about 0.005%, at least 0.01%, at least about 0.05%, at least about 0.1%, at least about 0.5%, at least about 1%, at least about 1.5%, at least about 2%, or at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10%.
170. A method for determining the dose response of an interaction between a target molecule and a test molecule, comprising: (a) Contacting multiple cell-free samples containing multiple of the target molecules with the test molecules, wherein the multiple cell-free samples are contacted with a series of test molecule doses; (b) In the presence of the series of doses of the test molecules, multiple target molecules are tracked over time to provide measurements of multiple spatiotemporal trajectories and / or rotational motions; (c) In the presence of the series of doses of the test molecule, analyze the measurements of the multiple spatiotemporal trajectories and / or rotational motions of the target molecule to determine the motion of the target molecule at each dose of the test molecule; (d) Compare the motion of the target molecule obtained in step (c) at different test molecule doses to determine the dose response of the target molecule to the test molecule.
171. A method for determining the difference in dose response of two target molecules to a test molecule, comprising: (a) Contacting a first plurality of cell-free samples containing a plurality of first target molecules with the test molecules, wherein the first plurality of cell-free samples are dose-contacted with a series of test molecules; (b) In the presence of the series of doses of the test molecules, a plurality of the target molecules are tracked over time to provide measurements of a first plurality of spatiotemporal trajectories and / or rotational motions; (c) In the presence of the series of doses of the test molecule, analyze the measurements of the multiple spatiotemporal trajectories and / or rotational motions of the target molecule to determine the motion of the first target molecule at each concentration of the test molecule; (d) Compare the motion of the target molecule obtained in step (c) at different test molecule doses to determine the dose response of the target molecule to the test molecule; (e) Repeat steps (a)-(d) with a second target molecule to determine the dose response of the second target molecule to the test molecule; as well as (f) The dose response of the first target molecule is compared with the dose response of the second target molecule to determine the difference in the response of the first target molecule and the second target molecule to the test molecule.
172. The method of claim 170 or 171, wherein the method is a high-throughput method.
173. The method of any one of claims 170 to 172, wherein the motion calculation is: (a) The diffusion coefficients of the multiple spatiotemporal trajectories obtained by the maximum likelihood estimator; (b) The geometric mean posterior diffusion coefficient of the plurality of spatiotemporal trajectories; (c) The median of the jump length distribution of the multiple spatiotemporal trajectories; (d) The third quartile of the jump length distribution of the plurality of spatiotemporal trajectories; (e) The median radius of rotation of the plurality of spatiotemporal trajectories; (f) The average posterior diffusion coefficient of the multiple spatiotemporal trajectories; (g) The mean square displacement of the multiple spatiotemporal trajectories; (h) The median key angle of the multiple spatiotemporal trajectories; (i) The spatiotemporal trajectory length of the multiple spatiotemporal trajectories; (j) Anisotropic decay time; (k) The spatial range of the detection; (l) The number and wavelength of the conjugated fluorescent markers; (m) Occupancy rate of different diffusion states obtained from the state array; (n) Polarization of the conjugated fluorescent label; or (o) The state obtained through inference occupies.
174. The method of any one of claims 170 to 173, wherein the motion is calculated as a diffusion coefficient.
175. The method of any one of claims 170 to 174, wherein the interaction between the target molecule and the test molecule is reversible or irreversible.
176. The method of any one of claims 170 to 175, wherein comparing the motion of the target molecule obtained in step (c) at different test molecule doses further comprises comparing the duration and / or reversibility of the motion changes of the target molecule.
177. The method of any one of claims 170 to 176, wherein the first target molecule, the second target molecule and / or the test molecule are components of a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts or animal extracts.
178. The method of claim 177, wherein the bacterial extract, the cell extract, the tissue extract, the plant extract, or the animal extract is a lysate.
179. The method of any one of claims 170 to 178, wherein the first target molecule, the second target molecule and / or the test molecule are components of a mixture of serum, blood and other biological samples.
180. The method of any one of claims 170 to 179, wherein the first target molecule, the second target molecule and / or the test molecule are components comprising a mixture of buffer and glycerol.
181. The method of any one of claims 170 to 180, wherein the first target molecule, the second target molecule and / or the test molecule are organic molecules with a value of less than 1 kDa.
182. The method of any one of claims 170 to 181, wherein the first target molecule, the second target molecule and / or the test molecule are selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates and lipids.
183. The method of claim 182, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
184. The method of claim 182 or 183, wherein the protein comprises disordered domains and / or does not comprise structured domains.
185. The method of claim 182, wherein the peptide is a ligand.
186. The method of any one of claims 170 to 180, wherein the first target molecule, the second target molecule and / or the test molecule are nanomaterials or synthetic polymers.
187. The method of any one of claims 170 to 186, wherein the first target molecule, the second target molecule, and / or the test molecule are labeled.
188. The method of any one of claims 170 to 187, wherein the first target molecule, the second target molecule, and / or the test molecule are fluorescently labeled.
189. The method of any one of claims 170 to 188, wherein the first target molecule, the second target molecule, and / or the test molecule are labeled with a fluorescent protein.
190. The method of any one of claims 170 to 189, wherein the first target molecule, the second target molecule, and / or the test molecule are labeled by conjugation of synthetic nanomaterials or polymers.
191. The method of any one of claims 170 to 190, wherein the first target molecule and the second target molecule are distinguished by the difference in their fluorescent labels.
192. The method of claim 171, wherein the first target molecule and the second target molecule are related target molecules.
193. The method of claim 192, wherein at least one of the target molecules is a wild-type form of the target molecule; wherein at least one of the target molecules is a mutant form of the target molecule; and / or wherein at least one of the target molecules is a post-translational modified form of the target molecule.
194. The method of any one of claims 171 to 192, wherein the first target molecule and the second target molecule are target molecules in the same or different conformational states; wherein the first target molecule and the second target molecule are homologs, orthologs, or paralogs; and / or wherein the first target molecule and the second target molecule are unrelated target molecules.
195. The method of claim 171, wherein the first cell-free sample and the second cell-free sample comprise a solution containing a dissociative agent, a carrier, a viscosity agent, or a combination thereof.
196. The method of claim 195, wherein the viscosity agent comprises glycerin.
197. The method of claim 196, wherein the solution contains at least about 30% glycerol.
198. The method of any one of claims 195 to 197, wherein the solution comprises a temperature gradient, a chemical gradient, at least two phases, or a combination thereof.
199. The method of any one of claims 170 to 198, wherein three or more target molecules are analyzed.
200. A method for identifying a test molecule capable of distinguishing at least two target molecules, comprising: (a) Contact a cell-free sample containing a plurality of first target molecules and a plurality of second target molecules with a plurality of said test molecules; (b) Track multiple first target molecules over time to provide measurements of multiple spatiotemporal trajectories and / or rotational motions; (c) Analyze the measurement results of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the first target molecule in the presence of the test molecule; (d) Track multiple second target molecules over time to provide measurements of multiple spatiotemporal trajectories and / or rotational motions; (e) Analyze the measurement results of the plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the second target molecule in the presence of the test molecule; as well as (f) The motions of the first target molecule and the second target molecule obtained in (c) and (f) are compared; The changes in the motion of the first target molecule and the second target molecule indicate that the test molecule can distinguish between the two target molecules.
201. The method of claim 200, wherein the method is a high-throughput method.
202. The method of claim 200 or 201, wherein the change in motion is calculated as the following change: (a) Diffusion coefficient obtained from the maximum likelihood estimator; (b) Geometric mean posterior diffusion coefficient; (c) The median of the jump length distribution; (d) The third quartile of the jump length distribution; (e) Median radius of gyration; (f) Mean posterior diffusion coefficient; (g) Mean square displacement; (h) Median bond angle; (i) Spatiotemporal trajectory length; (j) Anisotropic decay time; (k) The spatial range of the detection; (l) The number and wavelength of the conjugated fluorescent markers; (m) Occupancy rate of different diffusion states obtained from the state array; (n) Polarization of the conjugated fluorescent label; or (o) The state obtained through inference occupies.
203. The method of any one of claims 200 to 202, wherein the change in motion is calculated as a change in the diffusion coefficient.
204. The method of any one of claims 200 to 203, wherein the duration and / or reversibility of the motion change of the first molecule, compared with the duration and / or reversibility of the motion change of the second molecule, indicates that the test molecule is able to distinguish the two target molecules.
205. The method of any one of claims 200 to 204, wherein the first target molecule, the second target molecule and / or the test molecule are components of a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts or animal extracts.
206. The method of claim 205, wherein the bacterial extract, the cell extract, the tissue extract, the plant extract, or the animal extract is a lysate.
207. The method of any one of claims 200 to 206, wherein the first target molecule, the second target molecule and / or the test molecule are components of a mixture of serum, blood and other biological samples.
208. The method of any one of claims 200 to 207, wherein the first target molecule, the second target molecule and / or the test molecule are components comprising a mixture of buffer and glycerol.
209. The method of any one of claims 200 to 208, wherein the first target molecule, the second target molecule and / or the test molecule are organic molecules with a value of less than 1 kDa.
210. The method of any one of claims 200 to 209, wherein the first target molecule, the second target molecule and / or the test molecule are selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates and lipids.
211. The method of claim 210, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
212. The method of claim 210 or 211, wherein the protein comprises disordered domains and / or does not comprise structured domains.
213. The method of claim 210, wherein the peptide is a ligand.
214. The method of any one of claims 200 to 208, wherein the first target molecule, the second target molecule and / or the test molecule are nanomaterials or synthetic polymers.
215. The method of any one of claims 200 to 214, wherein the first target molecule, the second target molecule, and / or the test molecule are labeled.
216. The method of any one of claims 200 to 215, wherein the first target molecule, the second target molecule, and / or the test molecule are fluorescently labeled.
217. The method of any one of claims 200 to 216, wherein the first target molecule, the second target molecule, and / or the test molecule are labeled with a fluorescent protein.
218. The method of any one of claims 200 to 217, wherein the first target molecule, the second target molecule, and / or the test molecule are labeled by conjugation of synthetic nanomaterials or polymers.
219. The method of any one of claims 200 to 218, wherein the first target molecule and the second target molecule are related target molecules.
220. The method of claim 219, wherein at least one of the target molecules is a wild-type form of the target molecule; wherein at least one of the target molecules is a mutant form of the target molecule; and / or wherein at least one of the target molecules is a post-translational modified form of the target molecule.
221. The method of any one of claims 200 to 219, wherein the first target molecule and the second target molecule are target molecules in the same or different conformational states; wherein the first target molecule and the second target molecule are homologs, orthologs, or paralogs; and / or wherein the first target molecule and the second target molecule are unrelated target molecules.
222. The method of any one of claims 200 to 221, further comprising: A cell-free sample containing multiple third target molecules is brought into contact with multiple of the test molecules; Tracking multiple third target molecules over time to provide measurements of a third plurality of spatiotemporal trajectories and / or rotational motions; analyzing the measurements of the third plurality of spatiotemporal trajectories and / or rotational motions to determine the motion of the third target molecules in the presence of the test molecules; and comparing the motion of the third target molecules with the motions obtained in (c) and (f); wherein the change in the motion of the third target molecules relative to the first and second target molecules indicates that the test molecules are able to distinguish the three target molecules.
223. A method for analyzing a test solution containing a target molecule, comprising: (a) Tracking multiple target molecules in the test solution over time to provide measurements of multiple spatiotemporal trajectories and / or rotational motions; (b) Analyze the measurement results of the multiple spatiotemporal trajectories and / or rotational motions to determine the motion of the target molecules in the test solution; as well as (c) The motion of the target molecule obtained in (b) is compared with the motion of a reference target molecule, wherein the motion of the reference target molecule is the motion of the target molecule in a reference solution; Wherein: the comparison in step (c) is used to determine the properties of the test solution.
224. The method of claim 223, wherein the method is a high-throughput method.
225. The method of claim 223 or 224, wherein the motion of the target molecule is calculated as follows: (a) Diffusion coefficient obtained from the maximum likelihood estimator; (b) Geometric mean posterior diffusion coefficient; (c) The median of the jump length distribution; (d) The third quartile of the jump length distribution; (e) Median radius of gyration; (f) Mean posterior diffusion coefficient; (g) Mean square displacement; (g) Median bond angle; (i) Spatiotemporal trajectory length; (j) Anisotropic decay time; (k) The spatial range of the detection; (l) The number and wavelength of the conjugated fluorescent markers; (m) Occupancy rate of different diffusion states obtained from the state array; (n) Polarization of the conjugated fluorescent label; or (o) The state obtained through inference occupies.
226. The method of any one of claims 223 to 225, wherein the change in motion is calculated as a change in the diffusion coefficient.
227. The method of any one of claims 223 to 226, wherein comparing the motion of the target molecule obtained in (b) with the motion of a reference target molecule further comprises comparing the duration and / or reversibility of the motion change of the target molecule with the duration of the motion change of the reference target molecule.
228. The method of any one of claims 223 to 227, wherein the target molecule and / or the reference target molecule is a component of a mixture of bacterial extracts, cell extracts, tissue extracts, plant extracts, or animal extracts.
229. The method of claim 228, wherein the bacterial extract, the cell extract, the tissue extract, the plant extract, or the animal extract is a lysate.
230. The method of any one of claims 223 to 229, wherein the target molecule and / or the reference target molecule are components of a mixture of serum, blood, and other biological samples.
231. The method of any one of claims 223 to 230, wherein the target molecule and / or the reference target molecule is a component comprising a mixture of buffer and glycerol.
232. The method of any one of claims 223 to 231, wherein the target molecule and / or the reference target molecule are organic molecules with a value of less than 1 kDa.
233. The method of any one of claims 223 to 232, wherein the target molecule and / or the reference target molecule is selected from the group consisting of peptides, proteins, nucleic acids, carbohydrates, and lipids.
234. The method of claim 233, wherein the protein is selected from the group consisting of antibodies, receptors, and enzymes.
235. The method of claim 233 or 234, wherein the protein comprises disordered domains and / or does not comprise structured domains.
236. The method of claim 233, wherein the peptide is a ligand.
237. The method of any one of claims 223 to 231, wherein the target molecule and / or the reference target molecule is a nanomaterial or a synthetic polymer.
238. The method of any one of claims 223 to 237, wherein the target molecule and / or the reference target molecule are labeled.
239. The method of any one of claims 223 to 238, wherein the target molecule and / or the reference target molecule are fluorescently labeled.
240. The method of any one of claims 223 to 239, wherein the test solution comprises a liquid release agent and / or a viscosity agent.
241. The method of claim 240, wherein the liquid release agent is urea.
242. The method of claim 240 or 241, wherein the viscosity agent is glycerin.
243. The method of any one of claims 223 to 242, wherein the test solution comprises a gradient.
244. The method of claim 243, wherein the gradient is a temperature gradient, a chemical gradient, or a combination thereof.
245. The method of any one of claims 223 to 244, wherein the test solution comprises at least two phases or a combination thereof.
246. The method of any one of claims 223 to 245, wherein the interaction between the target molecule and the test solution results in a conformational change of the target molecule.
247. The method of any one of claims 223 to 246, wherein the interaction between the target molecule and the test solution is reversible or irreversible.
248. The method of any one of claims 223 to 247, wherein the property of the test solution is pH, ion concentration, organic molecule concentration, or viscoelasticity.
249. The method of claim 248, wherein the viscoelasticity is viscosity.
250. The method of any one of claims 223 to 249, wherein the test solution is a biological sample obtained from the subject.
251. The method of any one of claims 223 to 250, wherein the properties of the test solution are used to diagnose the subject's disease.
252. The method of claim 251, wherein the disease is cancer.
253. The method of any one of claims 1 to 252, wherein the motion change is calculated as a change in the polarization of the conjoined fluorescent marker, and wherein determining the change in the polarization of the conjoined fluorescent marker includes time-correlated single-photon counting.
254. The method of any one of claims 1 to 253, wherein the motion change is calculated as a change in the polarization of the conjugated fluorescent label, and wherein determining the change in the polarization of the conjugated fluorescent label comprises step-scan pump-probe spectral microscopy.
255. The method of any one of claims 1 to 254, wherein the target molecule and / or the test molecule is labeled with an ultralong-lifetime fluorophore.
256. The method of any one of claims 1 to 255, wherein the motion change is calculated as a change in the polarization of the coupled fluorescent marker, and wherein determining the change in the polarization of the coupled fluorescent marker comprises advanced optical techniques.
257. The method of any one of claims 1 to 256, wherein the motion change is calculated as a change in the polarization of the coupled fluorescent marker, and wherein determining the change in the polarization of the coupled fluorescent marker includes oscillation anisotropy and / or polarization filtering.
258. A system for performing the method as described in any one of claims 1 to 257.
259. The system of claim 258, further comprising a microfluidic device.
